uric acid has been researched along with Diabetes Mellitus, Type 2 in 646 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to examine the impact of liraglutide plus dapagliflozin on high uric acid (UA) and microalbuminuria (MAU) in patients with diabetes mellitus (DM) complicated with metabolic syndrome (MS)." | 9.51 | Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome. ( Dai, X; Hao, H; Li, Y; Ou, T; Wang, D; Wang, R; Wang, W; Yong, H, 2022) |
| "The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction." | 9.51 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. ( Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F, 2022) |
| "The present review summarizes findings of recent studies examining the epidemiology, pathophysiology, and treatment of type 4 renal tubular acidosis (RTA) and uric acid nephrolithiasis, two conditions characterized by an abnormally acidic urine." | 9.41 | Type 4 renal tubular acidosis and uric acid nephrolithiasis: two faces of the same coin? ( Adomako, EA; Maalouf, NM, 2023) |
| " We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM)." | 9.41 | Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. ( Dronamraju, N; Erlandsson, F; Johansson, S; Johnsson, E; Parkinson, J; Stack, AG; Terkeltaub, R, 2021) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " Compared with the placebo group, the empagliflozin group showed significant decreases in body weight, systolic blood pressure, and uric acid." | 9.34 | Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. ( Asai, K; Hoshika, Y; Ishikawa, M; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Ogano, M; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K, 2020) |
| " We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation." | 9.27 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018) |
| "Previous studies have discussed the relationship between simple renal cysts (SRC) and serum uric acid level in healthy individuals." | 9.24 | Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. ( Bao, Y; Chen, H; Han, J; Han, Y; Jia, W; Lu, J; Zhang, L; Zhang, M; Zhao, F, 2017) |
| "The study included two age-, weight-, lipid-, and prolactin level-matched groups of premenopausal women with hypecholesterolemia and a history of hyperprolactinemia: patients treated with bromocriptine (5." | 9.20 | The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2015) |
| "The aim of this study was to investigate the long-term effective control of serum uric acid by allopurinol on the carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2DM) and asymptomatic hyperuricemia (HUA)." | 9.20 | The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. ( Chen, Y; Liu, P; Wang, D; Wang, H; Wang, Y; Zhang, F, 2015) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 9.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| ": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan." | 9.15 | Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 9.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| "This meta-analysis aimed to investigate whether uric acid lowering treatment can improve β-cell function and insulin sensitivity." | 9.12 | Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials. ( Ma, G; Wang, T; Zong, Q, 2021) |
| " The Mesh Terms considered were: uric acid, antioxidant, oxidant, metabolic syndrome, diabetes, cerebrovascular diseases, stroke, haemorrhagic stroke, neurocognitive disorders, and their combinations." | 9.05 | Uric Acid in Metabolic and Cerebrovascular Disorders: A Review. ( Andriani, A; Calculli, G; Ciccone, MM; Cortese, AM; Cortese, F; Giordano, P; Meliota, G; Scicchitano, P; Truncellito, L, 2020) |
| "The relationship between elevated serum uric acid level and metabolic syndrome (MS) has been debated." | 8.90 | Association of serum uric acid and metabolic syndrome in type 2 diabetes. ( Bonakdaran, S; Kharaqani, B, 2014) |
| "The upper limits of normal serum uric acid (SUA) or the lower limits of hyperuricemia were frequently set at 420 or 360 μmol/L (7." | 8.31 | High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort. ( Chen, Y; Fu, H; Li, Y; Lv, Y; Ma, C; Wan, G; Xie, R; Yang, G; Yu, H; Yuan, M; Yuan, S; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023) |
| "To determine the association of uric acid (UA) and glucose in aqueous humor with diabetic macular edema (DME) in patients with Type 2 diabetes." | 8.12 | ELEVATED LEVEL OF URIC ACID, BUT NOT GLUCOSE, IN AQUEOUS HUMOR AS A RISK FACTOR FOR DIABETIC MACULAR EDEMA IN PATIENTS WITH TYPE 2 DIABETES. ( Chan, SO; He, BT; Qin, YJ; Wang, S; Yu, HH; Zhang, HY; Zhang, YL; Zhang, YQ, 2022) |
| "Serum uric acid (SUA) is associated with many cardiovascular risk factors, such as metabolic syndrome (MetS) and subclinical atherosclerosis." | 8.12 | Association Between Serum Uric Acid Level and Carotid Atherosclerosis and Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus. ( Li, M; Li, T; Li, W; Liu, R; Liu, S; Liu, X; Ouyang, S; Wang, Y; Zhang, Y, 2022) |
| "Multiple observational studies have reported the close associations of obstructive sleep apnea (OSA) with serum uric acid (SUA) levels and gout." | 8.12 | Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study. ( Cen, H; Ding, C; He, W; Huang, L; Jin, T; Ni, J; Xie, Y; Zeng, Z; Zhang, L, 2022) |
| "This study assessed the predictive value of uric acid (UA) for contrast-induced acute kidney injury (CI-AKI) in patients with type 2 diabetes mellitus (T2DM) who underwent coronary angiography (CAG)." | 8.12 | Association between uric acid level and contrast-induced acute kidney injury in patients with type 2 diabetes mellitus after coronary angiography: a retrospective cohort study. ( Chen, H; Li, Z; Liu, H; Tang, C; Tang, H; Xu, S; Yan, G, 2022) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 8.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "This study assessed temporal relationships of serum uric acid (SUA) with blood glucose and determine the mediating effects of body mass index (BMI) and dyslipidemia on the relation of SUA and risk of type 2 diabetes." | 8.02 | Mediating Effect of Body Mass Index and Dyslipidemia on the Relation of Uric Acid and Type 2 Diabetes: Results From China Health and Retirement Longitudinal Study. ( Cheng, F; Jia, H; Li, Y; Tian, L; Zheng, H, 2021) |
| "Circulating uric acid levels were associated with insulin resistance, but the causality is unclear." | 8.02 | Association between plasma uric acid and insulin resistance in type 2 diabetes: A Mendelian randomization analysis. ( Bao, W; Chen, L; Hu, X; Liu, L; Rong, S; Sun, T; Wang, Q, 2021) |
| "To analyze the correlations between plasma coagulation factor VII (FVII), plasma plasminogen activator inhibitor-1 (PAI-1), uric acid, and insulin resistance (IR) and diabetic macroangiopathy (DMAP) in elderly patients with type 2 diabetes mellitus (T2DM)." | 8.02 | Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes. ( Li, L; Lu, Y; Ma, L; Shi, Z, 2021) |
| "To investigate the association between serum uric acid (SUA) levels and vision-threatening diabetic retinopathy (VTDR) in patients with type 2 diabetes." | 8.02 | Higher Serum Uric Acid Levels Are Associated With an Increased Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes Patients. ( Chan, Z; Chen, H; Gu, C; Hu, Y; Li, C; She, X; Shi, Y; Wang, Y; Zhao, S; Zheng, Z; Zhou, C, 2021) |
| "To evaluate the impact of changes in uric acid over 2 years on changes in insulin sensitivity, beta-cell function, and glycemia in women with and without recent gestational diabetes (GDM), a model of the early natural history of T2DM." | 7.96 | Changes Over Time in Uric Acid in Relation to Changes in Insulin Sensitivity, Beta-Cell Function, and Glycemia. ( Connelly, PW; Hanley, AJ; Retnakaran, R; Volpe, A; Ye, C; Zinman, B, 2020) |
| "This study aims to investigate the relationship between serum uric acid (SUA) and the severity of diabetic nephropathy (DN) and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM)." | 7.96 | Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. ( Hu, AP; Li, DM; Su, S; Xia, Q; Yang, SM; Zhang, SH; Zhu, J; Zhu, XL, 2020) |
| "Conflicting findings have been reported regarding the sex-specific association between serum uric acid (SUA) level and type 2 diabetes mellitus (T2DM) risk, and no study has explored the association between the change in hyperuricemia status and T2DM risk." | 7.96 | Sex-Specific Association of Serum Uric Acid Level and Change in Hyperuricemia Status with Risk of Type 2 Diabetes Mellitus: A Large Cohort Study in China. ( Chen, H; Han, D; Hu, D; Hu, F; Li, Y; Liu, D; Lou, Y; Ma, J; Peng, X; Qin, P; Wang, C; Wang, L; Xu, S; Zhao, D; Zhao, P, 2020) |
| "To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout." | 7.96 | Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study. ( Crittenden, DB; Greenberg, J; Pike, VC; Pillinger, MH; Qian, Y; Slobodnick, A; Toprover, M; Zhong, H, 2020) |
| "To analyze the associations of serum uric acid (SUA) level with diabetic microvascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN), in patients with type 2 diabetes mellitus (DM)." | 7.96 | Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. ( Chen, Q; Hou, L; Li, Q; Shi, Y; Wang, S; Zhao, M; Zhou, X, 2020) |
| "Serum uric acid (UA), which has both antioxidant and pro-oxidant properties, is thought to be involved in cellular aging processes." | 7.91 | Negative Association of Serum URIC Acid with Peripheral Blood Cellular Aging Markers. ( He, S; Li, P; Li, W; Li, Y; Liu, H; Liu, Y; Lv, L; Ma, C; Ma, M; Ping, F; Sun, Q; Xu, L; Yu, J; Zhang, H, 2019) |
| "Little is known about the relationship between high baseline serum uric acid (SUA) and incident hypertension in patients with type 2 diabetes (T2D)." | 7.88 | Relationship Between Serum Uric Acid and Incident Hypertension in Patients with Type 2 Diabetes. ( Amini, M; Aminorroaya, A; Ghanbari, H; Janghorbani, M, 2018) |
| "Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk predictors and often coexist in patients with type 2 diabetes (T2D)." | 7.85 | Metabolic syndrome, serum uric acid and renal risk in patients with T2D. ( Ceriello, A; De Cosmo, S; Fioretto, P; Genovese, S; Giorda, C; Guida, P; Piscitelli, P; Pontremoli, R; Russo, G; Viazzi, F, 2017) |
| "We assessed the prospective association between baseline serum uric acid levels and consequent risk of developing diabetic retinopathy." | 7.85 | Serum uric acid levels are associated with increased risk of newly developed diabetic retinopathy among Japanese male patients with type 2 diabetes: A prospective cohort study (diabetes distress and care registry at Tenri [DDCRT 13]). ( Hayashino, Y; Ishii, H; Kuwata, H; Okamura, S; Tsujii, S, 2017) |
| "Although the relation between serum uric acid (SUA) and left ventricular hypertrophy (LVH) has been studied for decades, however, their association remains debatable." | 7.85 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. ( Bao, H; Chen, Y; Cheng, D; Fan, Y; Jian, G; Li, J; Sheng, X; Wang, N; Zeng, C, 2017) |
| "To disclose the link between the composition of urolithiasis, especially that of uric acid calculi, and obesity, prediabetes, type 2 diabetes mellitus, and hypertension." | 7.85 | The Association of Uric Acid Calculi with Obesity, Prediabetes, Type 2 Diabetes Mellitus, and Hypertension. ( Chang, CC; Chu, FY; Ho, JL; Huang, PH; Ku, PW; Lin, YN; Su, MJ; Sun, JT; Yen, TH, 2017) |
| "This study aimed to investigate whether uric acid to creatinine (UA/Cr) ratio is associated with higher risk of metabolic syndrome (MetS) and its components." | 7.85 | Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients. ( Al-Attas, OS; Al-Daghri, NM; Alokail, MS; Sabico, S; Wani, K, 2017) |
| " Patients in the 3rd serum uric acid tertile had a higher prevalence of any cardiac conduction defects than those belonging to 2nd or 1st tertile, respectively (35." | 7.85 | Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. ( Bonapace, S; Bonora, E; Dugo, C; Mantovani, A; Morani, G; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2017) |
| "To evaluate the relationship of vitamin D status and vitamin D replacement therapy with glycemic control, serum uric acid (SUA) levels, and microalbuminuria (MAU) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD)." | 7.85 | The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. ( Acikgoz, SB; Genc, AB; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M, 2017) |
| "We aim to explore the associations between serum uric acid (SUA) and obesity and cardio-cerebrovascular events (CCEs) in Chinese inpatients with type 2 diabetes mellitus (T2DM)." | 7.85 | Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Yu, TP; Zhao, CC; Zhu, Y, 2017) |
| "Although it is known that high uric acid (UA) level is associated with type 2 diabetes (T2DM) and metabolic syndrome (MetS), most of the previous studies were focused on adults." | 7.85 | The Role of Uric Acid for Predicting Future Metabolic Syndrome and Type 2 Diabetes in Older People. ( Chang, JB; Chen, YL; Hsieh, CH; Hung, YJ; Lee, CH; Liang, YJ; Lin, CM; Lin, JD; Pei, D; Wu, CZ, 2017) |
| "To assess the prospective association between baseline serum uric acid level and subsequent risk of development or progression in albuminuria." | 7.83 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. ( Hayashino, Y; Ishii, H; Okamura, S; Tsujii, S, 2016) |
| "Serum uric acid (SUA) is associated with many cardiovascular risk factors such as hypertension (HTN) and metabolic syndrome (MetS)." | 7.81 | Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Dong, XH; Jia, WP; Li, LX; Li, MF; Li, TT; Shen, J; Zhang, R, 2015) |
| "To explore the associations between urine uric acid excretion (UUAE) and diabetic retinopathy (DR)/lower limb atherosclerotic lesions in hospitalized Chinese patients with type 2 diabetes." | 7.81 | Decreased urine uric acid excretion is associated with diabetic retinopathy but not with lower limb atherosclerosis in hospitalized patients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Lu, JX; Shuai, HP; Wang, JW; Xia, HF; Zhang, R, 2015) |
| "The relationships between uric acid and chronic disease risk factors such as metabolic syndrome, type 2 diabetes mellitus, and hypertension have been studied in adults." | 7.81 | Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study. ( Chen, YL; Lue, KH; Pei, D; Sun, HL, 2015) |
| "To investigate the relationship between elevated serum uric acid levels and the presence of diabetic foot ulcer (DFU) in Chinese patients with type 2 diabetes (T2D)." | 7.80 | Elevated serum uric acid levels are independent risk factors for diabetic foot ulcer in female Chinese patients with type 2 diabetes. ( Cao, Y; Fu, X; Gao, F; Li, J; Xue, Y; Yang, Q; Ye, X; Zhang, Q, 2014) |
| "Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome." | 7.80 | Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. ( Esteghamati, A; Fotouhi, A; Hafezi-Nejad, N; Nakhjavani, M; Sheikhbahaei, S, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "To explore the role of serum uric acid (SUA) concentration in diabetic retinopathy (DR) for patients with type 2 diabetes mellitus (T2DM)." | 7.80 | Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan--a 3-year prospective study. ( Chen, CH; Chen, YJ; Chung, MS; Kuo, HK; Lee, JJ; Liu, RT; Yang, IH, 2014) |
| " Of note, diabetic subjects with glycosuria, who represented 24% of the diabetic participants, had a null prevalence of hyperuricemia, and statistically higher values for fractional excretion of uric acid, Na excretion index, and prevalence of microalbuminuria than those without glycosuria." | 7.80 | Serum uric acid and disorders of glucose metabolism: the role of glycosuria. ( Andrade, JA; Garcia Rosa, ML; Greffin, S; Kang, HC; Lugon, JR, 2014) |
| "The association between serum uric acid (SUA) levels and atrial fibrillation (AF) is currently poorly known." | 7.79 | Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. ( Arcaro, G; Bertolini, L; Bonapace, S; Byrne, CD; Targher, G; Valbusa, F; Zenari, L; Zoppini, G, 2013) |
| " The aim of this study was to examine the relationship between serum C-reactive protein (CRP), serum uric acid, and albuminuria in Chinese type 2 diabetic patients." | 7.79 | Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. ( Gao, X; Li, XM; Ling, Y, 2013) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 7.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| "Substance P (SP) is an important neurotransmitter and is an important pathogenic factor in obesity." | 7.77 | Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus. ( Fu, J; Li, G; Liu, B; Liu, L; Liu, P; Liu, X; Wu, B, 2011) |
| "Uric acid is an independent predictor of diabetes in primary hypertension." | 7.77 | Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. ( Deferrari, G; Leoncini, G; Pontremoli, R; Vercelli, M; Viazzi, F, 2011) |
| "To explore the association of elevated serum uric acid with metabolic disorders and the risk factors of hyperuricemia in type 2 diabetes mellitus (T2DM)." | 7.77 | [Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus]. ( LI, SH; LIU, H; WU, D, 2011) |
| "Type 2 diabetes mellitus (T2DM) is an independent risk factor for uric acid nephrolithiasis, and obesity augments this risk." | 7.77 | Analysis of risk factors for uric acid nephrolithiasis in type 2 diabetes. ( Hari Kumar, KV; Modi, KD, 2011) |
| "We aimed to investigate whether elevated serum uric acid concentrations are associated with higher risk of metabolic syndrome (MetS) and carotid atherosclerosis in patients with type 2 diabetes." | 7.77 | Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. ( Chen, L; He, M; Hu, R; Huang, Y; Li, Q; Lu, B; Qu, S; Tao, X; Wen, J; Yang, Z; Ye, Z; Zhang, W; Zhang, Z, 2011) |
| "To study the relationship of dyslipidemia and serum uric acid with the risk of myocardial infarction among the hypertensive type 2 diabetic and non-diabetic patients of Trinidad." | 7.77 | Relationship of dyslipidemia and uric acid with the risk of myocardial infarction among hypertensive patients in Trinidad. ( Evernden, K; Fane, U; Fatt, LA; Maharaj, D; Maharaj, N; Maharaj, S; Maharaj, SS; Maharaj, V; Maloney, V; Nayak, BS, 2011) |
| "Allopurinol was administered to end-stage renal disease (ESRD) patients with elevated uric acid levels presenting with symptoms of gout and also had risk factors of metabolic syndrome." | 7.75 | The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. ( Beavers, D; Bowden, RG; Hartman, J; Shelmadine, B; Wilson, RL, 2009) |
| " The aim of this study was to evaluate the relationships between serum uric acid concentration and degree of urinary albumin excretion as well as markers of subclinical atherosclerosis in men with type 2 diabetes mellitus." | 7.74 | Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. ( Asano, M; Fukui, M; Harusato, I; Hasegawa, G; Hosoda, H; Kadono, M; Nakamura, N; Shiraishi, E; Tanaka, M; Yoshikawa, T, 2008) |
| "The levels of the liporegulatory hormone leptin are increased in obesity, which contributes to the metabolic syndrome; the latter is associated with elevated cardiovascular risk and morbidity." | 7.73 | Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans. ( Chraibi, A; Israili, ZH; Lyoussi, B; Mguil, M; Ragala, MA, 2005) |
| " Lipid profiles, ACR, bilirubin, uric acid, creatine kinase, and hsCRP were not changed in DM patients with different diabetic duration or diabetic retinopathy." | 7.73 | Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. ( Chang, MH; Chen, TH; Chen, YJ; Hsu, HH; Huang, CY; Huang, EJ; Kuo, WW; Lee, SD; Lu, MC; Tzang, BS, 2006) |
| "We examined the association of serum uric acid (SUA) with development of hypertension (blood pressure > or = 140/90 mmHg and/or medication for hypertension) and impaired fasting glucose (IFG) (a fasting plasma glucose level 6." | 7.72 | Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. ( Matsuo, Y; Nakanishi, N; Okamoto, M; Suzuki, K; Tatara, K; Yoshida, H, 2003) |
| "Male type 2 diabetic patients with stroke had significantly higher mean levels of serum uric acid than simple diabetic patients, but such patients of both genders all had lower HDL levels." | 7.71 | [Serum uric acid in type 2 diabetic patients complicated by stroke]. ( Gao, F; Guan, MP; Li, CZ; Liu, SQ; Shen, J; Xue, YM; Zhou, L, 2002) |
| "To assess the impacts of insulin resistance and renal function on plasma total homocysteine (tHcy) levels in patients with type 2 diabetes with a wide range of nephropathy." | 7.71 | Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. ( Emoto, M; Inaba, M; Ishimura, E; Kanda, H; Kawagishi, T; Komatsu, M; Mori, K; Nishizawa, Y; Okuno, Y; Shoji, T; Tahara, H, 2001) |
| "To investigate the association of serum uric acid level with the risk for hypertension and Type 2 diabetes." | 7.71 | Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. ( Endo, G; Fujii, S; Hayashi, T; Okada, K; Taniguchi, Y; Tsumura, K, 2001) |
| "High uric acid concentration is a common finding in subjects with risk factors for cardiovascular disease (CVD), including some characteristics of the metabolic syndrome." | 7.71 | Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome. ( Bedini, J; Conget, I; Costa, A; Igualá, I; Quintó, L, 2002) |
| "The aim of the present study was to evaluate the relationship of C-peptide and the C-peptide/bloodsugar ratio with clinical/biochemical variables presenting a well-known association with insulin resistance in NIDDM patients in acceptable control, obtained without the use of exogenous insulin." | 7.69 | Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997) |
| "The relationship between elevated serum uric acid (SUA) and coronary heart disease (CHD) is discussed controversially." | 7.68 | Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. ( Dannehl, K; Gries, FA; Hauner, H; Rathmann, W, 1993) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Phthalimide derivatives have been extensively researched with various biological actions." | 5.72 | Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance. ( da Rocha, IG; da Silva Júnior, JG; da Silva Neto, JC; de Araújo, HDA; de Menezes Lima, VL; de Oliveira Assis, SP; Oliveira, RN, 2022) |
| "Allopurinol treatment significantly reduced hepatic steatosis, epididymal fat, serum UA, HOMA-IR, hepatic enzyme levels, and cholesterol in the OLETF-HFrD-Allo group." | 5.62 | Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. ( Ahn, KJ; Cho, IJ; Chung, HY; Hwang, YC; Jeong, IK; Jeong, SW; Lee, SH; Lim, SJ; Moon, JY; Oh, DH; Yoo, J, 2021) |
| "A total of 518 individuals with type 2 diabetes were included." | 5.56 | Associations of serum uric acid and urinary albumin with the severity of diabetic retinopathy in individuals with type 2 diabetes. ( Chen, D; Liu, Y; Sun, X; Zhao, X, 2020) |
| "The study aimed to examine the impact of liraglutide plus dapagliflozin on high uric acid (UA) and microalbuminuria (MAU) in patients with diabetes mellitus (DM) complicated with metabolic syndrome (MS)." | 5.51 | Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome. ( Dai, X; Hao, H; Li, Y; Ou, T; Wang, D; Wang, R; Wang, W; Yong, H, 2022) |
| "The sodium-glucose cotransporter-2 inhibitor empagliflozin decreases the risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF with reduced ejection fraction." | 5.51 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. ( Anker, SD; Brueckmann, M; Butler, J; Doehner, W; Ferreira, JP; Filippatos, G; Januzzi, JL; Kaempfer, C; Packer, M; Pocock, SJ; Salsali, A; Zannad, F, 2022) |
| "Hyperuricemia was common in youth with T2D." | 5.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "There was an obvious increase in both NAFLD prevalence (26." | 5.43 | Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Wang, AP; Yu, TP; Zhao, CC; Zhu, Y, 2016) |
| "Furthermore, the prevalence rate of NAFLD increased progressively across the sex-specific SUA tertiles only in men (37." | 5.43 | Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. ( Fan, N; Peng, L; Peng, Y; Wang, Y; Xia, Z; Zhang, L, 2016) |
| "Patients with type 2 diabetes mellitus (DM) may experience chronic microvascular complications such as diabetic retinopathy (DR) and diabetic nephropathy (DN) during their lifetime." | 5.43 | Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus. ( Chen, SC; Hsiao, PJ; Hsu, WH; Lee, MY; Liang, CC; Lin, KD; Lin, PC; Shin, SJ, 2016) |
| "Early detection diabetic nephropathy (DN) is important." | 5.43 | Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. ( Fathy, H; Fouad, M; Zidan, A, 2016) |
| "The risk factors for T2DM patients with NAFLD are mainly BMI, WHR, TG, and SUA." | 5.42 | The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid. ( Li, YL; Mei, CX; Musha, H; Wang, HJ; Wulasihan, M; Xie, H; Xing, Y, 2015) |
| "The present review summarizes findings of recent studies examining the epidemiology, pathophysiology, and treatment of type 4 renal tubular acidosis (RTA) and uric acid nephrolithiasis, two conditions characterized by an abnormally acidic urine." | 5.41 | Type 4 renal tubular acidosis and uric acid nephrolithiasis: two faces of the same coin? ( Adomako, EA; Maalouf, NM, 2023) |
| "The aim of the present study is to present a historical and unified perspective on the association of serum uric acid (SUA) in the cause of cardiovascular diseases (CVDs)." | 5.41 | Association of hyperuricemia with cardiovascular diseases: current evidence. ( Chrysant, SG, 2023) |
| " We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM)." | 5.41 | Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. ( Dronamraju, N; Erlandsson, F; Johansson, S; Johnsson, E; Parkinson, J; Stack, AG; Terkeltaub, R, 2021) |
| "In conclusion, in patients with Type 2 diabetes mellitus and confirmed CAD, elevated levels of UA predict mortality independently of known cardiovascular risk factors." | 5.39 | Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. ( Braun, S; Cassese, S; Fusaro, M; Haase, HU; Hadamitzky, M; Kastrati, A; King, L; Ndrepepa, G; Schömig, A; Tada, T, 2013) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " Compared with the placebo group, the empagliflozin group showed significant decreases in body weight, systolic blood pressure, and uric acid." | 5.34 | Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. ( Asai, K; Hoshika, Y; Ishikawa, M; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Ogano, M; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K, 2020) |
| " SGLT2 inhibitors ameliorate cardiovascular morbidity and mortality as well as kidney disease progression by reducing body weight (BW), blood pressure (BP), visceral adiposity, albuminuria, and serum uric acid and blood glucose levels." | 5.34 | Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients. ( Aoki, T; Fujikura, T; Hashimoto, T; Ishigaki, S; Isobe, S; Kato, A; Matsuyama, T; Morita, H; Ohashi, N; Tsuriya, D; Yasuda, H, 2020) |
| "Metabolic syndrome was diagnosed using the WHO criteria." | 5.34 | Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks. ( Akande, AA; Akinyinka, OA; Jimoh, AK; Olarinoye, GO, 2007) |
| "6 years) with hyperuricemia (fasting serum uric acid ≥0." | 5.27 | Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. ( Davis, TME; Davis, WA; Drinkwater, JJ; Keen, HI; Latkovic, E; Nossent, J, 2018) |
| " We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation." | 5.27 | Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. ( Ansquer, JC; Best, JD; Buizen, L; d'Emden, MC; Davis, TME; Feher, MD; Flack, J; Foucher, C; Gebski, V; Hedley, J; Jenkins, AJ; Keech, AC; Kesaniemi, YA; Li, L; McGill, N; Scott, RS; Sullivan, DR; Waldman, B, 2018) |
| "Previous studies have discussed the relationship between simple renal cysts (SRC) and serum uric acid level in healthy individuals." | 5.24 | Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes. ( Bao, Y; Chen, H; Han, J; Han, Y; Jia, W; Lu, J; Zhang, L; Zhang, M; Zhao, F, 2017) |
| " Additional endpoints included other hemodynamic measures, serum uric acid, fasting plasma glucose, body weight, blood lipids and heart rate." | 5.22 | Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. ( Alessi, F; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA, 2016) |
| " No significant changes were observed in fasting plasma glucose, quantitative insulin sensitivity check index, hs-CRP, superoxide dismutase, catalase and uric acid in the RS2 group as compared with the control group." | 5.22 | The Therapeutic Potential of Resistant Starch in Modulation of Insulin Resistance, Endotoxemia, Oxidative Stress and Antioxidant Biomarkers in Women with Type 2 Diabetes: A Randomized Controlled Clinical Trial. ( Dehghan, P; Farhangi, MA; Gargari, BP; Karimi, P; Pouraghaei, M; Sarmadi, B; Zare Javid, A, 2016) |
| "Elevated plasma uric acid concentration is a risk factor for gout, insulin resistance and type 2 diabetes." | 5.22 | Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial. ( Shi, Y; Williamson, G, 2016) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| "The study included two age-, weight-, lipid-, and prolactin level-matched groups of premenopausal women with hypecholesterolemia and a history of hyperprolactinemia: patients treated with bromocriptine (5." | 5.20 | The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. ( Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W, 2015) |
| "The aim of this study was to investigate the long-term effective control of serum uric acid by allopurinol on the carotid intima-media thickness (IMT) in patients with type 2 diabetes (T2DM) and asymptomatic hyperuricemia (HUA)." | 5.20 | The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. ( Chen, Y; Liu, P; Wang, D; Wang, H; Wang, Y; Zhang, F, 2015) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 5.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| ": A multicenter study with randomized, placebo-controlled, double-blind, parallel-group comparison was carried out to evaluate the efficacy and safety of febuxostat in 103 patients with hyperuricemia (including patients with gout) in Japan." | 5.15 | Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. ( Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M, 2011) |
| "Type 2 diabetes is associated with excessively low urine pH, which increases the risk for uric acid nephrolithiasis." | 5.14 | Metabolic basis for low urine pH in type 2 diabetes. ( Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2010) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 5.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| "This meta-analysis aimed to investigate whether uric acid lowering treatment can improve β-cell function and insulin sensitivity." | 5.12 | Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials. ( Ma, G; Wang, T; Zong, Q, 2021) |
| "We assessed the additive effect of dual peroxisome proliferators activated receptors (PPAR) alpha/gamma induction, achieved by the addition of fenofibrate to rosiglitazone, on metabolic control and diabetic dyslipidemia." | 5.12 | The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. ( Altuntas, Y; Basat, O; Seber, S; Ucak, S, 2006) |
| "To examine the relationship between raised serum uric acid and subsequent cardiovascular events (mortality, myocardial infarction, stroke)." | 5.09 | Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans? ( Longo-Mbenza, B; Luila, EL; Mbete, P; Vita, EK, 1999) |
| " We sought to assess the antihypertensive and metabolic effects of the new dihydropyridine calcium antagonist manidipine (M) in patients with diabetes mellitus and essential hypertension as compared with the ACE inhibitor enalapril (E)." | 5.09 | Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. ( Agabiti-Rosei, E; Casati, R; Fogari, R; Leonetti, G; Mancia, G; Montemurro, G; Nami, R; Omboni, S; Pessina, AC; Pirrelli, A; Zanchetti, A, 2000) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| " The Mesh Terms considered were: uric acid, antioxidant, oxidant, metabolic syndrome, diabetes, cerebrovascular diseases, stroke, haemorrhagic stroke, neurocognitive disorders, and their combinations." | 5.05 | Uric Acid in Metabolic and Cerebrovascular Disorders: A Review. ( Andriani, A; Calculli, G; Ciccone, MM; Cortese, AM; Cortese, F; Giordano, P; Meliota, G; Scicchitano, P; Truncellito, L, 2020) |
| " While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes." | 5.05 | Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. ( Agabiti-Rosei, E; Borghi, C; Johnson, RJ; Kielstein, JT; Lurbe, E; Mancia, G; Redon, J; Stack, AG; Tsioufis, KP, 2020) |
| " The indirect effects involve a reduction in insulin levels and resistance, uric acid concentration, body weight, and blood pressure." | 4.98 | The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. ( Ito, M; Tanaka, T, 2018) |
| " SGLT2 inhibitors can decrease blood pressure levels and serum uric acid levels and may also reduce the degree of diabetes-related albuminuria." | 4.95 | Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. ( Elisaf, MS; Filippatos, TD; Tsimihodimos, V, 2017) |
| "The relationship between elevated serum uric acid level and metabolic syndrome (MS) has been debated." | 4.90 | Association of serum uric acid and metabolic syndrome in type 2 diabetes. ( Bonakdaran, S; Kharaqani, B, 2014) |
| "There is an increased prevalence of nephrolithiasis and an increase in the incidence of renal colic in patients with diabetes, obesity, hypertension and insulin resistance because of an increased frequency of uric acid crystallization." | 4.88 | Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes. ( Bell, DS, 2012) |
| "The aim of this study was to examine trends in serum uric acid (SUA) levels over a recent 5-year period according to age, sex, obesity, and abdominal obesity among Korean children and adolescents." | 4.31 | Trends in serum uric acid levels among Korean children and adolescents between 2016 and 2020: a nationwide study. ( Kim, EY; Kwon, YJ; Lee, HW; Lee, JW; Son, NH, 2023) |
| "Patients with metabolic syndrome We can observe that the Blood urea level showed positive correlation with uric acid level (p value 0." | 4.31 | Endocrinology. ( Konan, V; Swamy, N, 2023) |
| "The upper limits of normal serum uric acid (SUA) or the lower limits of hyperuricemia were frequently set at 420 or 360 μmol/L (7." | 4.31 | High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort. ( Chen, Y; Fu, H; Li, Y; Lv, Y; Ma, C; Wan, G; Xie, R; Yang, G; Yu, H; Yuan, M; Yuan, S; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023) |
| " Hyperuricemia was defined as a serum uric acid level above 7." | 4.31 | Hip circumference has independent association with the risk of hyperuricemia in middle-aged but not in older male patients with type 2 diabetes mellitus. ( Feng, Y; Lu, W; Niu, Y; Sheng, J; Tang, Q; Zhang, H; Zhao, X, 2023) |
| "001), fibroblast growth factor 21, homeostasis model assessment of insulin resistance as an insulin resistance index and uric acid, and was negatively correlated with levels of high-density lipoprotein cholesterol and adiponectin." | 4.12 | Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. ( Furuhashi, M; Higashiura, Y; Koyama, M; Ohnishi, H; Saitoh, S; Sakai, A; Shimamoto, K; Takahashi, S; Tanaka, M, 2022) |
| "To determine the association of uric acid (UA) and glucose in aqueous humor with diabetic macular edema (DME) in patients with Type 2 diabetes." | 4.12 | ELEVATED LEVEL OF URIC ACID, BUT NOT GLUCOSE, IN AQUEOUS HUMOR AS A RISK FACTOR FOR DIABETIC MACULAR EDEMA IN PATIENTS WITH TYPE 2 DIABETES. ( Chan, SO; He, BT; Qin, YJ; Wang, S; Yu, HH; Zhang, HY; Zhang, YL; Zhang, YQ, 2022) |
| "Serum uric acid (SUA) is associated with many cardiovascular risk factors, such as metabolic syndrome (MetS) and subclinical atherosclerosis." | 4.12 | Association Between Serum Uric Acid Level and Carotid Atherosclerosis and Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus. ( Li, M; Li, T; Li, W; Liu, R; Liu, S; Liu, X; Ouyang, S; Wang, Y; Zhang, Y, 2022) |
| "Multiple observational studies have reported the close associations of obstructive sleep apnea (OSA) with serum uric acid (SUA) levels and gout." | 4.12 | Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study. ( Cen, H; Ding, C; He, W; Huang, L; Jin, T; Ni, J; Xie, Y; Zeng, Z; Zhang, L, 2022) |
| " Our previous studies confirmed that hyperuricemia or high uric acid (HUA) treatment induced an IR state in several peripheral tissues to promote the development of type 2 diabetes mellitus (T2DM)." | 4.12 | Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway ( Chen, B; Cheng, J; He, F; Koyama, H; Liu, W; Lu, J; Wang, M; Wang, Q; Wang, W; Xi, Y; Xu, C; Yamamoto, T; Yan, Y; Yu, L; Yu, W; Zhang, C; Zhao, H, 2022) |
| "This study assessed the predictive value of uric acid (UA) for contrast-induced acute kidney injury (CI-AKI) in patients with type 2 diabetes mellitus (T2DM) who underwent coronary angiography (CAG)." | 4.12 | Association between uric acid level and contrast-induced acute kidney injury in patients with type 2 diabetes mellitus after coronary angiography: a retrospective cohort study. ( Chen, H; Li, Z; Liu, H; Tang, C; Tang, H; Xu, S; Yan, G, 2022) |
| "Previous studies suggested that increased serum uric acid (SUA) level is an independent risk factor for albuminuria in Type 2 diabetes (T2D) patients." | 4.12 | Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations. ( An, X; Sun, J; Tian, R; Wang, X; Yu, J; Zhou, Y; Zhu, L, 2022) |
| "Self-reported gout or hyperuricemia and uric acid level." | 4.02 | Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). ( Engel, B; Freitag, MH; Hoffmann, F; Jacobs, H, 2021) |
| " Nevertheless, the association between uric acid levels and the development of albuminuria has been under-investigated in patients with type 2 diabetes mellitus." | 4.02 | Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study. ( Chen, LJ; Chen, YY; Ku, PW; Lai, YJ; Yen, YF, 2021) |
| "This study assessed temporal relationships of serum uric acid (SUA) with blood glucose and determine the mediating effects of body mass index (BMI) and dyslipidemia on the relation of SUA and risk of type 2 diabetes." | 4.02 | Mediating Effect of Body Mass Index and Dyslipidemia on the Relation of Uric Acid and Type 2 Diabetes: Results From China Health and Retirement Longitudinal Study. ( Cheng, F; Jia, H; Li, Y; Tian, L; Zheng, H, 2021) |
| " Current data suggest that the mechanism of action of metformin contributes to the development of an anti-inflammatory effect, as well as a decrease in the level of uric acid, and its use can be potentially useful in patients with hyperuricemia and gout." | 4.02 | [Advantages of the use of metformin in patients with impaired uric acid metabolism]. ( Eliseev, MS; Nasonov, EL; Panevin, TS; Zhelyabina, OV, 2021) |
| "Circulating uric acid levels were associated with insulin resistance, but the causality is unclear." | 4.02 | Association between plasma uric acid and insulin resistance in type 2 diabetes: A Mendelian randomization analysis. ( Bao, W; Chen, L; Hu, X; Liu, L; Rong, S; Sun, T; Wang, Q, 2021) |
| "To analyze the correlations between plasma coagulation factor VII (FVII), plasma plasminogen activator inhibitor-1 (PAI-1), uric acid, and insulin resistance (IR) and diabetic macroangiopathy (DMAP) in elderly patients with type 2 diabetes mellitus (T2DM)." | 4.02 | Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes. ( Li, L; Lu, Y; Ma, L; Shi, Z, 2021) |
| "Uric acid has long been considered responsible for a single specific disease, namely gout." | 4.02 | The URRAH study. ( Carubbi, F; Del Pinto, R; Ferri, C; Pontremoli, R; Russo, E; Viazzi, F, 2021) |
| "To investigate the association between serum uric acid (SUA) levels and vision-threatening diabetic retinopathy (VTDR) in patients with type 2 diabetes." | 4.02 | Higher Serum Uric Acid Levels Are Associated With an Increased Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes Patients. ( Chan, Z; Chen, H; Gu, C; Hu, Y; Li, C; She, X; Shi, Y; Wang, Y; Zhao, S; Zheng, Z; Zhou, C, 2021) |
| "Both the presence of diabetes and obesity blunt the serum uric acid response to fructose ingestion." | 3.96 | Fructose tolerance test in obese people with and without type 2 diabetes. ( Al Salem, D; Al-Ozairi, E; Alhubail, A; Asad, RA; Bjornstad, P; Johnson, RJ; Kuwabara, M; Lanaspa, MA; Megahed, A; Rivard, CJ; Sanchez Lozada, LG, 2020) |
| "To evaluate the impact of changes in uric acid over 2 years on changes in insulin sensitivity, beta-cell function, and glycemia in women with and without recent gestational diabetes (GDM), a model of the early natural history of T2DM." | 3.96 | Changes Over Time in Uric Acid in Relation to Changes in Insulin Sensitivity, Beta-Cell Function, and Glycemia. ( Connelly, PW; Hanley, AJ; Retnakaran, R; Volpe, A; Ye, C; Zinman, B, 2020) |
| "This study aims to investigate the relationship between serum uric acid (SUA) and the severity of diabetic nephropathy (DN) and diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM)." | 3.96 | Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus. ( Hu, AP; Li, DM; Su, S; Xia, Q; Yang, SM; Zhang, SH; Zhu, J; Zhu, XL, 2020) |
| "Conflicting findings have been reported regarding the sex-specific association between serum uric acid (SUA) level and type 2 diabetes mellitus (T2DM) risk, and no study has explored the association between the change in hyperuricemia status and T2DM risk." | 3.96 | Sex-Specific Association of Serum Uric Acid Level and Change in Hyperuricemia Status with Risk of Type 2 Diabetes Mellitus: A Large Cohort Study in China. ( Chen, H; Han, D; Hu, D; Hu, F; Li, Y; Liu, D; Lou, Y; Ma, J; Peng, X; Qin, P; Wang, C; Wang, L; Xu, S; Zhao, D; Zhao, P, 2020) |
| "To assess the impact of allopurinol on diabetes in a retrospective cohort of Veterans' Affairs patients with gout." | 3.96 | Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study. ( Crittenden, DB; Greenberg, J; Pike, VC; Pillinger, MH; Qian, Y; Slobodnick, A; Toprover, M; Zhong, H, 2020) |
| "To analyze the associations of serum uric acid (SUA) level with diabetic microvascular complications, including diabetic retinopathy (DR) and diabetic nephropathy (DN), in patients with type 2 diabetes mellitus (DM)." | 3.96 | Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus. ( Chen, Q; Hou, L; Li, Q; Shi, Y; Wang, S; Zhao, M; Zhou, X, 2020) |
| "In this study, we aimed to analyze the relationship between serum uric acid (UA) and microalbuminuria as a marker of renal injury in type 2 diabetes mellitus." | 3.91 | Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy? ( Aktas, G; Atak, BM; Duman, TT; Kocak, MZ; Savli, H, 2019) |
| " This review discussed the non-glycemic effects of SGLT-2is in patients with T2D and renal impairment, including reductions in systolic and diastolic blood pressure, decreases in albuminuria and plasma uric acid, changes in estimated glomerular filtration rate, and minimal changes in electrolytes." | 3.91 | Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. ( Weir, MR, 2019) |
| "Serum uric acid (UA), which has both antioxidant and pro-oxidant properties, is thought to be involved in cellular aging processes." | 3.91 | Negative Association of Serum URIC Acid with Peripheral Blood Cellular Aging Markers. ( He, S; Li, P; Li, W; Li, Y; Liu, H; Liu, Y; Lv, L; Ma, C; Ma, M; Ping, F; Sun, Q; Xu, L; Yu, J; Zhang, H, 2019) |
| " We aimed to follow the variation of some biochemical and clinical parameters in T2D patients before and after Ramadan; and to determine the incidence of fasting on hypoglycaemia and lactic acidosis associated with antidiabetic agents such as metformin." | 3.91 | Follow-up of glycemic index before and after Ramadan fasting in type 2 diabetes patients under antidiabetic medications. ( Abdessadek, M; Ajdi, F; Khabbal, Y; Magoul, R; Marmouzi, I, 2019) |
| " Hyperuricemia was defined as a serum uric acid level >7 mg/dl for men and >6 mg/dl for women or allopurinol use." | 3.88 | Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. ( Bolzan, B; Bonapace, S; Bonora, E; Civettini, A; Dugo, C; Mantovani, A; Morani, G; Rigolon, R; Targher, G; Zoppini, G, 2018) |
| " (i) Insulin is considered to stimulate uric acid reabsorption via specific transporter and the effect of hyperuricaemia on the new-onset T2DM should be evaluated by considering insulin resistance." | 3.88 | Hyperuricaemia and type 2 diabetes mellitus. ( Kawada, T, 2018) |
| "Little is known about the relationship between high baseline serum uric acid (SUA) and incident hypertension in patients with type 2 diabetes (T2D)." | 3.88 | Relationship Between Serum Uric Acid and Incident Hypertension in Patients with Type 2 Diabetes. ( Amini, M; Aminorroaya, A; Ghanbari, H; Janghorbani, M, 2018) |
| "These findings indicated that increased uric acid levels probably associated with obesity and type 2 diabetes, and more definite research is needed to define any role for uric acid in relation to these diseases." | 3.88 | Temporal relationship between hyperuricemia and obesity, and its association with future risk of type 2 diabetes. ( Guo, X; Han, T; Li, Y; Liu, L; Ma, H; Meng, X; Na, L; Qu, R; Shan, R; Shi, D; Sun, C; Zhao, Y; Zi, T, 2018) |
| "Our study indicates LDJB-LSG is similar to LRYGB in the improvements of the body weight, blood glucose, insulin resistance, islet β cell function, blood lipid profile and serum uric acid, and thus LDJB-LSG is applicable in T2DM patients with 27." | 3.88 | Laparoscopic sleeve gastrectomy combined with single-anastomosis duodenal-jejunal bypass in the treatment of type 2 diabetes mellitus of patients with body mass index higher than 27.5 kg/m2 but lower than 32.5 kg/m2. ( Fang, DH; Li, YX; Liu, TX, 2018) |
| "Metabolic Syndrome (Mets) and increased serum uric acid (SUA), are well known renal risk predictors and often coexist in patients with type 2 diabetes (T2D)." | 3.85 | Metabolic syndrome, serum uric acid and renal risk in patients with T2D. ( Ceriello, A; De Cosmo, S; Fioretto, P; Genovese, S; Giorda, C; Guida, P; Piscitelli, P; Pontremoli, R; Russo, G; Viazzi, F, 2017) |
| "We assessed the prospective association between baseline serum uric acid levels and consequent risk of developing diabetic retinopathy." | 3.85 | Serum uric acid levels are associated with increased risk of newly developed diabetic retinopathy among Japanese male patients with type 2 diabetes: A prospective cohort study (diabetes distress and care registry at Tenri [DDCRT 13]). ( Hayashino, Y; Ishii, H; Kuwata, H; Okamura, S; Tsujii, S, 2017) |
| "Although the relation between serum uric acid (SUA) and left ventricular hypertrophy (LVH) has been studied for decades, however, their association remains debatable." | 3.85 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. ( Bao, H; Chen, Y; Cheng, D; Fan, Y; Jian, G; Li, J; Sheng, X; Wang, N; Zeng, C, 2017) |
| "To disclose the link between the composition of urolithiasis, especially that of uric acid calculi, and obesity, prediabetes, type 2 diabetes mellitus, and hypertension." | 3.85 | The Association of Uric Acid Calculi with Obesity, Prediabetes, Type 2 Diabetes Mellitus, and Hypertension. ( Chang, CC; Chu, FY; Ho, JL; Huang, PH; Ku, PW; Lin, YN; Su, MJ; Sun, JT; Yen, TH, 2017) |
| "This study aimed to investigate whether uric acid to creatinine (UA/Cr) ratio is associated with higher risk of metabolic syndrome (MetS) and its components." | 3.85 | Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients. ( Al-Attas, OS; Al-Daghri, NM; Alokail, MS; Sabico, S; Wani, K, 2017) |
| " Patients in the 3rd serum uric acid tertile had a higher prevalence of any cardiac conduction defects than those belonging to 2nd or 1st tertile, respectively (35." | 3.85 | Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. ( Bonapace, S; Bonora, E; Dugo, C; Mantovani, A; Morani, G; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2017) |
| "Serum uric acid (SUA) is an emerging risk factor for incident hypertension and type 2 diabetes." | 3.85 | Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study. ( Borghi, C; Bove, M; Cicero, AF; D'Addato, S; Fogacci, F; Giovannini, M; Rosticci, M; Urso, R, 2017) |
| "To evaluate the relationship of vitamin D status and vitamin D replacement therapy with glycemic control, serum uric acid (SUA) levels, and microalbuminuria (MAU) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD)." | 3.85 | The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. ( Acikgoz, SB; Genc, AB; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M, 2017) |
| "We aim to explore the associations between serum uric acid (SUA) and obesity and cardio-cerebrovascular events (CCEs) in Chinese inpatients with type 2 diabetes mellitus (T2DM)." | 3.85 | Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Yu, TP; Zhao, CC; Zhu, Y, 2017) |
| "Although it is known that high uric acid (UA) level is associated with type 2 diabetes (T2DM) and metabolic syndrome (MetS), most of the previous studies were focused on adults." | 3.85 | The Role of Uric Acid for Predicting Future Metabolic Syndrome and Type 2 Diabetes in Older People. ( Chang, JB; Chen, YL; Hsieh, CH; Hung, YJ; Lee, CH; Liang, YJ; Lin, CM; Lin, JD; Pei, D; Wu, CZ, 2017) |
| " Hyperuricemia was defined as a serum uric acid level >7 mg/dl for men and >6 mg/dl for women or allopurinol use." | 3.83 | Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. ( Bergamini, C; Bonora, E; Mantovani, A; Pernigo, M; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2016) |
| " Variables included were waist circumference (WC), glucose, high-density lipoprotein (HDL), triglycerides (TGL), blood pressure, insulin resistance (by homeostatic model assessment HOMA-index), acanthosis nigricans (AN), uric acid, serum glutamic oxaloacetic transaminase (GOT) and alanine transaminase, and hepatic sonogram." | 3.83 | Models Predictive of Metabolic Syndrome Components in Obese Pediatric Patients. ( Barrera-de Leon, JC; Colunga Rodríguez, C; Hurtado López, EF; López Beltrán, AL; Ortega-Cortes, R; Tlacuilo-Parra, A; Trujillo, X, 2016) |
| "To assess the prospective association between baseline serum uric acid level and subsequent risk of development or progression in albuminuria." | 3.83 | Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)]. ( Hayashino, Y; Ishii, H; Okamura, S; Tsujii, S, 2016) |
| " Multiple linear regression analysis using eGFR as the dependent variable demonstrated that uric acid (UA), FFA, triglyceride (TG), total cholesterol (TC), albuminuria, hypertension, smoking and duration of diabetes were all independent risk factors for decreased eGFR (all P<0." | 3.83 | [Correlation between serum free fatty acid level and estimated glomerular filtration rate in type 2 diabetic patients]. ( Li, H; Lin, X; Xuan, L; Yin, X; Zheng, F; Zhu, W, 2016) |
| "We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone." | 3.81 | Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015) |
| "Serum uric acid (SUA) is associated with many cardiovascular risk factors such as hypertension (HTN) and metabolic syndrome (MetS)." | 3.81 | Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. ( Bao, YQ; Dong, XH; Jia, WP; Li, LX; Li, MF; Li, TT; Shen, J; Zhang, R, 2015) |
| " We investigated the role of soluble uric acid in NLRP3 inflammasome activation in macrophages to demonstrate the effect of systemic hyperuricemia on progressive kidney damage in type 2 diabetes." | 3.81 | Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. ( Choi, YW; Ihm, CG; Jeong, KH; Kim, DJ; Kim, SM; Kim, SY; Kim, YG; Lee, SH; Lee, TW; Moon, JY; Seo, JW; Won, KY, 2015) |
| "To explore the associations between urine uric acid excretion (UUAE) and diabetic retinopathy (DR)/lower limb atherosclerotic lesions in hospitalized Chinese patients with type 2 diabetes." | 3.81 | Decreased urine uric acid excretion is associated with diabetic retinopathy but not with lower limb atherosclerosis in hospitalized patients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Lu, JX; Shuai, HP; Wang, JW; Xia, HF; Zhang, R, 2015) |
| " There were positive correlations between NAFLD and insulin resistance index (HOMA-IR), free fatty acids (FFA), tumor necrosis factor-α (TNF-α), omentin-1, visceral fat area, homocysteine (HCY), and serum uric acid (UA)." | 3.81 | Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. ( Di, F; Gao, L; Jia, G; Li, N; Li, Q; Shao, J; Wang, L; Wang, Q, 2015) |
| "The relationships between uric acid and chronic disease risk factors such as metabolic syndrome, type 2 diabetes mellitus, and hypertension have been studied in adults." | 3.81 | Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study. ( Chen, YL; Lue, KH; Pei, D; Sun, HL, 2015) |
| "To investigate the relationship between elevated serum uric acid levels and the presence of diabetic foot ulcer (DFU) in Chinese patients with type 2 diabetes (T2D)." | 3.80 | Elevated serum uric acid levels are independent risk factors for diabetic foot ulcer in female Chinese patients with type 2 diabetes. ( Cao, Y; Fu, X; Gao, F; Li, J; Xue, Y; Yang, Q; Ye, X; Zhang, Q, 2014) |
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| "Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome." | 3.80 | Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. ( Esteghamati, A; Fotouhi, A; Hafezi-Nejad, N; Nakhjavani, M; Sheikhbahaei, S, 2014) |
| "Increased serum uric acid levels and vascular atherosclerosis are very common in diabetes." | 3.80 | Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus. ( Sun, H; Xiang, G; Xiang, L; Zhang, J, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Serum uric acid levels have been reported to be associated with non-alcoholic fatty liver disease (NAFLD)." | 3.80 | Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. ( Chen, Y; Liu, PJ; Lou, HP; Ma, F; Zhu, YN, 2014) |
| "To explore the role of serum uric acid (SUA) concentration in diabetic retinopathy (DR) for patients with type 2 diabetes mellitus (T2DM)." | 3.80 | Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan--a 3-year prospective study. ( Chen, CH; Chen, YJ; Chung, MS; Kuo, HK; Lee, JJ; Liu, RT; Yang, IH, 2014) |
| " Of note, diabetic subjects with glycosuria, who represented 24% of the diabetic participants, had a null prevalence of hyperuricemia, and statistically higher values for fractional excretion of uric acid, Na excretion index, and prevalence of microalbuminuria than those without glycosuria." | 3.80 | Serum uric acid and disorders of glucose metabolism: the role of glycosuria. ( Andrade, JA; Garcia Rosa, ML; Greffin, S; Kang, HC; Lugon, JR, 2014) |
| "The association between serum uric acid (SUA) levels and atrial fibrillation (AF) is currently poorly known." | 3.79 | Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. ( Arcaro, G; Bertolini, L; Bonapace, S; Byrne, CD; Targher, G; Valbusa, F; Zenari, L; Zoppini, G, 2013) |
| " The AD group was older, had higher BMI, waist circumference, higher proportion of metabolic syndrome and stroke, higher levels of triglyceride, high sensitivity C-reactive protein (hsCRP), uric acid, and lower levels of total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) than the normal testosterone group." | 3.79 | The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes. ( Chancellor, MB; Chen, CD; Chuang, YC; Chung, MS; Lee, JJ; Lee, WC; Liu, RT; Wang, PW; Yang, KD, 2013) |
| " The aim of this study was to examine the relationship between serum C-reactive protein (CRP), serum uric acid, and albuminuria in Chinese type 2 diabetic patients." | 3.79 | Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. ( Gao, X; Li, XM; Ling, Y, 2013) |
| "Current evidence suggests a direct association of uric acid with diabetes risk, but it is still unclear whether this is independent of risk factors such as obesity and diet." | 3.79 | Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. ( Beulens, JW; Schulze, MB; Sluijs, I; Spijkerman, AM; van der A, DL; van der Schouw, YT, 2013) |
| "Serum uric acid is a predictor of cardiac events and correlates to N-terminal pro-B-type natriuretic peptide and albuminuria, underscoring the importance of uric acid as a cardiovascular risk marker in patients with diabetes." | 3.78 | Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. ( Clodi, M; Hülsmann, M; Kromoser, H; Luger, A; Neuhold, S; Pacher, R; Prager, R; Resl, M; Riedl, M; Strunk, G; Vila, G, 2012) |
| " The following parameters discriminated progressors from non-progressors by univariate analysis: baseline-blood pressure (BP) parameters, eGFR and proteinuria as well as serum uric acid." | 3.78 | A study of the natural history of diabetic kidney disease (DKD). ( Altemtam, N; El Nahas, M; Russell, J, 2012) |
| " We assessed performance of base model (model 1: age, sex, BMI, smoking, parental diabetes and hypertension) and two clinical models: model 1 plus fasting glucose (model 2); and model 2 plus uric acid (model 3)." | 3.78 | External validation of the KORA S4/F4 prediction models for the risk of developing type 2 diabetes in older adults: the PREVEND study. ( Abbasi, A; Bakker, SJ; Beulens, JW; Corpeleijn, E; de Jong, PE; Gans, RO; Gansevoort, RT; Hillege, HL; Kowall, B; Meisinger, C; Navis, G; Peelen, LM; Rathmann, W; Stolk, RP, 2012) |
| "Baseline levels of serum uric acid were negatively correlated with HbA1c, were higher in men and in the elderly and were independently associated with components of the metabolic syndrome." | 3.78 | Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. ( Barutta, F; Bruno, G; Cavallo-Perin, P; Fornengo, P; Ghezzo, G; Greco, E; Gruden, G; Panero, F; Perotto, M; Runzo, C, 2012) |
| "As elevated serum uric acid (SUA) is an independent risk factor for hypertension, we examined whether baseline SUA may influence the blood pressure (BP) response to antihypertensive medications." | 3.78 | Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients. ( Chen, H; Hong, D; Lin, C; Lin, F; Lin, K; Zhu, P, 2012) |
| "Substance P (SP) is an important neurotransmitter and is an important pathogenic factor in obesity." | 3.77 | Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus. ( Fu, J; Li, G; Liu, B; Liu, L; Liu, P; Liu, X; Wu, B, 2011) |
| "Uric acid is an independent predictor of diabetes in primary hypertension." | 3.77 | Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. ( Deferrari, G; Leoncini, G; Pontremoli, R; Vercelli, M; Viazzi, F, 2011) |
| "To explore the association of elevated serum uric acid with metabolic disorders and the risk factors of hyperuricemia in type 2 diabetes mellitus (T2DM)." | 3.77 | [Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus]. ( LI, SH; LIU, H; WU, D, 2011) |
| "Type 2 diabetes mellitus (T2DM) is an independent risk factor for uric acid nephrolithiasis, and obesity augments this risk." | 3.77 | Analysis of risk factors for uric acid nephrolithiasis in type 2 diabetes. ( Hari Kumar, KV; Modi, KD, 2011) |
| "We aimed to investigate whether elevated serum uric acid concentrations are associated with higher risk of metabolic syndrome (MetS) and carotid atherosclerosis in patients with type 2 diabetes." | 3.77 | Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. ( Chen, L; He, M; Hu, R; Huang, Y; Li, Q; Lu, B; Qu, S; Tao, X; Wen, J; Yang, Z; Ye, Z; Zhang, W; Zhang, Z, 2011) |
| "To study the relationship of dyslipidemia and serum uric acid with the risk of myocardial infarction among the hypertensive type 2 diabetic and non-diabetic patients of Trinidad." | 3.77 | Relationship of dyslipidemia and uric acid with the risk of myocardial infarction among hypertensive patients in Trinidad. ( Evernden, K; Fane, U; Fatt, LA; Maharaj, D; Maharaj, N; Maharaj, S; Maharaj, SS; Maharaj, V; Maloney, V; Nayak, BS, 2011) |
| "We developed a point system to estimate chronic kidney disease risk at 4 years using the following variables: age (8 points), body mass index (2 points), diastolic blood pressure (2 points), and history of type 2 diabetes (1 point) and stroke (4 points) for the clinical model, with the addition of uric acid (2 points), postprandial glucose (1 point), hemoglobin A1c (1 point), and proteinuria 100 mg/dL or greater (6 points) for the biochemical model." | 3.76 | A prediction model for the risk of incident chronic kidney disease. ( Chen, MF; Chien, KL; Hsu, HC; Lee, BC; Lee, YT; Lin, HJ, 2010) |
| "to obtain prevalence of insulin resistance among siblings of subjects with type 2 DM and their metabolic abnormality profiles as measured by their BMI, waist circumference (WC), blood pressure, glucose intolerance, concentration of triglyceride, HDL cholesterol, and uric acid." | 3.76 | Insulin resistance profile among siblings of type 2 diabetes mellitus (preliminary study). ( Gumiwang, I; Oemardi, M; Purnamasari, D; Soegondo, S, 2010) |
| " Rosiglitazone was also administered to demonstrate whether improved insulin sensitivity would prevent high-purine diet induced renal injury and gouty-like lesions." | 3.75 | Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions. ( Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S, 2009) |
| " At moderate or high doses, an effect on any one marker may be absent or even the opposite of that observed at very high or excessive doses; examples include fasting plasma triglyceride, insulin sensitivity, and the putative marker uric acid." | 3.75 | Fructose ingestion: dose-dependent responses in health research. ( Livesey, G, 2009) |
| "Allopurinol was administered to end-stage renal disease (ESRD) patients with elevated uric acid levels presenting with symptoms of gout and also had risk factors of metabolic syndrome." | 3.75 | The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. ( Beavers, D; Bowden, RG; Hartman, J; Shelmadine, B; Wilson, RL, 2009) |
| " In both sexes, those who developed diabetes were slightly older, were more obese, had a more adverse metabolic profile (higher glucose values, HbA(1c), fasting insulin, uric acid, and triglycerides) and were more likely to have hypertension at baseline than were participants remaining free of diabetes (P < 0." | 3.75 | Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. ( Giani, G; Heier, M; Holle, R; Meisinger, C; Rathmann, W; Strassburger, K; Thorand, B, 2009) |
| "The relationship between serum uric acid (SUA) and risk of coronary heart disease (CHD) mortality remains controversial, particularly in diabetic subjects." | 3.74 | Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL). ( Casiglia, E; Mazza, A; Pessina, AC; Rizzato, E; Schiavon, L; Tikhonoff, V; Zamboni, S, 2007) |
| "Plasma levels for fasting glucose, glycosylated hemoglobin, ceruloplasmin and serum concentrations for fructosamine and uric acid were significantly increased in diabetic foot patients vs." | 3.74 | Diabetic foot patients with and without retinopathy and plasma oxidative stress. ( Coman, A; Găman, L; Greabu, M; Gruia, V; Mohora, M; Muscurel, C; Vîrgolici, B, 2007) |
| "Elevated serum uric acid level is associated with obesity, insulin resistance, diabetes, nephropathy, and hypertension." | 3.74 | Genome scan for determinants of serum uric acid variability. ( Abboud, HE; Arar, NH; Bauer, R; Blangero, J; Comuzzie, AG; Lopez-Alvarenga, JC; MacCluer, JW; Nath, SD; Thameem, F; Voruganti, VS, 2007) |
| "Type 2 diabetes is associated with an increased risk of nephrolithiasis, specifically in the form of uric acid (UA) nephrolithiasis." | 3.74 | Diabetes and nephrolithiasis. ( Daudon, M; Jungers, P, 2007) |
| " The aim of this study was to evaluate the relationships between serum uric acid concentration and degree of urinary albumin excretion as well as markers of subclinical atherosclerosis in men with type 2 diabetes mellitus." | 3.74 | Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus. ( Asano, M; Fukui, M; Harusato, I; Hasegawa, G; Hosoda, H; Kadono, M; Nakamura, N; Shiraishi, E; Tanaka, M; Yoshikawa, T, 2008) |
| "High serum uric acid levels lead to gout and have been reported to be associated with an increased risk of hypertension, obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease." | 3.74 | Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI. ( Adams, TD; Brandstätter, A; Coassin, S; Heid, IM; Hopkins, PN; Hunt, SC; Illig, T; Kiechl, S; Kollerits, B; Kronenberg, F; Willeit, J, 2008) |
| "The levels of the liporegulatory hormone leptin are increased in obesity, which contributes to the metabolic syndrome; the latter is associated with elevated cardiovascular risk and morbidity." | 3.73 | Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans. ( Chraibi, A; Israili, ZH; Lyoussi, B; Mguil, M; Ragala, MA, 2005) |
| "The respective uric acid levels for normoalbuminuria (N= 166), microalbuminuria (N= 130), and macroalbuminuria (N= 47) were 5." | 3.73 | Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. ( Tseng, CH, 2005) |
| " Lipid profiles, ACR, bilirubin, uric acid, creatine kinase, and hsCRP were not changed in DM patients with different diabetic duration or diabetic retinopathy." | 3.73 | Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. ( Chang, MH; Chen, TH; Chen, YJ; Hsu, HH; Huang, CY; Huang, EJ; Kuo, WW; Lee, SD; Lu, MC; Tzang, BS, 2006) |
| " Because insulin resistance, characteristic of the metabolic syndrome and type 2 diabetes, results in lower urine pH through impaired kidney ammoniagenesis and because a low urine pH is the main factor of uric acid (UA) stone formation, it was hypothesized that type 2 diabetes should favor the formation of UA stones." | 3.73 | Type 2 diabetes increases the risk for uric acid stones. ( Conort, P; Daudon, M; Jungers, P; Lacour, B; Traxer, O, 2006) |
| "To test the hypothesis that stone-forming patients with type II diabetes (DM-II) have a high prevalence of uric acid (UA) stones and present with some of the biochemical features of gouty diathesis (GD)." | 3.72 | Biochemical profile of stone-forming patients with diabetes mellitus. ( Ekeruo, W; Moe, O; Pak, CY; Peterson, RD; Pietrow, P; Poindexter, JR; Preminger, GM; Sakhaee, K, 2003) |
| "We examined the association of serum uric acid (SUA) with development of hypertension (blood pressure > or = 140/90 mmHg and/or medication for hypertension) and impaired fasting glucose (IFG) (a fasting plasma glucose level 6." | 3.72 | Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. ( Matsuo, Y; Nakanishi, N; Okamoto, M; Suzuki, K; Tatara, K; Yoshida, H, 2003) |
| " The objective of the present study was determination of incidence of selected risk factors of IHD, such as overweight and obesity, tobacco smoking, arterial hypertension, type 2 diabetes mellitus, dyslipidaemia, and elevated serum concentration of uric acid." | 3.72 | Selected risk factors of ischemic heart disease in Polish seafarers. Preliminary report. ( Filikowski, J; Renke, W; Rzepiak, M; Smolińska, D; Winnicka, A, 2003) |
| " The aim of our study was to evaluate the relation of SPECT result to diabetes compensation, presence of micro/macroalbuminuria, blood level of fibrinogen, CRP, homocysteine and uric acid." | 3.72 | [Relation between diabetes compensation, albuminuria and biochemical parameters and the results of stress myocardial SPECT in asymptomatic type 2 diabetics]. ( Charvát, J; Chlumský, J; Kvapil, M; Michalová, K; Táborská, K; Vojácek, J, 2004) |
| " Except for them, the gamma-GTP level was positively correlated with levels of insulin resistance, uric acid, total cholesterol, triglyceride, and body mass index." | 3.71 | Significant correlation between insulin resistance and serum gamma-glutamyl transpeptidase (gamma-GTP) activity in non-drinkers. ( Hirose, H; Moriya, S; Saito, I; Yokoyama, H, 2002) |
| "Male type 2 diabetic patients with stroke had significantly higher mean levels of serum uric acid than simple diabetic patients, but such patients of both genders all had lower HDL levels." | 3.71 | [Serum uric acid in type 2 diabetic patients complicated by stroke]. ( Gao, F; Guan, MP; Li, CZ; Liu, SQ; Shen, J; Xue, YM; Zhou, L, 2002) |
| " When the cluster of metabolic syndrome was analyzed, SG was inversely related to uric acid levels and to the waist-hip index." | 3.71 | [Glucose effectiveness and components of the metabolic syndrome in recently diagnosed hypertensive patients]. ( Carneado de la Fuente, J; García Morillo, JS; García-Junco, PS; Miranda Guisado, ML; Muñiz Grigalvo, O; Pamies Andreu, E; Vallejo Maroto, I; Villar Ortiz, J, 2002) |
| "To assess the impacts of insulin resistance and renal function on plasma total homocysteine (tHcy) levels in patients with type 2 diabetes with a wide range of nephropathy." | 3.71 | Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. ( Emoto, M; Inaba, M; Ishimura, E; Kanda, H; Kawagishi, T; Komatsu, M; Mori, K; Nishizawa, Y; Okuno, Y; Shoji, T; Tahara, H, 2001) |
| "To investigate the association of serum uric acid level with the risk for hypertension and Type 2 diabetes." | 3.71 | Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. ( Endo, G; Fujii, S; Hayashi, T; Okada, K; Taniguchi, Y; Tsumura, K, 2001) |
| "High uric acid concentration is a common finding in subjects with risk factors for cardiovascular disease (CVD), including some characteristics of the metabolic syndrome." | 3.71 | Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome. ( Bedini, J; Conget, I; Costa, A; Igualá, I; Quintó, L, 2002) |
| " The serum leptin concentration, body mass index (BMI), percent body fat, total fat mass (FM), waist and hip circumference, waist to hip ratio (WHR), prevalence of hypertension, and triglyceride (TG), lipoprotein, and uric acid concentration were determined in 86 type 2 diabetic (n = 59) and healthy (n = 27) subjects." | 3.70 | Serum leptin is associated with serum uric acid concentrations in humans. ( Beyer, J; Fruehwald-Schultes, B; Kern, W; Peters, A; Pfützner, A, 1999) |
| "family history of T2DM on the maternal side increased both systolic blood pressure and serum uric acid level in probands, without modification in their insulin sensitivity." | 3.70 | Maternal effect of Type 2 diabetes mellitus on insulin sensitivity and metabolic profile in healthy young Mexicans. ( González-Ortiz, M; Martínez-Abundis, E, 1999) |
| " In 273 Type 2 diabetics, serum uric acid was analysed against basic demographic data (age, sex, smoking and alcohol habits, body mass index, number of years since the diagnosis of diabetes), present medications, control of diabetic state (attending physician's estimation of the patient's diet compliance, fasting serum sugar, HbA1c), and complications (serum creatinine, total cholesterol, triglyceride, urine proteinuria, retinopathy, last blood pressure readings, history of hypertension, coronary heart disease, stroke)." | 3.70 | Hyperuricaemia in Type 2 diabetes mellitus. ( Chan, CS; Lui, CS; Wun, YT, 1999) |
| " Patients within the lowest C-peptide quartile showed significantly higher duration of diabetes, prevalence of retinopathy and values of HDL-cholesterol, albumin excretion rate and HbA1c, while BMI, diastolic blood pressure, percentages of hypertension and metabolic syndrome, and values of triglycerides and uric acid were significantly higher in the highest C-peptide quartile." | 3.70 | Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. ( Bo, S; Cavallo-Perin, P; Gentile, L; Pagano, G; Repetti, E, 2000) |
| "The aim of the present study was to evaluate the relationship of C-peptide and the C-peptide/bloodsugar ratio with clinical/biochemical variables presenting a well-known association with insulin resistance in NIDDM patients in acceptable control, obtained without the use of exogenous insulin." | 3.69 | Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. ( Acosta, D; Astorga, R; García de Pesquera, F; Losada, F; Morales, F; Pumar, A; Relimpio, F, 1997) |
| "The relationship between elevated serum uric acid (SUA) and coronary heart disease (CHD) is discussed controversially." | 3.68 | Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. ( Dannehl, K; Gries, FA; Hauner, H; Rathmann, W, 1993) |
| "To investigate the risk factors for acute ischemic stroke (AIS) in patients with type 2 diabetes mellitus (T2DM) patients." | 3.30 | Risk factors for acute ischemic stroke in patients with type 2 diabetes mellitus. ( Li, X; Liu, J; Qu, J, 2023) |
| "A total of 7020 patients with type 2 diabetes (T2D) were randomized to either empagliflozin (10 or 25 mg) or placebo." | 3.11 | Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. ( Ferreira, JP; Inzucchi, SE; Mattheus, M; Meinicke, T; Steubl, D; Wanner, C; Zinman, B, 2022) |
| "Undertreated, gout can progress to palpable tophi and joint damage." | 3.01 | Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. ( Terkeltaub, R, 2023) |
| "Records of 63 subjects with type 2 diabetes mellitus, receiving EMPA were drawn for this study." | 3.01 | Effects of empagliflozin on proinflammatory cytokines and other coronary risk factors in patients with type 2 diabetes mellitus: A single-arm real-world observation. ( Fatima, G; Fedacko, J; Isaza, A; Joshi, S; Kumar, P; Maheshwari, A; Mojto, V; Saboo, B; Saxena, M; Singh, RB; SinghVerma, N, 2021) |
| "Patients with type 2 diabetes and CV disease received empagliflozin or placebo." | 2.94 | Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. ( Al-Omran, M; Bhatt, DL; Fitchett, D; George, JT; Inzucchi, SE; Ji, Q; Mazer, CD; Ofstad, AP; Verma, S; Wanner, C; Zinman, B; Zwiener, I, 2020) |
| "Fourteen subjects with type 2 diabetes (aged 49·5 (sd 8·6) years, BMI 29·4 (sd 4·5) kg/m2, low habitual Ca consumption (<600 mg/d)) were included in this randomised, crossover clinical trial." | 2.90 | High calcium intake from fat-free milk, body composition and glycaemic control in adults with type 2 diabetes: a randomised crossover clinical trial. ( Alfenas, RCG; de Assis Costa, J; Gomes, JMG; Ribeiro, PVM, 2019) |
| "Insulin sensitivity was assessed by hyperinsulinaemic-euglycaemic clamps and cardiovascular variables were measured." | 2.84 | Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: A randomized clinical trial. ( Hornemann, S; Markova, M; Pfeiffer, AFH; Pivovarova, O; Rohn, S; Rudovich, N; Schneeweiss, R; Sucher, S; Thomann, R, 2017) |
| "Gout is a common hyperuricaemic metabolic condition that leads to painful inflammatory arthritis and a high comorbidity burden, especially cardiometabolic-renal (CMR) conditions, including hypertension, myocardial infarction, stroke, obesity, hyperlipidaemia, type 2 diabetes mellitus and chronic kidney disease." | 2.82 | Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. ( Choi, HK; McCormick, N; Yokose, C, 2022) |
| " The linear dose-response analysis revealed that the risk of DKD increased by 24% for each 1 mg/dl increase of SUA." | 2.82 | Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis. ( Feng, J; Ji, P; Li, H; Qin, H; Wei, L; Yu, Q; Zhang, J; Zhu, J, 2022) |
| "Hypertension is common in CKD patients and many mechanisms inducing it (upregulation of renin-angiotensin-aldosterone system, endothelial dysfunction and atherosclerosis) may be influenced by XOR products." | 2.82 | Chronic kidney disease: Which role for xanthine oxidoreductase activity and products? ( Battelli, MG; Bolognesi, A; Bortolotti, M; Polito, L, 2022) |
| "Hyperuricemia is associated with the presence and severity of obstructive sleep apnea (OSA)." | 2.78 | Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial. ( Prudon, B; Roddy, E; Stradling, JR; West, SD, 2013) |
| "Hyperuricemia is associated with insulin resistance, pancreatic β-cell dysfunction and consequently with development of type 2 diabetes." | 2.72 | Uric acid-induced pancreatic β-cell dysfunction. ( Ghasemi, A, 2021) |
| "Patients with type 2 diabetes and UASF had lower 24-h urine pH than NV." | 2.72 | Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. ( Adams-Huet, B; Cameron, MA; Maalouf, NM; Moe, OW; Sakhaee, K, 2006) |
| "The mean SUA level of patients having type 2 diabetes was significantly lower than that of control subjects (6." | 2.71 | Association of a 27-bp repeat polymorphism in intron 4 of endothelial constitutive nitric oxide synthase gene with serum uric acid levels in Chinese subjects with type 2 diabetes. ( Chang, DM; Lee, YJ; Tsai, JC, 2003) |
| "Ten male subjects with untreated type 2 diabetes were given, in random sequence, 50 g protein in the form of very lean beef or only water at 0800 h and studied over the subsequent 8 h." | 2.70 | Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes. ( Damberg, G; Gannon, MC; Gupta, V; Nuttall, FQ; Nuttall, JA, 2001) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| " Although there were no statistically significant differences among the 100-, 200-, and 300-mg treatment groups, there was a trend toward a dose-response relationship for most plasma glucose variables that were measured." | 2.68 | Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. ( Beisswenger, P; Coniff, RF; Kleinfield, R; McGill, JB; Robbins, D; Seaton, TB; Shapiro, JA, 1995) |
| "Obesity was prevalent in both groups." | 2.67 | [Forestier disease and metabolism disorders. A prospective controlled study of 25 cases]. ( Gerster, JC; Troillet, N, 1993) |
| "This has been ascribed, in part, to haemodynamic changes, body weight reduction and several possible effects on myocardial, endothelial and tubulo-glomerular functions, as well as to reduced glucotoxicity." | 2.61 | Uric acid and the cardio-renal effects of SGLT2 inhibitors. ( Bailey, CJ, 2019) |
| "Treatment with empagliflozin resulted in a superior reduction in SUA (WMD -45." | 2.58 | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. ( Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H, 2018) |
| "Hyperuricemia has been linked to metabolic syndrome, cardiovascular disease, and chronic kidney disease." | 2.55 | Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. ( Ahmadieh, H; Azar, S, 2017) |
| "Hyperuricemia has recently emerged as an independent risk factor in the development of type 2 diabetes mellitus and hypertension through several proposed mechanisms." | 2.55 | Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association. ( Mortada, I, 2017) |
| "Gout is both an inflammatory and a metabolic disease." | 2.55 | Gout and Metabolic Syndrome: a Tangled Web. ( Krasnokutsky, S; Pillinger, MH; Thottam, GE, 2017) |
| "Hyperuricemia was also significantly associated with increased risk of peripheral neuropathy in patients with type 2 diabetes (risk ratio [RR] = 2." | 2.53 | Serum Uric Acid Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysis. ( Che, K; Chen, Y; Hou, X; Li, C; Wang, B; Wang, Y; Xu, D; Yan, S; Yu, S, 2016) |
| " Dose-response analysis showed the risk of type 2 diabetes was increased by 6% per 1 mg/dl increment in serum uric acid level (RR 1." | 2.49 | High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. ( Chen, S; Gao, P; He, FF; Huang, K; Liu, JS; Lv, Q; Meng, XF; Su, H; Tian, XJ; Xiong, J; Zhang, C; Zhu, ZH, 2013) |
| " Dose-response relationship was assessed by restricted cubic spline model and multivariate random-effect meta-regression." | 2.49 | Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. ( Jia, Z; Kang, S; Wu, Y; Zhang, X, 2013) |
| "Hyperuricemia is a specific risk factor for cardiovascular morbidity and mortality." | 2.47 | [Hyperuricemia and uro-nephrological disorders]. ( Hurtes, X; Meria, P, 2011) |
| "In contrary, the so-called type 2 diabetes is a multifactorial, often hyperinsulinaemic condition of insulin resistance and it occurs mainly in the adults." | 2.40 | [From type 2 diabetes to metabolic X syndrome]. ( Pogátsa, G, 1999) |
| "Insulin resistance/hyperinsulinemia, in turn, is associated with a series of hypertensiogenic and atherogenic side effects, aggravating the individual components of the metabolic syndrome." | 2.39 | [The metabolic syndrome. Pathophysiologic causes, diagnosis, therapy]. ( Rett, K; Standl, E; Wicklmayr, M, 1994) |
| "One hundred sixty NIDDM patients who had undergone the clamp study were stratified into 5 groups according to the serum uric acid level." | 2.39 | [Hyperuricemia and insulin resistance]. ( Iwatani, M; Katsumori, K; Saeki, A; Wasada, T, 1996) |
| "However, in women, the risk of type 2 diabetes incidence was higher in the group with uric acid levels 5." | 1.91 | Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11. ( Fukui, M; Hamaguchi, M; Ito, M; Kobayashi, G; Kurogi, K; Murata, H; Okada, H, 2023) |
| "The baseline hyperinsulinemia-follow-up hyperuricemia group showed the highest incidence rate of T2DM (27." | 1.91 | Bidirectional temporal relationships between uric acid and insulin and their joint impact on incident diabetes. ( Bazzano, L; Chen, W; Fan, L; He, J; Li, S; Sun, D; Wang, X; Yan, Y; Zhang, T, 2023) |
| "Uric acid is a kind of natural antioxidant that plays a major role in the antioxidant capacity against oxidative stress." | 1.91 | Serum Uric Acid Levels Are Related to Diabetic Peripheral Neuropathy, Especially for Motor Conduction Velocity of Tibial Nerve in Type 2 Diabetes Mellitus Patients. ( Chen, Y; He, M; Vladmir, C; Wang, W; Xu, J; Zhang, H; Zhang, Y; Zhang, Z; Zhao, W; Zhou, W, 2023) |
| "Fifty-five patients with type II diabetes mellitus were divided into two groups: case and control." | 1.91 | Serum Levels of Indoxyl Sulfate and P-cresol in Type II Diabetic Patients With and Without Nephropathy. ( Aliasgharzadeh, A; Jouyban, A; Moradi, M; Oladi-Ghadikolaei, R; Shayanfar, A; Soleymani, J; Tayebi Khosroshahi, H, 2023) |
| "In total, 673 patients with type 2 diabetes met the inclusion criteria." | 1.91 | The Triglyceride Glucose (TyG) Index as a Sensible Marker for Identifying Insulin Resistance and Predicting Diabetic Kidney Disease. ( Li, HF; Li, Y; Miao, X, 2023) |
| "Abdominal obesity is the strongest risk factor for type 2 diabetes in lean nonalcoholic fatty liver disease." | 1.91 | Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period. ( Chang, M; Li, D; Li, N; Tan, H; Wu, S; Xang, W; Xie, C; Zhang, MY, 2023) |
| "In cinical, some acute pancreatitis patients with diabetes may have diabetic ketoacidosis (DKA)." | 1.91 | Risk factors for diabetic ketoacidosis in acute pancreatitis patients with type 2 diabetes. ( Li, L, 2023) |
| "Uric acid was also found to have significant positive correlation with triglyceride (r = ." | 1.91 | Correlation of Serum Uric Acid and Lipid Profile in Patients with Type 2 Diabetes Mellitus. ( Khanal, MP; Malla, P; Pathak, S; Pokhrel, A; Sah, B; Sapkota, S; Subedi, A, 2023) |
| "First-degree relatives (FDR) of type 2 diabetes mellitus have increased risk of developing insulin resistance-related disorders including hyperuricemia." | 1.91 | The role of high fat diet on serum uric acid level among healthy male first degree relatives of type 2 diabetes mellitus. ( Muhadi, M; Purnamasari, D; Tahapary, DL; Tarigan, TJE; Tricaesario, C; Umpuan, ARM; Wisnu, W, 2023) |
| "In this study, type 2 diabetes (T2D), sex, and menopausal status were combined to refine the stratification of obesity regarding the risk of advanced SLD and gain further insight into disease physiopathology." | 1.91 | Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study. ( Baud, G; Bauvin, P; Caiazzo, R; Chatelain, E; Chetboun, M; Gnemmi, V; Lasailly, G; Lefebvre, P; Legendre, B; Leteurtre, E; Marciniak, C; Marot, G; Mathurin, P; Oukhouya-Daoud, N; Pattou, F; Raverdy, V; Staels, B; Vandel, J; Vantyghem, MC; Verkindt, H, 2023) |
| "Collectively, Gln attenuates diabetic nephropathy and other complications in type 2 diabetes mellitus in rats through its antioxidant and anti-inflammatory activities." | 1.91 | Exogenous glutamine ameliorates diabetic nephropathy in a rat model of type 2 diabetes mellitus through its antioxidant and anti-inflammatory activities. ( Adibhesami, G; Ahmadvand, H; Babaeenezhad, E; Mahdavifard, S; Nasri, M, 2023) |
| "Incidence rate for ESRD among patients with no episodes of AKI and one, two, and three or more episodes of AKI was 7." | 1.72 | Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes. ( Chan, JCN; Cheng, YL; Chow, CC; Chow, EYK; Fan, B; Fung, S; Hiu, G; Huang, Y; Jiang, G; Kam, G; Kong, APS; Lan, HY; Lau, E; Lau, ES; Lau, IT; Lau, KP; Lee, KF; Leung, JY; Li, JK; Lim, CKP; Lo, S; Luk, AO; Ma, RCW; Oram, RA; Ozaki, R; Siu, SC; So, WY; Szeto, CC; Tam, CHT; Tang, NLS; Tsang, CC; Tsang, MW; Yeung, VT, 2022) |
| "In total, 230 patients with type 2 diabetes were examined." | 1.72 | The relation between serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes in Guilan, north of Iran. ( Assadinia, AS; Fayazi, HS; Mortazavi, SS; Sharifhassan, Z; Yaseri, M, 2022) |
| "Insulin sensitivity was assessed using Homeostatic Model Assessment of Insulin Resistance and the Matsuda Insulin Sensitivity Index." | 1.72 | Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. ( Dufour, S; Li, F; Petersen, KF; Rothman, DL; Shulman, GI, 2022) |
| "Low-grade inflammation has been postulated to have a key role in the pathogenesis of MetS and has been linked to insulin resistance (IR)." | 1.72 | Association Between Low-Grade Inflammation and Hyperuricemia in Adults With Metabolic Syndrome in Yucatán, México. ( Avila-Nava, A; Banik, SD; Chim Aké, R; Gutiérrez Solis, AL; Lugo, R, 2022) |
| "Patients with type 2 diabetes mellitus hospitalized over the period between January 2010 and September 2018 were retrospectively collected." | 1.72 | Using Machine Learning Techniques to Develop Risk Prediction Models for the Risk of Incident Diabetic Retinopathy Among Patients With Type 2 Diabetes Mellitus: A Cohort Study. ( Chen, W; Dong, M; Gao, Z; Li, P; Li, S; Li, X; Liu, X; Yu, H; Yu, Q; Zhang, M; Zhao, Y, 2022) |
| "Diabetic nephropathy is one of the chronic microvascular complications of diabetes and is a leading cause of end-stage renal disease." | 1.72 | Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy. ( Li, N; Zhou, H, 2022) |
| "Subjects with type 2 diabetes mellitus (T2DM) are susceptible to osteoporosis." | 1.72 | Increased Glycemic Variability Evaluated by Continuous Glucose Monitoring is Associated with Osteoporosis in Type 2 Diabetic Patients. ( Cai, T; Ding, B; Huang, R; Li, H; Ma, J; Shen, Z; Wang, H; Wang, Y; Wu, J; Xia, W; Yan, R; Zhou, Y, 2022) |
| "299 patients with type 2 diabetes mellitus (T2DM) hospitalized in the Second Affiliated Hospital of Soochow University were enrolled." | 1.72 | Genomic DNA Methylation in Diabetic Chronic Complications in Patients With Type 2 Diabetes Mellitus. ( Hu, J; Jiang, M; Wang, X; Yang, W; Zhang, HH; Zhang, S; Zhu, Y, 2022) |
| "Obesity is an important risk factor for hyperuricemia." | 1.72 | The perirenal fat thickness was independently associated with serum uric acid level in patients with type 2 diabetes mellitus. ( Cheng, Y; Fang, Y; Ke, J; Ma, Y; Xu, Y; Yang, Y; Zhao, D, 2022) |
| "Phthalimide derivatives have been extensively researched with various biological actions." | 1.72 | Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance. ( da Rocha, IG; da Silva Júnior, JG; da Silva Neto, JC; de Araújo, HDA; de Menezes Lima, VL; de Oliveira Assis, SP; Oliveira, RN, 2022) |
| "This study was to investigate the correlation between glycated haemoglobin (HbA1c) level, cardiac function, and prognosis in patients with diabetes mellitus combined with myocardial infarction." | 1.72 | Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction. ( An, H; Fang, D; Li, W; Sun, M; Zeng, G; Zheng, Q, 2022) |
| "The relationship between XO levels and type 2 diabetes (T2D) is not clear yet or little is known so far." | 1.72 | Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: a cross-sectional study. ( Ali, N; Barman, Z; Fariha, KA; Habib, A; Hasan, M; Miah, R; Mou, AD; Tuba, HR, 2022) |
| "Hyperuricemia has been associated with a number of chronic diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases." | 1.62 | Dietary Acid Load Is Positively Associated with the Incidence of Hyperuricemia in Middle-Aged and Older Korean Adults: Findings from the Korean Genome and Epidemiology Study. ( Lee, KW; Shin, D, 2021) |
| "Hyperuricemia was not significantly associated to uncontrolled diabetes (OR=2." | 1.62 | Association between hyperuricemia and glycated hemoglobin in type 2 diabetes at the District Hospital of Dschang. ( Donkeng, M; Koudjou, PN; Kuaté, D; Kuiate, JR; Noubiap, JJ, 2021) |
| "Patients with type 2 diabetes mellitus (T2DM) are susceptible to coexisted with chronic kidney disease (CKD), which may increase cardiovascular mortality in these patients." | 1.62 | The additive effects of kidney dysfunction on left ventricular function and strain in type 2 diabetes mellitus patients verified by cardiac magnetic resonance imaging. ( Jiang, L; Li, Y; Ren, Y; Wang, J; Yan, WF; Yang, ZG; Zhang, Y, 2021) |
| "The odds of NAFLD were increasingly higher from the second to the fourth quartile of SUA as compared to the lowest quartile." | 1.62 | Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. ( Cui, Y; Hu, W; Liu, J; Shi, H; Song, L; Zhao, Q, 2021) |
| "In the reverse direction analysis, genetic predisposition to both urate and gout were not associated with T2D or any of 4 glycemic traits being investigated." | 1.62 | Genetic Predisposition to Type 2 Diabetes and Insulin Levels Is Positively Associated With Serum Urate Levels. ( Fan, J; Li, Y; Sun, L; Tse, LA; Yang, J; Zhu, J, 2021) |
| "Participants with osteopenia or osteoporosis documented by dual-energy X-ray absorptiometry were defined as having "at least osteopenia." | 1.62 | Association between serum uric acid and bone mineral density in patients with type 2 diabetes: A 6-year longitudinal study in China. ( Huang, D; Liu, B; Miao, H; Ping, Z; Wu, X; Yang, K; Zhao, R; Zheng, S, 2021) |
| "Allopurinol treatment significantly reduced hepatic steatosis, epididymal fat, serum UA, HOMA-IR, hepatic enzyme levels, and cholesterol in the OLETF-HFrD-Allo group." | 1.62 | Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway. ( Ahn, KJ; Cho, IJ; Chung, HY; Hwang, YC; Jeong, IK; Jeong, SW; Lee, SH; Lim, SJ; Moon, JY; Oh, DH; Yoo, J, 2021) |
| "When uric acid was examined as a continuous variable, multivariable-adjusted HR of diabetes for each 1 mg/dL (60 μmol/L) increase in serum uric acid was 1." | 1.62 | Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China. ( Fan, Y; Hu, G; Li, Y; Liu, M; Liu, T; Meng, Z; Su, H; Wang, B; Zhang, Q, 2021) |
| "Comparative analysis with obesity, type 2 diabetes, ankylosing spondylitis and rheumatoid arthritis indicated that gout metagenomes were more similar to those of autoimmune than metabolic diseases." | 1.62 | Metagenomic analysis revealed the potential role of gut microbiome in gout. ( Bai, X; Chen, X; Chu, Y; Ding, F; Fang, X; Gao, Q; He, X; Huang, Q; Huang, R; Huang, Y; Jiang, Y; Li, J; Liang, L; Sun, S; Wang, M; Wang, P; Wang, Z; Wei, X; Wu, J; Wu, X; Xie, X; Yang, J; Yue, Z; Zhang, Y; Zhao, Y; Zhou, C, 2021) |
| "Sarcopenia has been recognized as a diabetic complication, and hyperuricemia is often accompanied by type 2 diabetes mellitus (T2DM)." | 1.62 | Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus. ( Kanazawa, I; Notsu, M; Sugimoto, T; Tanaka, KI, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) commonly occurs in patients with type 2 diabetes mellitus (T2DM)." | 1.56 | Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. ( Chen, W; He, M; Li, S; Liu, D; Long, M; Peng, J; Wang, C; Yang, G; Zhang, L, 2020) |
| "Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline." | 1.56 | The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. ( Cain, V; Correa-Rotter, R; Heerspink, HJL; Sartipy, P; Scholtes, RA; Sjöström, CD; Stefánsson, BV; Toto, RD; van Raalte, DH, 2020) |
| "This positive gradient for the risk of type 2 diabetes across quartiles of SUA was evident in both genders and across age groups." | 1.56 | Serum Uric Acid Level as a Harbinger of Type 2 Diabetes: A Prospective Observation in Taiwan. ( Bai, CH; Chou, YC; Lai, YW; Liao, YC; Sun, CA; Wu, WC; You, SL, 2020) |
| "Median time to recurrence was 64 months." | 1.56 | Predictive Factors for Kidney Stone Recurrence in Type 2 Diabetes Mellitus. ( Monga, M; Prasanchaimontri, P, 2020) |
| "Gout is the most prevalent inflammatory arthritis in adults." | 1.56 | Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study. ( Chung, YL; Fang, YJ; Lim, YP; Lin, CL, 2020) |
| "A total of 518 individuals with type 2 diabetes were included." | 1.56 | Associations of serum uric acid and urinary albumin with the severity of diabetic retinopathy in individuals with type 2 diabetes. ( Chen, D; Liu, Y; Sun, X; Zhao, X, 2020) |
| "Drug-naïve subjects with type 2 diabetes (T2DM) received 50 - 100 mg/day canagliflozin monotherapy (n = 40) for 3 months." | 1.51 | Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function . ( Hayashi, J; Kuto, AN; Kutoh, E; Wada, A, 2019) |
| "We recruited 98 Taiwanese patients with type 2 diabetes and 10 patients with early chronic kidney disease (CKD) into this study." | 1.51 | Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy. ( Chen, CM; Chen, HL; Kuo, CW; Tu, MY, 2019) |
| "Gout is independently associated with increased risk of type 2 diabetes mellitus (T2DM)." | 1.51 | Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. ( Chang, HW; Lan, YC; Lin, MH; Lin, YW; Wang, RY, 2019) |
| "Hyperuricemia was common in youth with T2D." | 1.51 | Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu ( Bjornstad, P; El Ghormli, L; Laffel, L; Lynch, J; Nadeau, KJ; Tollefsen, SE; Weinstock, RS, 2019) |
| "Type 2 diabetes was induced by dietary manipulation for 56 days via (high fat- high fructose diet) and intraperitoneal administration of streptozocin (30 mg/kg)." | 1.51 | The freeze-dried extracts of Rotheca myricoides (Hochst.) Steane & Mabb possess hypoglycemic, hypolipidemic and hypoinsulinemic on type 2 diabetes rat model. ( Chege, BM; Frederick, B; Nyaga, NM; Waweru, MP, 2019) |
| "NAFLD was determined by hepatic ultrasonography, then its clinical features were analyzed and its associated risk factors evaluated." | 1.48 | Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. ( Chen, MY; Jia, WP; Li, LX; Li, TT; Lu, JX; Tang, ZH; Wang, AP; Zhao, CC, 2018) |
| "Hepatic insulin resistance was estimated by the liver IR index." | 1.48 | Higher serum levels of uric acid are associated with a reduced insulin clearance in non-diabetic individuals. ( Andreozzi, F; Fiorentino, TV; Hribal, ML; Pedace, E; Perticone, F; Sciacqua, A; Sesti, F; Sesti, G; Succurro, E, 2018) |
| "Uric acid is a final breakdown product of purine catabolism in humans." | 1.46 | Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus. ( Azreen-Redzal, A; Nyi-Nyi, N; Vinuthinee-Naidu, MN; Zunaina, E, 2017) |
| "Urolithiasis is common and is becoming more prevalent worldwide." | 1.46 | Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients. ( Ha, YS; Kang, HW; Kim, WJ; Kim, WT; Kim, YJ; Lee, SC; Seo, SP; Yun, SJ, 2017) |
| "Type 2 diabetes was induced in three groups using high-fat diet combined with a single dose of streptozotocin (35mg/kg body weight, intraperitoneally)." | 1.46 | Pancreatic and renal function in streptozotocin-induced type 2 diabetic rats administered combined inositol hexakisphosphate and inositol supplement. ( Alexander-Lindo, RL; Dilworth, LL; Foster, SR; Omoruyi, FO; Thompson, R, 2017) |
| "A total of 8274 patients with type 2 diabetes from the Shanghai Diabetes Registry (SDR) participated." | 1.43 | Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study. ( Bao, Y; Deng, Z; Gu, Y; Hou, X; Hu, C; Jia, W; Zhang, L, 2016) |
| "In 3207 type 2 diabetes patients, seventeen SNPs (single nucleotide polymorphisms) related to uric acid were genotyped." | 1.43 | A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis. ( Bao, Y; Chen, H; He, Z; Hu, C; Jia, W; Jiang, F; Peng, D; Wang, J; Wang, S; Wang, T; Yan, D; Zhang, R, 2016) |
| "There was an obvious increase in both NAFLD prevalence (26." | 1.43 | Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes. ( Bao, YQ; Chen, MY; Jia, WP; Li, LX; Li, TT; Wang, AP; Yu, TP; Zhao, CC; Zhu, Y, 2016) |
| "Furthermore, the prevalence rate of NAFLD increased progressively across the sex-specific SUA tertiles only in men (37." | 1.43 | Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. ( Fan, N; Peng, L; Peng, Y; Wang, Y; Xia, Z; Zhang, L, 2016) |
| "Patients with type 2 diabetes mellitus (DM) may experience chronic microvascular complications such as diabetic retinopathy (DR) and diabetic nephropathy (DN) during their lifetime." | 1.43 | Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus. ( Chen, SC; Hsiao, PJ; Hsu, WH; Lee, MY; Liang, CC; Lin, KD; Lin, PC; Shin, SJ, 2016) |
| "Metformin is a biguanaide antidiabetic drug used worldwide, and its effectiveness and benefits have already been established." | 1.43 | Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin. ( Hiraoka, S; Nishihara, M; Tsuji, H; Yokoyama, S, 2016) |
| "Early detection diabetic nephropathy (DN) is important." | 1.43 | Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. ( Fathy, H; Fouad, M; Zidan, A, 2016) |
| " B06-treated groups were given B06 by gavage at a dosage of 0." | 1.42 | [Protective effect of curcumin derivative B06 on kidney of type 2 diabetic rats]. ( Chen, GR; Chen, SM; Cheng, JG; Liu, WW; Liu, X; Wang, L; Zeng, CC, 2015) |
| "Uric acid was positively correlated with albuminuria and creatinine levels (p < 0." | 1.42 | Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population. ( Bao, Y; Hu, C; Jia, W; Jiang, F; Sun, X; Tu, Y; Wang, J; Wang, S; Wang, T; Yan, D; Zhang, R, 2015) |
| "Uric acid was not significantly associated with stiffness of the aorta, or the carotid or femoral artery among adults aged 40-75 years without and with type 2 diabetes mellitus." | 1.42 | Association between serum uric acid, aortic, carotid and femoral stiffness among adults aged 40-75 years without and with type 2 diabetes mellitus: The Maastricht Study. ( Arts, IC; Boonen, A; Dagnelie, PC; Henry, RM; Koster, A; Schram, MT; Sep, SJ; Stehouwer, CD; van der Kallen, CJ; van der Linden, S; van Sloten, TT; Wijnands, JM, 2015) |
| "Genotype TT is associated with type 2 diabetes (OR = 2." | 1.42 | [The study of the association of polymorphism rs5219 gene KCNJ11 with obesity and the risk of type 2 diabetes among residents of the Moscow Region]. ( Baturin, AK; Makurina, ON; Peskova, EV; Pogozheva, AV; Sorokina, EY; Tutelyan, VA, 2015) |
| "The risk factors for T2DM patients with NAFLD are mainly BMI, WHR, TG, and SUA." | 1.42 | The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid. ( Li, YL; Mei, CX; Musha, H; Wang, HJ; Wulasihan, M; Xie, H; Xing, Y, 2015) |
| "Sixty patients with type 2 diabetes mellitus were enrolled to the study." | 1.40 | Association of serum uric acid with level of blood pressure in type 2 diabetic patients. ( Behradmanesh, S; Kheiri, S; Nasri, H; Rafieian-Kopaei, M, 2014) |
| "We measured serum FFA levels from type 2 diabetes mellitus (T2DM) and acute myocardial infarction (AMI) patients and assay the correlation between serum FFA levels and related factors." | 1.40 | Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction. ( Han, L; Li, SW; Luo, W; Lv, ZH; Ma, P; Tu, JC; Xiong, H; Zhou, X, 2014) |
| "Hyperuricemia is known to be a risk factor for incident type 2 diabetes mellitus, but the absolute magnitude of the association is not known." | 1.39 | Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. ( Akhras, KS; Krishnan, E; Liu, J; Marynchenko, M; Sharma, H; Shi, L; Tawk, R; Wu, EQ, 2013) |
| "Patients with type 2 diabetes have similar changes in urinary pH, net acid excretion, and ammonium in 24-h urine collections at baseline, even after controlling for dietary factors, and are at increased risk for uric acid nephrolithiasis." | 1.39 | Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. ( Adams-Huet, B; Bobulescu, IA; Capolongo, G; Maalouf, NM; Moe, OW; Rosenthal, TR; Sakhaee, K, 2013) |
| "In conclusion, in patients with Type 2 diabetes mellitus and confirmed CAD, elevated levels of UA predict mortality independently of known cardiovascular risk factors." | 1.39 | Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. ( Braun, S; Cassese, S; Fusaro, M; Haase, HU; Hadamitzky, M; Kastrati, A; King, L; Ndrepepa, G; Schömig, A; Tada, T, 2013) |
| "By analysing factors associated with diabetic nephropathy rather than microvascular disease in general, this study provides evidence that night-time diastolic BP and a relative increase in platelet count are associated with incipient diabetic nephropathy." | 1.38 | Factors associated with diabetic nephropathy in subjects with proliferative retinopathy. ( Buhagiar, G; Calleja, N; Fava, S; Magri, CJ; Vassallo, J, 2012) |
| "Lovastatin, 20 mg/d, was administered for 90 days." | 1.38 | Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy. ( Davari-Farid, S; Ghorashi, S; Hashemi-Aghdam, Y; Khosraviani, K; Nargabad, ON; Nezami, N; Safa, J; Salari, B; Tabrizi, JS, 2012) |
| "Diabetes is a common risk factor for overactive bladder (OAB) syndrome and erectile dysfunction (ED)." | 1.38 | The presence of overactive bladder wet increased the risk and severity of erectile dysfunction in men with type 2 diabetes. ( Chancellor, MB; Chang, HW; Chuang, YC; Chung, MS; Lee, JJ; Lee, WC; Liu, RT; Yang, KD, 2012) |
| "KK-A(y)/Ta mice, an animal model of type 2 diabetes, were provided access to either regular drinking water or drinking water containing 10 mg/dl of allopurinol." | 1.38 | Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy. ( Choi, YW; Ihm, CG; Jeong, KH; Kim, SM; Lee, SH; Lee, TW; Lim, SJ; Moon, JY; Seok, HY, 2012) |
| "INTRODUCTION." | 1.37 | Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. ( Bonakdaran, S; Hami, M; Shakeri, MT, 2011) |
| "We studied 25 patients with type 2 diabetes and other 25 age- and sex-matched health control." | 1.37 | Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics. ( Al-Rawi, NH, 2011) |
| "Ninety-eight subjects developed type 2 diabetes during the 3." | 1.37 | Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese. ( Bi, Y; Huang, Y; Li, X; Ning, G; Wang, T; Wang, W; Xu, M; Xu, Y, 2011) |
| "In all, 202 patients with type 2 diabetes (male/female: 91/111, aged: 58." | 1.37 | Which anthropometric parameter is best related with urinary albumin excretion and creatinine clearance in type 2 diabetes: body mass index, waist circumference, waist-to-hip ratio, or conicity index? ( Afsar, B; Elsurer, R; Güner, E; Kirkpantur, A, 2011) |
| "Women with type 2 diabetes had higher S-Ca and lower S-Mg than non-diabetes women." | 1.37 | A structural equation model for assessment of links between changes in serum triglycerides, -urate, and -glucose and changes in serum calcium, -magnesium and -phosphate in type 2 diabetes and non-diabetes metabolism. ( Bäckman, L; Håglin, L; Törnkvist, B, 2011) |
| "A total of 102 type 2 diabetes mellitus patients were divided into 2 groups: DR group (age, 60 +/- 6 years [mean +/- SD]; n = 31) and no diabetic retinopathy (NDR) group (59 +/- 5 years, n = 71)." | 1.36 | Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients. ( Anan, F; Eshima, N; Eto, T; Ito, Y; Masaki, T; Saikawa, T; Umeno, Y; Yoshimatsu, H, 2010) |
| "95 men aged 45-65, suffering from type 2 diabetes for 0." | 1.36 | [Interrelations of uric acid metabolism indices with insulin and testosterone levels in men with type 2 diabetes]. ( Hurina, NM; Korpacheva-Zinych, OV; Shuprovych, AA, 2010) |
| "Fourteen patients developed symptomatic brain infarction (BI) during follow-up." | 1.35 | Association between future events of brain infarction and soluble levels of intercellular adhesion molecule-1 and C-reactive protein in patients with type 2 diabetes mellitus. ( Hamada, Y; Hotta, N; Kanai, A; Kawamura, T; Nagashima, M; Nakamura, J; Nakamura, N; Nakashima, E; Nakayama, M; Sano, T; Umemura, T, 2008) |
| "We documented 1215 new cases of type 2 diabetes." | 1.35 | Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. ( Choi, HK; De Vera, MA; Krishnan, E, 2008) |
| "Uric acid may be a useful predictor of type 2 diabetes in older adults with impaired fasting glucose." | 1.35 | Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. ( Barrett-Connor, E; Jassal, SK; Kramer, CK; von Mühlen, D, 2009) |
| "Allopurinol treatment significantly lowered uric acid levels, reduced albuminuria, and ameliorated tubulointerstitial injury, but it did not prevent mesangial expansion." | 1.35 | Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. ( Heinig, M; Johnson, RJ; Kosugi, T; Nakagawa, T; Nakayama, T; Roncal, C; Sanchez-Lozada, LG; Yuzawa, Y; Zhang, L, 2009) |
| "Adiponectin levels were higher in type 1 diabetes." | 1.35 | Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link. ( Boras, J; Erzen, DJ; Jazbec, A; Ljubic, S; Lovrencic, MV; Mileta, D; Vidjak, V, 2009) |
| "Sixteen patients with type 1 diabetes mellitus (DM), 25 patients with type 2 DM, and 24 systemically healthy patients, all with inflammatory periodontal disease, were recruited." | 1.35 | Salivary antioxidants in patients with type 1 or 2 diabetes and inflammatory periodontal disease: a case-control study. ( Buduneli, N; Cetinkalp, S; Gümüş, P; Hawkins, SI; Kinane, DF; Renaud, D; Scott, DA, 2009) |
| "Metabolic syndrome was diagnosed using the WHO criteria." | 1.34 | Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks. ( Akande, AA; Akinyinka, OA; Jimoh, AK; Olarinoye, GO, 2007) |
| "Mean uric acid was 371." | 1.34 | Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study. ( Brennan, DM; Hoar, BM; Hoogwerf, BJ; Ioachimescu, AG; Kashyap, SR, 2007) |
| "Obesity was significantly associated with a history of diabetes mellitus (18 vs." | 1.32 | Prevalence of obesity in an elderly Hungarian population. ( Antal, M; Donáth, J; Gergely, P; Kiss, C; Paksy, A; Poór, G; Zajkás, G, 2003) |
| "Seven male subjects with untreated type 2 diabetes were given 50 g protein in the form of very lean beef at 8 AM after an overnight fast." | 1.31 | A fasting-induced decrease in plasma glucose concentration does not affect the insulin response to ingested protein in people with type 2 diabetes. ( Gannon, MC; Jones, SA; Nuttall, FQ; Saeed, A, 2002) |
| "Non-insulin-dependent DM (NIDDM) and insulin-dependent DM (IDDM) were diagnosed in 369 and 166 patients, respectively." | 1.31 | [Main causes of hyperuricemia in diabetes mellitus]. ( Balabolkin, MI; Madianov, IV; Markov, DS; Markova, TN, 2000) |
| "We conclude that PIDDM patients have more severe renal dysfunction than NIDDM patients and, since glycosylated haemoglobin concentrations are comparable in these groups, we attribute this to a renal insult due to malnutrition predating the onset of the PIDDM." | 1.30 | Kidney function in phasic insulin dependent diabetes mellitus in Jamaica. ( Bennett, F; Morrison, EY; Ragoobirsingh, D, 1997) |
| "Patients with NIDDM had 11% increase of high density lipoprotein-cholesterol (HDL-C) level at the end of the first, and 18% increase at the end of the second month, while patients with primary hyperlipoproteinaemia did not change significantly." | 1.30 | Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia. ( Balogh, Z; Boda, J; Kárpáti, L; Kovács, P; Leövey, A; Paragh, G; Szabó, J, 1997) |
| "Hyperuricemia is a common finding in NIDDM, but its significance as an independent risk factor for cardiovascular disease has remained uncertain." | 1.30 | Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. ( Laakso, M; Lehto, S; Niskanen, L; Rönnemaa, T, 1998) |
| "The rates of progression to type 2 diabetes were lowest from the NGT subgroup, highest from the IGT group, with the PFH group in the middle, suggesting that PFH might be a transitional condition that precedes IGT and diabetes." | 1.30 | Progression to type 2 diabetes among high-risk groups in Kin-Chen, Kinmen. Exploring the natural history of type 2 diabetes. ( Chou, P; Li, CL; Tsai, ST; Wu, GS, 1998) |
| "Insulin resistance was estimated by homeostasis model assessment (HOMA(IR)), preliminarily validated against a euglycemic-hyperinsulinemic clamp in 85 subjects." | 1.30 | Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. ( Alberiche, M; Bonadonna, RC; Bonora, E; Egger, G; Kiechl, S; Muggeo, M; Oberhollenzer, F; Targher, G; Willeit, J, 1998) |
| "The plasma of NIDDM patients with CHD had a significantly higher value of unidentified antioxidative potential than that of patients without CHD." | 1.30 | The association between the total antioxidant potential of plasma and the presence of coronary heart disease and renal dysfunction in patients with NIDDM. ( Alho, H; Koivula, T; Lehtimäki, T; Leinonen, J; Pasternack, A; Rantalaiho, V; Wirta, O, 1998) |
| "In conclusion, the data suggest that NIDDM, hypertension, tallness, obesity, high insulin and low HDL cholesterol levels constitute risk factors for the development of BPH." | 1.30 | Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. ( Hammarsten, J; Högstedt, B, 1999) |
| "The majority (72%) who progressed to NIDDM did so in year 1." | 1.29 | High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance. ( Gouws, E; Motala, AA; Omar, MA, 1993) |
| "Epidemiologically, diabetes mellitus affects men by 64% and women by 36%." | 1.29 | [Diabetes mellitus at the National Hospital Center of Ouagadougou (Burkina Faso)]. ( Drabo, PY; Ilboudo, PD; Kabore, J; Lengani, A, 1996) |
| "Of 201 NIDDM patients without a diminished glomerular filtration rate, 66 patients (32." | 1.28 | Diabetic hypouricemia as an indicator of clinical nephropathy. ( Iwamoto, H; Marumo, F; Shichiri, M, 1990) |
| "The diagnosis coronary heart disease is based on the ECG at rest (Minnesota-code), in 796 test persons an exercise electrocardiogram was made." | 1.27 | [The value of hypertension and metabolic factors on the development of coronary heart disease in type II diabetic patients]. ( Hanefeld, M; Julius, U; Lippold, C; Schmechel, H; Schulze, J; Schwanebeck, U, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (1.24) | 18.7374 |
| 1990's | 59 (9.13) | 18.2507 |
| 2000's | 91 (14.09) | 29.6817 |
| 2010's | 292 (45.20) | 24.3611 |
| 2020's | 196 (30.34) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, C | 1 |
| Wang, Y | 22 |
| Li, J | 17 |
| Gao, J | 1 |
| Luan, Z | 1 |
| Cui, X | 2 |
| Ren, H | 1 |
| Ferreira, JP | 2 |
| Inzucchi, SE | 2 |
| Mattheus, M | 1 |
| Meinicke, T | 1 |
| Steubl, D | 1 |
| Wanner, C | 2 |
| Zinman, B | 3 |
| Delanaye, P | 1 |
| Scheen, AJ | 1 |
| Hu, X | 5 |
| Yang, Y | 5 |
| Jia, X | 1 |
| Liu, H | 9 |
| Wei, M | 1 |
| Lyu, Z | 1 |
| Shibata, Y | 1 |
| Yamazaki, M | 1 |
| Kitahara, J | 1 |
| Okubo, Y | 1 |
| Oiwa, A | 1 |
| Sato, A | 1 |
| Komatsu, M | 2 |
| Shin, D | 2 |
| Lee, KW | 2 |
| Engel, B | 1 |
| Hoffmann, F | 1 |
| Freitag, MH | 1 |
| Jacobs, H | 1 |
| Zhao, Y | 9 |
| Fan, K | 1 |
| Jin, L | 2 |
| Galvão, AIR | 1 |
| Beleigoli, AMR | 1 |
| Vidigal, PG | 1 |
| Duncan, BB | 1 |
| Schmidt, MI | 1 |
| Appleton, SL | 1 |
| Barreto, SM | 1 |
| Diniz, MFHS | 1 |
| Lai, YJ | 1 |
| Chen, YY | 1 |
| Ku, PW | 2 |
| Chen, LJ | 1 |
| Yen, YF | 1 |
| Kimura, Y | 1 |
| Tsukui, D | 1 |
| Kono, H | 1 |
| Tanaka, M | 3 |
| Takahashi, S | 2 |
| Higashiura, Y | 1 |
| Sakai, A | 1 |
| Koyama, M | 1 |
| Saitoh, S | 1 |
| Shimamoto, K | 1 |
| Ohnishi, H | 1 |
| Furuhashi, M | 1 |
| Zhang, R | 9 |
| Li, Y | 28 |
| Zhou, X | 6 |
| Zhang, F | 4 |
| Li, M | 7 |
| Zhang, S | 8 |
| Zhang, X | 11 |
| Wen, X | 2 |
| Ji, L | 4 |
| Choi, HK | 4 |
| McCormick, N | 2 |
| Yokose, C | 2 |
| Donkeng, M | 1 |
| Kuaté, D | 1 |
| Koudjou, PN | 1 |
| Noubiap, JJ | 1 |
| Kuiate, JR | 1 |
| Jiang, G | 1 |
| Luk, AO | 1 |
| Tam, CHT | 1 |
| Ozaki, R | 2 |
| Lim, CKP | 1 |
| Chow, EYK | 1 |
| Lau, ES | 1 |
| Kong, APS | 1 |
| Fan, B | 1 |
| Lee, KF | 1 |
| Siu, SC | 1 |
| Hiu, G | 1 |
| Tsang, CC | 1 |
| Lau, KP | 1 |
| Leung, JY | 1 |
| Tsang, MW | 1 |
| Kam, G | 1 |
| Lau, IT | 1 |
| Li, JK | 1 |
| Yeung, VT | 1 |
| Lau, E | 1 |
| Lo, S | 1 |
| Fung, S | 1 |
| Cheng, YL | 1 |
| Chow, CC | 1 |
| Tang, NLS | 1 |
| Huang, Y | 5 |
| Lan, HY | 1 |
| Oram, RA | 1 |
| Szeto, CC | 1 |
| So, WY | 1 |
| Chan, JCN | 1 |
| Ma, RCW | 1 |
| Svistounov, D | 1 |
| Solbu, MD | 1 |
| Jenssen, TG | 1 |
| Mathisen, UD | 1 |
| Hansen, T | 1 |
| Elgstøen, KBP | 1 |
| Zykova, SN | 1 |
| Hassan Al-Bayati, AA | 1 |
| Jawad Al-Khateeb, SM | 1 |
| Singhal, R | 1 |
| Hechanova, LA | 1 |
| Fayazi, HS | 2 |
| Yaseri, M | 2 |
| Mortazavi, SS | 1 |
| Sharifhassan, Z | 1 |
| Assadinia, AS | 1 |
| Liu, Y | 12 |
| Zhao, X | 7 |
| Yang, Z | 2 |
| Wang, S | 12 |
| Han, C | 2 |
| Zhang, H | 7 |
| Cheng, F | 1 |
| Zheng, H | 2 |
| Tian, L | 1 |
| Jia, H | 1 |
| Petersen, KF | 1 |
| Dufour, S | 1 |
| Li, F | 5 |
| Rothman, DL | 1 |
| Shulman, GI | 1 |
| Qin, YJ | 1 |
| Zhang, YL | 1 |
| Zhang, YQ | 1 |
| He, BT | 1 |
| Yu, HH | 1 |
| Chan, SO | 1 |
| Zhang, HY | 1 |
| Crawley, WT | 1 |
| Jungels, CG | 1 |
| Stenmark, KR | 1 |
| Fini, MA | 1 |
| Xu, J | 4 |
| He, W | 2 |
| Zhang, N | 1 |
| Sang, N | 1 |
| Zhao, J | 3 |
| Ji, P | 1 |
| Zhu, J | 8 |
| Feng, J | 5 |
| Li, H | 10 |
| Yu, Q | 3 |
| Qin, H | 1 |
| Wei, L | 3 |
| Zhang, J | 11 |
| Dong, X | 2 |
| Liu, X | 12 |
| Zhang, L | 14 |
| Tu, R | 1 |
| Liao, W | 2 |
| Li, R | 2 |
| Hou, J | 2 |
| Mao, Z | 1 |
| Wang, C | 8 |
| Gurung, RL | 1 |
| Yiamunaa, M | 1 |
| Liu, JJ | 3 |
| Dorajoo, R | 1 |
| Wang, J | 20 |
| Wang, L | 10 |
| Liu, S | 2 |
| Chan, C | 1 |
| Ang, K | 1 |
| Shao, YM | 1 |
| Subramaniam, T | 1 |
| Tang, WE | 1 |
| Fang Sum, C | 1 |
| Lim, SC | 1 |
| Najafi, S | 2 |
| Bahrami, M | 2 |
| Butler, AE | 2 |
| Sahebkar, A | 3 |
| Scolari, R | 1 |
| Cassol, JPE | 1 |
| Stein, CS | 2 |
| Carvalho, JAM | 1 |
| Moresco, RN | 3 |
| Banik, SD | 1 |
| Avila-Nava, A | 1 |
| Lugo, R | 1 |
| Chim Aké, R | 1 |
| Gutiérrez Solis, AL | 1 |
| Carter, S | 1 |
| Hendren, NS | 1 |
| Grodin, JL | 1 |
| Corso, LML | 1 |
| Wing, RR | 1 |
| Tate, DF | 1 |
| Espeland, MA | 1 |
| Blanchard, BE | 1 |
| McCaffery, JM | 1 |
| La Grotta, R | 1 |
| de Candia, P | 1 |
| Olivieri, F | 1 |
| Matacchione, G | 1 |
| Giuliani, A | 1 |
| Rippo, MR | 1 |
| Tagliabue, E | 1 |
| Mancino, M | 1 |
| Rispoli, F | 1 |
| Ferroni, S | 1 |
| Berra, CC | 1 |
| Ceriello, A | 10 |
| Prattichizzo, F | 1 |
| Patoulias, D | 1 |
| Papadopoulos, C | 1 |
| Doumas, M | 1 |
| Segar, MW | 1 |
| Kolkailah, AA | 1 |
| Frederich, R | 1 |
| Pong, A | 1 |
| Cannon, CP | 1 |
| Cosentino, F | 1 |
| Dagogo-Jack, S | 1 |
| McGuire, DK | 1 |
| Pratley, RE | 1 |
| Liu, CC | 1 |
| Maldonado, M | 1 |
| Liu, J | 7 |
| Cater, NB | 1 |
| Pandey, A | 1 |
| Cherney, DZI | 2 |
| Zhuang, Y | 1 |
| Huang, H | 3 |
| Cai, Q | 2 |
| Li, X | 19 |
| Li, S | 7 |
| Dong, M | 1 |
| Yu, H | 3 |
| Zhang, M | 8 |
| Chen, W | 7 |
| Li, P | 4 |
| Gao, Z | 5 |
| Borghi, C | 3 |
| Guaraldi, F | 1 |
| Li, N | 5 |
| Zhou, H | 1 |
| Ma, Y | 6 |
| Wang, Q | 7 |
| Chen, Y | 14 |
| Su, J | 2 |
| Gao, Q | 2 |
| Fan, Y | 4 |
| Liu, M | 3 |
| He, Q | 1 |
| Huang, R | 3 |
| Wang, H | 5 |
| Shen, Z | 1 |
| Cai, T | 1 |
| Zhou, Y | 3 |
| Xia, W | 1 |
| Ding, B | 1 |
| Yan, R | 1 |
| Wu, J | 4 |
| Ma, J | 3 |
| Ou, T | 1 |
| Wang, W | 7 |
| Yong, H | 1 |
| Hao, H | 1 |
| Wang, R | 1 |
| Dai, X | 1 |
| Wang, D | 3 |
| Li, W | 7 |
| Ouyang, S | 1 |
| Liu, R | 2 |
| Zhang, Y | 15 |
| Li, T | 1 |
| Doehner, W | 2 |
| Anker, SD | 1 |
| Butler, J | 1 |
| Zannad, F | 1 |
| Filippatos, G | 1 |
| Salsali, A | 1 |
| Kaempfer, C | 1 |
| Brueckmann, M | 1 |
| Pocock, SJ | 1 |
| Januzzi, JL | 1 |
| Packer, M | 2 |
| Wang, X | 16 |
| Yang, W | 3 |
| Zhu, Y | 4 |
| Jiang, M | 1 |
| Hu, J | 3 |
| Zhang, HH | 1 |
| Bai, F | 1 |
| Oguntuase, SO | 1 |
| Fasakin, OW | 1 |
| Oyeleye, SI | 1 |
| Oboh, G | 1 |
| Copur, S | 1 |
| Yildiz, A | 1 |
| Basile, C | 1 |
| Tuttle, KR | 1 |
| Kanbay, M | 2 |
| Cheng, Y | 1 |
| Xu, Y | 7 |
| Fang, Y | 1 |
| Ke, J | 1 |
| Zhao, D | 4 |
| Xian, W | 1 |
| Wu, D | 5 |
| Huo, Z | 1 |
| Hong, S | 1 |
| Xiao, H | 1 |
| Polito, L | 2 |
| Bortolotti, M | 1 |
| Battelli, MG | 2 |
| Bolognesi, A | 2 |
| Lin, H | 2 |
| Wang, G | 3 |
| Hu, C | 6 |
| Zheng, R | 1 |
| Hu, R | 2 |
| Shi, L | 3 |
| Du, R | 1 |
| Su, Q | 2 |
| Yu, X | 3 |
| Yan, L | 1 |
| Wang, T | 10 |
| Zhao, Z | 3 |
| Li, Q | 9 |
| Qin, G | 1 |
| Wan, Q | 2 |
| Chen, G | 5 |
| Xu, M | 4 |
| Dai, M | 1 |
| Zhang, D | 6 |
| Tang, X | 2 |
| Shen, F | 1 |
| Luo, Z | 3 |
| Qin, Y | 2 |
| Chen, L | 11 |
| Huo, Y | 1 |
| Ye, Z | 2 |
| Liu, C | 4 |
| Wu, S | 4 |
| Yang, T | 4 |
| Deng, H | 1 |
| Lai, S | 1 |
| Mu, Y | 3 |
| Li, D | 6 |
| Xu, G | 1 |
| Ning, G | 2 |
| Bi, Y | 3 |
| Lu, J | 6 |
| Chen, LY | 1 |
| Ye, XH | 1 |
| Cheng, JL | 1 |
| Xue, Y | 2 |
| Shao, J | 3 |
| da Silva Júnior, JG | 1 |
| de Araújo, HDA | 1 |
| da Rocha, IG | 1 |
| da Silva Neto, JC | 1 |
| Oliveira, RN | 1 |
| de Oliveira Assis, SP | 1 |
| de Menezes Lima, VL | 1 |
| Zeng, Z | 1 |
| Jin, T | 1 |
| Ni, J | 1 |
| Huang, L | 2 |
| Xie, Y | 1 |
| Ding, C | 1 |
| Cen, H | 1 |
| Zhao, H | 3 |
| He, F | 1 |
| Wang, M | 3 |
| Yan, Y | 2 |
| Chen, B | 2 |
| Xu, C | 4 |
| Liu, W | 1 |
| Yu, W | 1 |
| Xi, Y | 1 |
| Yu, L | 1 |
| Yamamoto, T | 4 |
| Koyama, H | 1 |
| Zhang, C | 2 |
| Cheng, J | 2 |
| Hu, Z | 1 |
| Zhi, X | 2 |
| Li, B | 3 |
| Zhang, Z | 8 |
| Zeng, G | 1 |
| An, H | 1 |
| Fang, D | 1 |
| Sun, M | 2 |
| Zheng, Q | 1 |
| Son, DH | 1 |
| Ha, HS | 1 |
| Park, HM | 1 |
| Kim, HY | 1 |
| Lee, YJ | 4 |
| Hernandez-Hernandez, ME | 1 |
| Torres-Rasgado, E | 1 |
| Pulido-Perez, P | 1 |
| Nicolás-Toledo, L | 1 |
| Martínez-Gómez, M | 1 |
| Rodríguez-Antolín, J | 1 |
| Pérez-Fuentes, R | 1 |
| Romero, JR | 1 |
| Antonijević, A | 1 |
| Stojanović, E | 1 |
| Jevtić, A | 1 |
| Živković, V | 1 |
| Bolevich, S | 1 |
| Jakovljević, V | 1 |
| Eliseev, MS | 2 |
| Panevin, TS | 1 |
| Zhelyabina, OV | 1 |
| Nasonov, EL | 1 |
| Shiina, K | 3 |
| Tomiyama, H | 3 |
| Tanaka, A | 3 |
| Imai, T | 3 |
| Hisauchi, I | 3 |
| Taguchi, I | 3 |
| Sezai, A | 3 |
| Toyoda, S | 3 |
| Dohi, K | 3 |
| Kamiya, H | 3 |
| Kida, K | 3 |
| Anzai, T | 3 |
| Chikamori, T | 3 |
| Node, K | 3 |
| Kobayashi, G | 3 |
| Okada, H | 3 |
| Hamaguchi, M | 3 |
| Kurogi, K | 3 |
| Murata, H | 3 |
| Ito, M | 4 |
| Fukui, M | 4 |
| Hasan, M | 3 |
| Fariha, KA | 3 |
| Barman, Z | 3 |
| Mou, AD | 3 |
| Miah, R | 3 |
| Habib, A | 3 |
| Tuba, HR | 3 |
| Ali, N | 3 |
| Tang, H | 2 |
| Chen, H | 8 |
| Li, Z | 9 |
| Xu, S | 4 |
| Yan, G | 2 |
| Tang, C | 2 |
| Zhu, L | 2 |
| Sun, J | 3 |
| Tian, R | 2 |
| Yu, J | 2 |
| An, X | 1 |
| Theofilis, P | 1 |
| Vordoni, A | 1 |
| Tsimihodimos, V | 2 |
| Kalaitzidis, RG | 1 |
| Sun, D | 2 |
| Fan, L | 1 |
| Bazzano, L | 1 |
| He, J | 1 |
| Zhang, T | 3 |
| Adomako, EA | 1 |
| Maalouf, NM | 4 |
| Osonoi, T | 1 |
| Saito, M | 1 |
| Hosoya, M | 1 |
| Douguchi, S | 1 |
| Ofuchi, K | 1 |
| Katoh, M | 1 |
| Chrysant, SG | 1 |
| Kim, EY | 1 |
| Lee, HW | 1 |
| Lee, JW | 1 |
| Kwon, YJ | 1 |
| Son, NH | 1 |
| Bargagli, M | 1 |
| Pinto, F | 1 |
| De Leonardis, R | 1 |
| Ragonese, M | 1 |
| Totaro, A | 1 |
| Recupero, S | 1 |
| Vittori, M | 1 |
| Bassi, P | 1 |
| Gambaro, G | 1 |
| Ferraro, PM | 1 |
| Xu, N | 1 |
| Guo, YN | 1 |
| Li, RX | 1 |
| Zhou, YM | 1 |
| Hu, Y | 4 |
| Jin, H | 1 |
| Konan, V | 1 |
| Swamy, N | 1 |
| Pei, Y | 1 |
| Shu, Y | 1 |
| Deng, B | 1 |
| Aktas, G | 4 |
| Yilmaz, S | 1 |
| Kantarci, DB | 1 |
| Duman, TT | 3 |
| Bilgin, S | 2 |
| Balci, SB | 1 |
| Atak Tel, BM | 1 |
| Rehman, HU | 1 |
| Ullah, K | 1 |
| Rasool, A | 1 |
| Manzoor, R | 1 |
| Yuan, Y | 3 |
| Tareen, AM | 1 |
| Kaleem, I | 1 |
| Riaz, N | 1 |
| Hameed, S | 1 |
| Bashir, S | 1 |
| Katsiki, N | 5 |
| Rizzo, M | 1 |
| Mikhailidis, DP | 5 |
| Vladmir, C | 1 |
| Zhou, W | 1 |
| Zhao, W | 2 |
| He, M | 5 |
| Lin, Z | 3 |
| Guo, W | 1 |
| Liu, Z | 5 |
| Wu, M | 5 |
| Lu, X | 2 |
| Mukherjee, D | 1 |
| Jiang, J | 3 |
| Lan, L | 2 |
| Weng, J | 1 |
| Ren, W | 2 |
| Oladi-Ghadikolaei, R | 1 |
| Aliasgharzadeh, A | 1 |
| Shayanfar, A | 1 |
| Soleymani, J | 1 |
| Moradi, M | 1 |
| Jouyban, A | 1 |
| Tayebi Khosroshahi, H | 1 |
| Singh, SK | 2 |
| Singh, R | 1 |
| Li, HF | 1 |
| Miao, X | 1 |
| Xang, W | 1 |
| Chang, M | 1 |
| Xie, C | 1 |
| Zhang, MY | 1 |
| Tan, H | 2 |
| Angelovski, M | 1 |
| Spirovska, M | 1 |
| Nikodinovski, A | 1 |
| Stamatoski, A | 1 |
| Atanasov, D | 1 |
| Mladenov, M | 1 |
| Hadzi-Petrushev, N | 1 |
| Dai, Y | 1 |
| Jiang, Y | 4 |
| Qiu, X | 1 |
| Gu, H | 1 |
| Meng, X | 3 |
| Wan, R | 1 |
| Yuan, T | 1 |
| Yang, L | 2 |
| Lei, Y | 2 |
| Wei, H | 3 |
| Hua, Y | 1 |
| Sun, L | 3 |
| Wei, J | 1 |
| Lu, N | 1 |
| Wexler, DJ | 1 |
| Aviña-Zubieta, JA | 1 |
| De Vera, MA | 2 |
| Mortazavi Khatibani, SS | 1 |
| Motamed, B | 1 |
| Li, L | 8 |
| Tong, XW | 1 |
| Zhang, YT | 1 |
| Yu, ZW | 1 |
| Pu, SD | 1 |
| Xu, YX | 1 |
| Shan, YY | 1 |
| Gao, XY | 1 |
| Ma, C | 3 |
| Zhang, W | 2 |
| Fu, H | 1 |
| Wan, G | 1 |
| Yang, G | 2 |
| Xie, R | 1 |
| Lv, Y | 1 |
| Yuan, S | 2 |
| Yuan, M | 1 |
| Gan, Y | 1 |
| Chen, M | 2 |
| Kong, L | 1 |
| Pu, Y | 1 |
| Zhou, J | 5 |
| Fan, X | 2 |
| Xiong, Z | 1 |
| Qi, H | 1 |
| González-Domínguez, Á | 1 |
| Belmonte, T | 1 |
| Domínguez-Riscart, J | 1 |
| Ruiz-Ocaña, P | 1 |
| Muela-Zarzuela, I | 1 |
| Saez-Benito, A | 1 |
| Montañez-Martínez, R | 1 |
| Mateos, RM | 1 |
| Lechuga-Sancho, AM | 1 |
| Ito, H | 1 |
| Inoue, H | 1 |
| Izutsu, T | 1 |
| Matsumoto, S | 1 |
| Antoku, S | 1 |
| Yamasaki, T | 1 |
| Mori, T | 2 |
| Togane, M | 1 |
| Lu, W | 1 |
| Sheng, J | 2 |
| Tang, Q | 1 |
| Feng, Y | 1 |
| Niu, Y | 1 |
| Malla, P | 1 |
| Khanal, MP | 1 |
| Pokhrel, A | 1 |
| Sah, B | 1 |
| Pathak, S | 1 |
| Subedi, A | 1 |
| Sapkota, S | 1 |
| Dong, W | 2 |
| Yan, S | 3 |
| Gu, W | 1 |
| Terkeltaub, R | 2 |
| Purnamasari, D | 2 |
| Umpuan, ARM | 1 |
| Tricaesario, C | 1 |
| Wisnu, W | 1 |
| Tarigan, TJE | 1 |
| Tahapary, DL | 1 |
| Muhadi, M | 1 |
| Lin, G | 1 |
| Nabrdalik, K | 1 |
| Lip, GYH | 1 |
| Raverdy, V | 1 |
| Chatelain, E | 1 |
| Lasailly, G | 1 |
| Caiazzo, R | 1 |
| Vandel, J | 1 |
| Verkindt, H | 1 |
| Marciniak, C | 1 |
| Legendre, B | 1 |
| Bauvin, P | 1 |
| Oukhouya-Daoud, N | 1 |
| Baud, G | 1 |
| Chetboun, M | 1 |
| Vantyghem, MC | 1 |
| Gnemmi, V | 1 |
| Leteurtre, E | 1 |
| Staels, B | 1 |
| Lefebvre, P | 1 |
| Mathurin, P | 1 |
| Marot, G | 1 |
| Pattou, F | 1 |
| Qu, J | 1 |
| He, Y | 2 |
| Zhang, B | 1 |
| Wu, Q | 2 |
| He, D | 1 |
| Zheng, D | 2 |
| Yang, J | 6 |
| Xu, K | 1 |
| Ren, Z | 1 |
| Yu, T | 1 |
| Suijk, DL | 1 |
| Smits, MM | 1 |
| Muskiet, MH | 1 |
| Tonneijck, L | 1 |
| Kramer, MH | 1 |
| Joles, JA | 1 |
| van Raalte, DH | 2 |
| Knipper, JA | 1 |
| Ding, X | 2 |
| Eming, SA | 1 |
| Shao, Y | 1 |
| Shao, H | 1 |
| Sawhney, MS | 1 |
| Al-Ozairi, E | 1 |
| Rivard, CJ | 2 |
| Sanchez Lozada, LG | 1 |
| Lanaspa, MA | 6 |
| Bjornstad, P | 3 |
| Al Salem, D | 1 |
| Alhubail, A | 1 |
| Megahed, A | 1 |
| Kuwabara, M | 1 |
| Johnson, RJ | 11 |
| Asad, RA | 1 |
| Peng, J | 1 |
| Long, M | 1 |
| Liu, D | 3 |
| Kutoh, E | 1 |
| Wada, A | 1 |
| Kuto, AN | 1 |
| Hayashi, J | 1 |
| Huang, JX | 1 |
| Liao, YF | 1 |
| Li, YM | 1 |
| Kocak, MZ | 3 |
| Atak, BM | 2 |
| Kurtkulagi, O | 1 |
| Savli, H | 1 |
| Han, Y | 2 |
| Yu, P | 1 |
| Shu, R | 1 |
| Song, H | 3 |
| Yuan, W | 1 |
| Liu, B | 3 |
| Shi, H | 2 |
| Hao, Y | 2 |
| Cui, L | 1 |
| Volpe, A | 1 |
| Ye, C | 2 |
| Hanley, AJ | 1 |
| Connelly, PW | 1 |
| Retnakaran, R | 1 |
| Scholtes, RA | 1 |
| Correa-Rotter, R | 1 |
| Toto, RD | 1 |
| Heerspink, HJL | 1 |
| Cain, V | 1 |
| Sjöström, CD | 1 |
| Sartipy, P | 1 |
| Stefánsson, BV | 1 |
| Lu, D | 1 |
| Huang, Z | 3 |
| Xiao, L | 1 |
| Pilemann-Lyberg, S | 1 |
| Hansen, TW | 1 |
| Rossing, P | 2 |
| Shriner, D | 2 |
| Doumatey, AP | 1 |
| Bentley, AR | 1 |
| Lei, L | 1 |
| Adeyemo, A | 2 |
| Rotimi, CN | 2 |
| Cortese, F | 1 |
| Scicchitano, P | 1 |
| Cortese, AM | 1 |
| Meliota, G | 1 |
| Andriani, A | 1 |
| Truncellito, L | 1 |
| Calculli, G | 1 |
| Giordano, P | 1 |
| Ciccone, MM | 1 |
| Chen, C | 2 |
| Tan, Y | 1 |
| Chen, J | 3 |
| Guo, H | 2 |
| Wang, B | 4 |
| Sun, Z | 2 |
| Song, Q | 2 |
| Yang, X | 8 |
| Kuchay, MS | 1 |
| Farooqui, KJ | 1 |
| Mishra, SK | 1 |
| Mithal, A | 1 |
| Lyu, J | 1 |
| Chi, X | 1 |
| Gong, DW | 1 |
| Zhao, Q | 3 |
| Verma, S | 1 |
| Ji, Q | 3 |
| Bhatt, DL | 1 |
| Mazer, CD | 1 |
| Al-Omran, M | 1 |
| Ofstad, AP | 1 |
| Zwiener, I | 1 |
| George, JT | 1 |
| Fitchett, D | 1 |
| Keerman, M | 1 |
| Yang, F | 1 |
| Hu, H | 1 |
| Wang, F | 3 |
| Yuan, J | 2 |
| Yao, P | 1 |
| Yang, H | 3 |
| Yamakage, H | 1 |
| Inoue, T | 2 |
| Odori, S | 1 |
| Kusakabe, T | 1 |
| Shimatsu, A | 1 |
| Satoh-Asahara, N | 1 |
| Xia, Q | 1 |
| Zhang, SH | 1 |
| Yang, SM | 1 |
| Zhu, XL | 1 |
| Su, S | 1 |
| Hu, AP | 1 |
| Li, DM | 1 |
| Huang, X | 1 |
| Yan, D | 4 |
| Pan, H | 1 |
| Ren, M | 1 |
| Wu, WC | 1 |
| Lai, YW | 1 |
| Chou, YC | 1 |
| Liao, YC | 1 |
| You, SL | 1 |
| Bai, CH | 1 |
| Sun, CA | 1 |
| Cao, JY | 1 |
| Waldman, B | 2 |
| O'Connell, R | 1 |
| Sullivan, DR | 2 |
| Scott, RS | 2 |
| Aryal, N | 1 |
| Gebski, V | 2 |
| Marschner, I | 1 |
| Taskinen, MR | 1 |
| Simes, JR | 1 |
| McGill, N | 2 |
| Jenkins, AJ | 3 |
| Keech, AC | 2 |
| Prasanchaimontri, P | 1 |
| Monga, M | 1 |
| Sun, X | 7 |
| Lee, WL | 1 |
| Wang, PH | 1 |
| Romeo, GR | 1 |
| Jain, M | 1 |
| Te Kampe, R | 1 |
| Janssen, M | 1 |
| van Durme, C | 1 |
| Jansen, TL | 1 |
| Boonen, A | 3 |
| Jing Liang, J | 1 |
| Ye, B | 1 |
| Tang, M | 1 |
| Agabiti-Rosei, E | 2 |
| Kielstein, JT | 1 |
| Lurbe, E | 1 |
| Mancia, G | 2 |
| Redon, J | 2 |
| Stack, AG | 2 |
| Tsioufis, KP | 1 |
| Fang, YJ | 1 |
| Chung, YL | 1 |
| Lin, CL | 1 |
| Lim, YP | 1 |
| Lou, Y | 1 |
| Qin, P | 1 |
| Peng, X | 1 |
| Zhao, P | 1 |
| Han, D | 1 |
| Hu, D | 1 |
| Hu, F | 1 |
| Kario, K | 1 |
| Okada, K | 2 |
| Murata, M | 2 |
| Suzuki, D | 1 |
| Yamagiwa, K | 1 |
| Abe, Y | 1 |
| Usui, I | 1 |
| Tsuchiya, N | 1 |
| Iwashita, C | 1 |
| Harada, N | 1 |
| Okawara, Y | 1 |
| Ishibashi, S | 2 |
| Hoshide, S | 1 |
| Bener, A | 1 |
| Al-Hamaq, AOAA | 1 |
| Zughaier, SM | 1 |
| Öztürk, M | 1 |
| Ömer, A | 1 |
| Zou, L | 1 |
| Qiu, J | 2 |
| Yu, R | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 2 |
| Maeda, K | 2 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 2 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 3 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Huang, W | 1 |
| Cui, Y | 3 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 3 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xiang, Y | 1 |
| Xu, X | 2 |
| Zhou, L | 3 |
| Tang, S | 2 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Tao, H | 1 |
| Gan, H | 1 |
| Shan, A | 1 |
| Ma, Q | 1 |
| Zhang, E | 1 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 7 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 5 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, YS | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 2 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 7 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 2 |
| Hu, W | 3 |
| Wu, X | 5 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Wei, Y | 2 |
| Gao, Y | 4 |
| Na, KJ | 1 |
| Choi, H | 2 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Kong, X | 1 |
| Dong, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liang, C | 1 |
| Song, Y | 2 |
| Yu, K | 1 |
| Zhu, C | 2 |
| Qian, J | 1 |
| Ge, J | 1 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 3 |
| Qi, Y | 1 |
| Lu, H | 2 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 5 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 2 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 2 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 4 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 2 |
| Xi, J | 1 |
| Li, C | 6 |
| Wang, Z | 2 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 8 |
| Lyu, Y | 1 |
| Huang, J | 2 |
| Yu, N | 1 |
| Wen, Z | 2 |
| Hou, H | 1 |
| Zhao, T | 2 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 2 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 3 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Luo, T | 2 |
| Su, H | 3 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 3 |
| He, X | 2 |
| Jiang, F | 5 |
| Yuan, D | 1 |
| Chen, Q | 2 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 2 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 2 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 2 |
| Lang, CC | 2 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 3 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 3 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 3 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 2 |
| Qi, MC | 1 |
| Chang, CC | 2 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 2 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 2 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 3 |
| Du, X | 2 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 2 |
| Chen, X | 3 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 4 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 2 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 2 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 2 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Cao, T | 1 |
| Guo, L | 3 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 2 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 2 |
| Cao, P | 1 |
| Gu, S | 1 |
| Zhou, G | 1 |
| Toma, C | 2 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Chapovetsky, A | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 2 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 3 |
| Hou, G | 1 |
| Cui, J | 2 |
| Xie, H | 2 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 2 |
| Cheng, Q | 1 |
| Ma, H | 3 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Slobodnick, A | 1 |
| Toprover, M | 1 |
| Greenberg, J | 1 |
| Crittenden, DB | 1 |
| Pike, VC | 1 |
| Zhong, H | 1 |
| Pillinger, MH | 2 |
| Shimizu, W | 1 |
| Kubota, Y | 1 |
| Hoshika, Y | 1 |
| Mozawa, K | 1 |
| Tara, S | 1 |
| Tokita, Y | 1 |
| Yodogawa, K | 1 |
| Iwasaki, YK | 1 |
| Takano, H | 1 |
| Tsukada, Y | 1 |
| Asai, K | 1 |
| Miyamoto, M | 1 |
| Miyauchi, Y | 1 |
| Kodani, E | 1 |
| Ishikawa, M | 1 |
| Maruyama, M | 1 |
| Ogano, M | 1 |
| Tanabe, J | 1 |
| Ohashi, N | 1 |
| Aoki, T | 1 |
| Matsuyama, T | 1 |
| Ishigaki, S | 1 |
| Isobe, S | 1 |
| Fujikura, T | 1 |
| Hashimoto, T | 1 |
| Tsuriya, D | 1 |
| Morita, H | 1 |
| Kato, A | 1 |
| Yasuda, H | 1 |
| Nasri, M | 1 |
| Adibhesami, G | 1 |
| Mahdavifard, S | 1 |
| Babaeenezhad, E | 1 |
| Ahmadvand, H | 1 |
| Matsushita, Y | 1 |
| Hasegawa, Y | 1 |
| Takebe, N | 1 |
| Onodera, K | 1 |
| Shozushima, M | 1 |
| Oda, T | 1 |
| Nagasawa, K | 1 |
| Honma, H | 1 |
| Nata, K | 1 |
| Sasaki, A | 1 |
| Ishigaki, Y | 1 |
| Fikri, AM | 1 |
| Smyth, R | 1 |
| Kumar, V | 1 |
| Al-Abadla, Z | 1 |
| Abusnana, S | 1 |
| Munday, MR | 1 |
| Tumova, S | 1 |
| Carr, IM | 1 |
| Williamson, G | 2 |
| Singh, RB | 1 |
| Fatima, G | 1 |
| Fedacko, J | 1 |
| Mojto, V | 1 |
| Isaza, A | 1 |
| SinghVerma, N | 1 |
| Maheshwari, A | 1 |
| Joshi, S | 1 |
| Saboo, B | 1 |
| Saxena, M | 1 |
| Dronamraju, N | 1 |
| Parkinson, J | 1 |
| Johansson, S | 1 |
| Johnsson, E | 1 |
| Erlandsson, F | 1 |
| Rong, S | 1 |
| Sun, T | 1 |
| Bao, W | 1 |
| Inaba, M | 3 |
| Kumeda, Y | 1 |
| Yamada, S | 1 |
| Toi, N | 1 |
| Hamai, C | 1 |
| Noguchi, K | 1 |
| Yasuda, E | 1 |
| Furumitsu, Y | 1 |
| Emoto, M | 3 |
| Ohno, Y | 1 |
| Sotomayor, CG | 1 |
| Oskooei, SS | 1 |
| Bustos, NI | 1 |
| Nolte, IM | 1 |
| Gomes-Neto, AW | 1 |
| Erazo, M | 1 |
| Gormaz, JG | 1 |
| Berger, SP | 1 |
| Navis, GJ | 1 |
| Rodrigo, R | 1 |
| Dullaart, RPF | 1 |
| Bakker, SJL | 1 |
| Hou, L | 1 |
| Zhao, M | 1 |
| Dimitriadis, GD | 1 |
| Peng, Y | 2 |
| Xiong, XF | 1 |
| Xiao, Y | 1 |
| Yan, WF | 1 |
| Jiang, L | 2 |
| Yang, ZG | 1 |
| Wang, CP | 1 |
| Lu, YC | 1 |
| Hung, WC | 1 |
| Tsai, IT | 1 |
| Chang, YH | 2 |
| Hu, DW | 1 |
| Hsu, CC | 2 |
| Wu, CC | 1 |
| Wei, CT | 1 |
| Chung, FM | 1 |
| Cui, S | 1 |
| Shen, X | 2 |
| Zuo, M | 1 |
| Zhu, H | 1 |
| Chang, B | 2 |
| Shi, Z | 1 |
| Ma, L | 1 |
| Teng, F | 1 |
| Qin, R | 1 |
| Geng, H | 1 |
| Xu, W | 2 |
| Lai, P | 1 |
| Liang, J | 1 |
| Jalal, DI | 1 |
| Chertow, GM | 1 |
| Nikbakht, E | 1 |
| Singh, I | 1 |
| Vider, J | 1 |
| Williams, LT | 1 |
| Vugic, L | 1 |
| Gaiz, A | 1 |
| Kundur, AR | 1 |
| Colson, N | 1 |
| Okuyama, T | 1 |
| Shirakawa, J | 1 |
| Nakamura, T | 3 |
| Murase, T | 2 |
| Miyashita, D | 1 |
| Inoue, R | 1 |
| Kyohara, M | 1 |
| Togashi, Y | 1 |
| Terauchi, Y | 1 |
| Ghasemi, A | 1 |
| Song, L | 1 |
| Weisman, A | 1 |
| Tomlinson, GA | 1 |
| Lipscombe, LL | 1 |
| Garg, AX | 1 |
| Perkins, BA | 1 |
| Hawker, GA | 1 |
| Del Pinto, R | 1 |
| Viazzi, F | 7 |
| Pontremoli, R | 7 |
| Ferri, C | 1 |
| Carubbi, F | 1 |
| Russo, E | 1 |
| Fan, J | 1 |
| Tse, LA | 1 |
| Chang, Z | 1 |
| Zhou, XH | 1 |
| Chan, Z | 1 |
| She, X | 1 |
| Gu, C | 1 |
| Zhou, C | 2 |
| Zheng, Z | 1 |
| Miao, H | 1 |
| Zhao, R | 1 |
| Zheng, S | 1 |
| Huang, D | 2 |
| Ping, Z | 1 |
| Cho, IJ | 1 |
| Oh, DH | 1 |
| Yoo, J | 1 |
| Hwang, YC | 1 |
| Ahn, KJ | 1 |
| Chung, HY | 1 |
| Jeong, SW | 1 |
| Moon, JY | 3 |
| Lee, SH | 3 |
| Lim, SJ | 2 |
| Jeong, IK | 1 |
| Xiang, S | 1 |
| Wang, K | 2 |
| Hua, F | 1 |
| Guler, B | 1 |
| Ertuglu, LA | 1 |
| Dagel, T | 1 |
| Afsar, B | 2 |
| Incir, S | 1 |
| Baygul, A | 1 |
| Covic, A | 1 |
| Andres-Hernando, A | 1 |
| Sánchez-Lozada, LG | 6 |
| Liu, T | 1 |
| Hu, G | 2 |
| Meng, Z | 1 |
| Vrachatis, DA | 1 |
| Papathanasiou, KA | 1 |
| Iliodromitis, KE | 1 |
| Giotaki, SG | 1 |
| Kossyvakis, C | 1 |
| Raisakis, K | 1 |
| Kaoukis, A | 1 |
| Lambadiari, V | 1 |
| Avramides, D | 1 |
| Reimers, B | 1 |
| Stefanini, GG | 1 |
| Cleman, M | 1 |
| Giannopoulos, G | 1 |
| Lansky, A | 1 |
| Deftereos, SG | 1 |
| Sun, S | 1 |
| Wang, P | 1 |
| Liang, L | 2 |
| Ding, F | 1 |
| Bai, X | 1 |
| Wei, X | 1 |
| Yue, Z | 1 |
| Fang, X | 1 |
| Huang, Q | 2 |
| Zong, Q | 1 |
| Ma, G | 1 |
| Zhao, L | 2 |
| Liu, JH | 1 |
| Wu, MZ | 1 |
| Li, SM | 1 |
| Ren, QW | 1 |
| Lin, QS | 1 |
| Ng, MY | 1 |
| Tse, HF | 1 |
| Yiu, KH | 1 |
| Lamacchia, O | 1 |
| Fontana, A | 1 |
| Pacilli, A | 4 |
| Copetti, M | 1 |
| Fariello, S | 1 |
| Garofolo, M | 1 |
| Penno, G | 2 |
| Trischitta, V | 1 |
| De Cosmo, S | 6 |
| Cignarelli, M | 1 |
| Cabrera-Rode, E | 1 |
| Rodríguez, J | 1 |
| Álvarez, A | 1 |
| Echevarría, R | 1 |
| Reyes, AD | 1 |
| Cubas-Dueñas, I | 1 |
| Turcios-Tristá, SE | 1 |
| Díaz-Díaz, O | 1 |
| Piscitelli, P | 1 |
| Giorda, C | 5 |
| Genovese, S | 2 |
| Russo, G | 4 |
| Guida, P | 2 |
| Fioretto, P | 4 |
| Miao, D | 1 |
| Pan, E | 1 |
| Rossi, MC | 3 |
| Lucisano, G | 2 |
| Nicolucci, A | 3 |
| Kuwata, H | 1 |
| Okamura, S | 2 |
| Hayashino, Y | 2 |
| Tsujii, S | 2 |
| Ishii, H | 2 |
| Cui, W | 1 |
| Rampersad, S | 1 |
| Yang, P | 1 |
| Sheng, C | 2 |
| Cheng, X | 1 |
| Qu, S | 3 |
| Vinuthinee-Naidu, MN | 1 |
| Zunaina, E | 1 |
| Azreen-Redzal, A | 1 |
| Nyi-Nyi, N | 1 |
| Han, J | 2 |
| Zhao, F | 1 |
| Bao, Y | 7 |
| Jia, W | 8 |
| van der Schaft, N | 1 |
| Brahimaj, A | 1 |
| Wen, KX | 1 |
| Franco, OH | 1 |
| Dehghan, A | 2 |
| Mantovani, A | 3 |
| Rigolon, R | 3 |
| Civettini, A | 1 |
| Bolzan, B | 1 |
| Morani, G | 2 |
| Bonapace, S | 3 |
| Dugo, C | 2 |
| Zoppini, G | 7 |
| Bonora, E | 7 |
| Targher, G | 9 |
| Sheng, X | 1 |
| Jian, G | 1 |
| Bao, H | 1 |
| Wang, N | 1 |
| Ahmadieh, H | 1 |
| Azar, S | 1 |
| Mortada, I | 1 |
| Kang, HW | 1 |
| Seo, SP | 1 |
| Ha, YS | 1 |
| Kim, WT | 1 |
| Kim, YJ | 1 |
| Yun, SJ | 1 |
| Kim, WJ | 1 |
| Lee, SC | 1 |
| Thottam, GE | 1 |
| Krasnokutsky, S | 1 |
| Xu, L | 3 |
| Tian, D | 1 |
| Xia, P | 1 |
| Ren, JP | 1 |
| Chen, DN | 1 |
| Xin, Z | 1 |
| Yuan, MX | 1 |
| You, QS | 1 |
| Yang, JK | 1 |
| Chu, FY | 1 |
| Huang, PH | 1 |
| Lin, YN | 1 |
| Sun, JT | 1 |
| Ho, JL | 1 |
| Yen, TH | 1 |
| Su, MJ | 1 |
| Al-Daghri, NM | 1 |
| Al-Attas, OS | 1 |
| Wani, K | 1 |
| Sabico, S | 1 |
| Alokail, MS | 1 |
| Kawamoto, R | 1 |
| Ninomiya, D | 1 |
| Kasai, Y | 1 |
| Senzaki, K | 1 |
| Kusunoki, T | 1 |
| Ohtsuka, N | 1 |
| Kumagi, T | 1 |
| Foster, SR | 1 |
| Dilworth, LL | 1 |
| Omoruyi, FO | 1 |
| Thompson, R | 1 |
| Alexander-Lindo, RL | 1 |
| Chang, YK | 1 |
| Huang, LF | 1 |
| Shin, SJ | 2 |
| Lin, KD | 2 |
| Chong, K | 2 |
| Yen, FS | 1 |
| Chang, HY | 1 |
| Chuang, SY | 1 |
| Hsieh, TJ | 1 |
| Hsiung, CA | 1 |
| Leng, J | 1 |
| Tian, H | 1 |
| Xun, P | 1 |
| Yu, Z | 1 |
| Pichiri, I | 3 |
| Allister Price, C | 1 |
| Stanhope, KL | 2 |
| Hao, J | 1 |
| Zhong, N | 1 |
| Cui, R | 1 |
| Zhang, G | 2 |
| Sheng, H | 1 |
| Nakatani, A | 1 |
| Nakatani, S | 1 |
| Ishimura, E | 2 |
| Sakura, M | 1 |
| Tateishi, Y | 1 |
| Tsuda, A | 1 |
| Kurajoh, M | 1 |
| Mori, K | 2 |
| Ouchi, M | 3 |
| Oba, K | 3 |
| Kaku, K | 2 |
| Suganami, H | 2 |
| Yoshida, A | 3 |
| Fukunaka, Y | 1 |
| Jutabha, P | 1 |
| Morita, A | 1 |
| Otani, N | 1 |
| Hayashi, K | 1 |
| Fujita, T | 2 |
| Suzuki, T | 3 |
| Yasutake, M | 2 |
| Anzai, N | 1 |
| Klisic, A | 1 |
| Kocic, G | 1 |
| Kavaric, N | 1 |
| Jovanovic, M | 1 |
| Stanisic, V | 1 |
| Ninic, A | 1 |
| Peng, L | 3 |
| Han, H | 1 |
| Bai, Y | 1 |
| Malmström, H | 1 |
| Walldius, G | 1 |
| Carlsson, S | 1 |
| Grill, V | 1 |
| Jungner, I | 1 |
| Gudbjörnsdottir, S | 1 |
| Kosiborod, M | 1 |
| Hammar, N | 1 |
| Lin, X | 2 |
| Pan, S | 1 |
| Li, GX | 1 |
| Jiao, XH | 1 |
| Cheng, XB | 1 |
| Gao, X | 3 |
| Pang, X | 1 |
| Deng, X | 1 |
| Sun, C | 2 |
| Keen, HI | 1 |
| Davis, WA | 3 |
| Latkovic, E | 1 |
| Drinkwater, JJ | 1 |
| Nossent, J | 1 |
| Davis, TME | 2 |
| Tanaka, T | 2 |
| Ansquer, JC | 1 |
| Buizen, L | 1 |
| Best, JD | 1 |
| Feher, MD | 1 |
| Foucher, C | 1 |
| Kesaniemi, YA | 1 |
| Flack, J | 1 |
| d'Emden, MC | 1 |
| Hedley, J | 1 |
| Lou, Q | 2 |
| Kawada, T | 2 |
| Wang, LX | 1 |
| Filipp, SL | 1 |
| Urbina, EM | 1 |
| Gurka, MJ | 2 |
| DeBoer, MD | 2 |
| Janghorbani, M | 1 |
| Ghanbari, H | 1 |
| Aminorroaya, A | 1 |
| Amini, M | 1 |
| Li, TT | 6 |
| Wang, AP | 4 |
| Lu, JX | 2 |
| Chen, MY | 5 |
| Zhao, CC | 3 |
| Tang, ZH | 1 |
| Li, LX | 8 |
| Jia, WP | 8 |
| Chai, T | 1 |
| Kahathuduwa, CN | 1 |
| Thomas, DM | 1 |
| Siu, C | 1 |
| Allison, DB | 1 |
| Fu, S | 1 |
| Guo, Y | 1 |
| Ye, P | 1 |
| Sunjaya, AP | 1 |
| Sunjaya, AF | 1 |
| Han, T | 1 |
| Shan, R | 1 |
| Zi, T | 1 |
| Shi, D | 1 |
| Qu, R | 1 |
| Guo, X | 2 |
| Na, L | 1 |
| Mudassir, HA | 1 |
| Qureshi, SA | 1 |
| Azmi, MB | 1 |
| Ahsan, M | 1 |
| Liang, Q | 1 |
| Wang, XY | 1 |
| Hu, HF | 1 |
| Lai, JB | 1 |
| Yao, WL | 1 |
| Chen, ML | 1 |
| Rao, X | 1 |
| Wu, YT | 1 |
| He, H | 2 |
| An, ZM | 1 |
| Huang, HJ | 2 |
| Fiorentino, TV | 1 |
| Sesti, F | 1 |
| Succurro, E | 1 |
| Pedace, E | 1 |
| Andreozzi, F | 1 |
| Sciacqua, A | 3 |
| Hribal, ML | 1 |
| Perticone, F | 3 |
| Sesti, G | 3 |
| Bell, DSH | 1 |
| Hanai, K | 1 |
| Tauchi, E | 1 |
| Nishiwaki, Y | 1 |
| Yokoyama, Y | 1 |
| Uchigata, Y | 1 |
| Babazono, T | 1 |
| Suyoto, PST | 1 |
| Marco-Ramell, A | 1 |
| Tulipani, S | 1 |
| Palau-Rodriguez, M | 1 |
| Gonzalez-Dominguez, R | 1 |
| Miñarro, A | 1 |
| Jauregui, O | 1 |
| Sanchez-Pla, A | 1 |
| Macias-Gonzalez, M | 1 |
| Cardona, F | 2 |
| Tinahones, FJ | 2 |
| Andres-Lacueva, C | 1 |
| Hu, MT | 1 |
| Dong, XD | 1 |
| Xiang, LT | 1 |
| Gu, QR | 1 |
| Du, ZY | 1 |
| Chen, SM | 2 |
| Chen, GR | 2 |
| Guo, XX | 1 |
| Ji, BP | 1 |
| Zhou, F | 1 |
| Yu, Y | 1 |
| Wei, S | 1 |
| Tang, Y | 1 |
| Yan, P | 1 |
| Li, YX | 1 |
| Fang, DH | 1 |
| Liu, TX | 1 |
| Zhou, XW | 1 |
| Fei, YY | 1 |
| Jiang, JL | 1 |
| Ye, SD | 1 |
| Molino Lova, R | 1 |
| Vassalle, C | 1 |
| Masini, E | 1 |
| Del Ry, S | 1 |
| Cabiati, M | 1 |
| Pasquini, G | 1 |
| Macchi, C | 1 |
| Gao, L | 3 |
| Huo, X | 1 |
| de Carvalho, JAM | 2 |
| Duarte, MMMF | 1 |
| da Cruz, IBM | 1 |
| Premaor, MO | 2 |
| Comim, FV | 2 |
| Moretto, MB | 1 |
| Kuo, CW | 1 |
| Chen, HL | 1 |
| Tu, MY | 1 |
| Chen, CM | 1 |
| Wardhana, W | 1 |
| Rudijanto, A | 1 |
| Olofsson, C | 1 |
| Anderstam, B | 1 |
| Bragfors-Helin, AC | 1 |
| Eriksson, M | 1 |
| Qureshi, AR | 1 |
| Lindholm, B | 1 |
| Hilding, A | 1 |
| Wiczkowski, W | 1 |
| Orsini, N | 1 |
| Stenvinkel, P | 1 |
| Rajamand Ekberg, N | 1 |
| Dong, P | 1 |
| Russo, GT | 1 |
| Tanaka, KI | 2 |
| Kanazawa, I | 2 |
| Notsu, M | 2 |
| Sugimoto, T | 2 |
| Wang, YJ | 1 |
| Hao, CM | 1 |
| Chang, HW | 2 |
| Lin, YW | 1 |
| Lin, MH | 1 |
| Lan, YC | 1 |
| Wang, RY | 1 |
| Erkus, E | 1 |
| Sincer, I | 1 |
| Atak, B | 1 |
| Duman, T | 1 |
| Bailey, CJ | 1 |
| Kojima, S | 1 |
| Matsui, K | 1 |
| Hiramitsu, S | 1 |
| Hisatome, I | 2 |
| Waki, M | 1 |
| Uchiyama, K | 1 |
| Yokota, N | 1 |
| Tokutake, E | 1 |
| Wakasa, Y | 1 |
| Jinnouchi, H | 1 |
| Kakuda, H | 1 |
| Hayashi, T | 2 |
| Kawai, N | 1 |
| Mori, H | 1 |
| Sugawara, M | 1 |
| Ohya, Y | 1 |
| Kimura, K | 1 |
| Saito, Y | 1 |
| Ogawa, H | 1 |
| Qiu, SH | 1 |
| Guo, HJ | 1 |
| Sun, ZL | 1 |
| Jiang, TN | 1 |
| Li, YF | 1 |
| Huo, LL | 1 |
| Wang, LY | 1 |
| Zhao, CL | 1 |
| Liu, LG | 1 |
| Wang, JW | 3 |
| Ke, JF | 1 |
| Yu, TP | 3 |
| Tian, S | 1 |
| Guo, D | 1 |
| An, K | 1 |
| Laffel, L | 1 |
| Lynch, J | 1 |
| El Ghormli, L | 1 |
| Tollefsen, SE | 1 |
| Nadeau, KJ | 1 |
| Bai, H | 1 |
| Yan, J | 2 |
| Chunlei, Y | 1 |
| Liubao, G | 1 |
| Tao, W | 1 |
| Changying, X | 1 |
| Jiao, X | 1 |
| Yin, X | 2 |
| Guarda, NS | 1 |
| Bollick, YS | 1 |
| Weir, MR | 1 |
| Kuo, KT | 1 |
| Chang, YF | 1 |
| Wu, IH | 1 |
| Lu, FH | 1 |
| Yang, YC | 1 |
| Wu, JS | 1 |
| Chang, CJ | 1 |
| Prosiannikov, MY | 1 |
| Yanenko, EK | 1 |
| Yarovoy, SK | 1 |
| Golovanov, SA | 1 |
| Konstantinova, OV | 1 |
| Anokhin, NV | 1 |
| Djalilov, OV | 1 |
| Sivkov, AV | 1 |
| Apolikhin, OI | 1 |
| He, S | 1 |
| Ping, F | 1 |
| Sun, Q | 1 |
| Lv, L | 1 |
| Abdessadek, M | 1 |
| Khabbal, Y | 1 |
| Magoul, R | 1 |
| Marmouzi, I | 1 |
| Ajdi, F | 1 |
| Kimball, AS | 1 |
| Davis, FM | 1 |
| denDekker, A | 1 |
| Joshi, AD | 1 |
| Schaller, MA | 1 |
| Bermick, J | 1 |
| Xing, X | 2 |
| Burant, CF | 1 |
| Obi, AT | 1 |
| Nysz, D | 1 |
| Robinson, S | 1 |
| Allen, R | 1 |
| Lukacs, NW | 1 |
| Henke, PK | 1 |
| Gudjonsson, JE | 1 |
| Moore, BB | 1 |
| Kunkel, SL | 1 |
| Gallagher, KA | 1 |
| Gomes, JMG | 1 |
| de Assis Costa, J | 1 |
| Ribeiro, PVM | 1 |
| Alfenas, RCG | 1 |
| Chege, BM | 1 |
| Waweru, MP | 1 |
| Frederick, B | 1 |
| Nyaga, NM | 1 |
| Lv, Q | 1 |
| Meng, XF | 1 |
| He, FF | 1 |
| Xiong, J | 1 |
| Gao, P | 1 |
| Tian, XJ | 1 |
| Liu, JS | 1 |
| Zhu, ZH | 1 |
| Huang, K | 1 |
| Chen, YL | 3 |
| Lin, JD | 2 |
| Hsia, TL | 1 |
| Mao, FC | 1 |
| Hsu, CH | 1 |
| Pei, D | 3 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Schwarz, JM | 1 |
| Havel, PJ | 1 |
| Simon, MC | 1 |
| Bilan, S | 1 |
| Nowotny, B | 1 |
| Dickhaus, T | 1 |
| Burkart, V | 1 |
| Schloot, NC | 1 |
| Jia, Z | 1 |
| Kang, S | 1 |
| Krishnan, E | 2 |
| Akhras, KS | 1 |
| Sharma, H | 1 |
| Marynchenko, M | 1 |
| Wu, EQ | 1 |
| Tawk, R | 1 |
| Valbusa, F | 1 |
| Bertolini, L | 1 |
| Zenari, L | 1 |
| Arcaro, G | 1 |
| Byrne, CD | 1 |
| Liu, RT | 3 |
| Chung, MS | 3 |
| Wang, PW | 1 |
| Chen, CD | 1 |
| Lee, JJ | 3 |
| Lee, WC | 2 |
| Chancellor, MB | 2 |
| Yang, KD | 2 |
| Chuang, YC | 2 |
| Aoyama, J | 1 |
| Watanabe, K | 1 |
| Ishii, K | 1 |
| Yano, H | 1 |
| Motoyama, M | 1 |
| Sekimizu, K | 1 |
| Matsumura, N | 1 |
| Igari, Y | 1 |
| Nakano, H | 1 |
| Kivity, S | 1 |
| Kopel, E | 1 |
| Steinlauf, S | 1 |
| Segev, S | 1 |
| Sidi, Y | 1 |
| Olchovsky, D | 1 |
| Ohara, C | 1 |
| Inoue, K | 1 |
| Kashima, S | 1 |
| Inoue, M | 1 |
| Akimoto, K | 1 |
| Ye, X | 1 |
| Cao, Y | 1 |
| Yang, Q | 2 |
| Fu, X | 1 |
| Shao, HL | 1 |
| Song, CQ | 1 |
| Xu, DH | 1 |
| Shang, XJ | 1 |
| Hao, ZH | 1 |
| Szwejkowski, BR | 1 |
| Gandy, SJ | 1 |
| Rekhraj, S | 1 |
| Houston, JG | 1 |
| Morris, AD | 1 |
| George, J | 1 |
| Bobulescu, IA | 1 |
| Capolongo, G | 1 |
| Adams-Huet, B | 2 |
| Rosenthal, TR | 1 |
| Moe, OW | 3 |
| Sakhaee, K | 5 |
| Nakagawa, T | 5 |
| Shafiu, M | 2 |
| Sundaram, S | 1 |
| Le, M | 1 |
| Ishimoto, T | 2 |
| Sautin, YY | 2 |
| Prudon, B | 1 |
| Roddy, E | 1 |
| Stradling, JR | 1 |
| West, SD | 1 |
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Susa, N | 1 |
| Kanou, N | 1 |
| Nakayama, T | 3 |
| Asai, S | 1 |
| Shen, C | 1 |
| Matfin, G | 1 |
| Ling, Y | 2 |
| Li, XM | 2 |
| Onat, A | 1 |
| Altuğ Çakmak, H | 1 |
| Can, G | 1 |
| Yüksel, M | 1 |
| Köroğlu, B | 1 |
| Yüksel, H | 1 |
| Dalbeth, N | 1 |
| Chen, P | 1 |
| White, M | 1 |
| Gamble, GD | 1 |
| Barratt-Boyes, C | 1 |
| Gow, PJ | 1 |
| Orr-Walker, B | 1 |
| Gilbert, RE | 1 |
| Ayyavoo, A | 1 |
| Derraik, JG | 1 |
| Hofman, PL | 1 |
| Cutfield, WS | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Sheikhbahaei, S | 1 |
| Fotouhi, A | 1 |
| Hafezi-Nejad, N | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Feng, S | 1 |
| Bonakdaran, S | 2 |
| Kharaqani, B | 1 |
| Xiang, G | 1 |
| Xiang, L | 1 |
| Rafieian-Kopaei, M | 1 |
| Behradmanesh, S | 1 |
| Kheiri, S | 1 |
| Nasri, H | 1 |
| Assimos, D | 1 |
| Vitale, A | 1 |
| Cantarini, L | 1 |
| Rigante, D | 1 |
| Bardelli, M | 1 |
| Galeazzi, M | 1 |
| Joo, K | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Joo, H | 1 |
| Park, W | 1 |
| Liu, PJ | 1 |
| Ma, F | 1 |
| Lou, HP | 1 |
| Zhu, YN | 1 |
| Tang, W | 1 |
| Qian, L | 1 |
| Shan, S | 1 |
| Yamagishi, S | 1 |
| Ishibashi, Y | 1 |
| Ojima, A | 1 |
| Sugiura, T | 1 |
| Matsui, T | 1 |
| Yang, IH | 1 |
| Kuo, HK | 1 |
| Chen, YJ | 2 |
| Chen, CH | 1 |
| Andrade, JA | 1 |
| Kang, HC | 1 |
| Greffin, S | 1 |
| Garcia Rosa, ML | 1 |
| Lugon, JR | 1 |
| Shimodaira, M | 1 |
| Niwa, T | 1 |
| Hanyu, N | 1 |
| Lv, ZH | 1 |
| Ma, P | 1 |
| Luo, W | 1 |
| Xiong, H | 1 |
| Han, L | 1 |
| Li, SW | 1 |
| Tu, JC | 1 |
| Dong, XH | 1 |
| Li, MF | 1 |
| Bao, YQ | 6 |
| Yu, S | 1 |
| Hou, X | 2 |
| Xu, D | 1 |
| Che, K | 1 |
| Davies, MJ | 1 |
| Trujillo, A | 1 |
| Vijapurkar, U | 1 |
| Damaraju, CV | 1 |
| Meininger, G | 1 |
| Peng, D | 3 |
| Kim, SM | 2 |
| Kim, YG | 1 |
| Kim, SY | 1 |
| Seo, JW | 1 |
| Choi, YW | 2 |
| Kim, DJ | 1 |
| Jeong, KH | 2 |
| Lee, TW | 2 |
| Ihm, CG | 2 |
| Won, KY | 1 |
| Zheng, X | 1 |
| Xing, A | 1 |
| Qi, S | 1 |
| Hong, J | 1 |
| Schievink, B | 1 |
| de Zeeuw, D | 2 |
| Parving, HH | 2 |
| Lambers Heerspink, HJ | 2 |
| Sluijs, I | 2 |
| Holmes, MV | 1 |
| van der Schouw, YT | 2 |
| Beulens, JW | 3 |
| Asselbergs, FW | 1 |
| Huerta, JM | 1 |
| Palmer, TM | 1 |
| Arriola, L | 1 |
| Balkau, B | 2 |
| Barricarte, A | 1 |
| Boeing, H | 1 |
| Clavel-Chapelon, F | 1 |
| Fagherazzi, G | 1 |
| Franks, PW | 1 |
| Gavrila, D | 1 |
| Kaaks, R | 1 |
| Khaw, KT | 2 |
| Kühn, T | 1 |
| Molina-Montes, E | 1 |
| Mortensen, LM | 1 |
| Nilsson, PM | 1 |
| Overvad, K | 1 |
| Palli, D | 1 |
| Panico, S | 1 |
| Quirós, JR | 1 |
| Rolandsson, O | 1 |
| Sacerdote, C | 1 |
| Sala, N | 1 |
| Schmidt, JA | 1 |
| Scott, RA | 1 |
| Sieri, S | 1 |
| Slimani, N | 1 |
| Spijkerman, AM | 2 |
| Tjonneland, A | 1 |
| Travis, RC | 1 |
| Tumino, R | 1 |
| van der A, DL | 2 |
| Sharp, SJ | 1 |
| Forouhi, NG | 2 |
| Langenberg, C | 2 |
| Riboli, E | 1 |
| Wareham, NJ | 2 |
| Bjornstad, PS | 1 |
| Merriman, T | 2 |
| Sundborn, G | 1 |
| Zhan, L | 1 |
| Su, B | 1 |
| Sui, H | 1 |
| Wu, B | 2 |
| Zeng, CC | 1 |
| Liu, WW | 1 |
| Cheng, JG | 1 |
| Tu, Y | 1 |
| Kosugi, T | 2 |
| Kume, S | 1 |
| Jalal, D | 1 |
| Maahs, DM | 1 |
| Snell-Bergeon, JK | 1 |
| Wijnands, JM | 2 |
| Houben, AJ | 1 |
| Muris, DM | 1 |
| Schram, MT | 2 |
| Sep, SJ | 2 |
| van der Kallen, CJ | 2 |
| Henry, RM | 2 |
| Dagnelie, PC | 2 |
| van der Linden, S | 2 |
| Schaper, NC | 1 |
| Arts, IC | 2 |
| Stehouwer, CD | 2 |
| Virdis, A | 1 |
| Grassi, G | 1 |
| van Sloten, TT | 1 |
| Koster, A | 1 |
| Krysiak, R | 1 |
| Gilowski, W | 1 |
| Szkrobka, W | 1 |
| Okopien, B | 1 |
| Shuai, HP | 1 |
| Xia, HF | 1 |
| Pernigo, M | 1 |
| Bergamini, C | 1 |
| Ding, Y | 1 |
| Xu, P | 1 |
| An, N | 1 |
| Xie, J | 1 |
| Liu, P | 2 |
| Gentile, S | 2 |
| Feig, D | 1 |
| Li, K | 1 |
| Lou, D | 1 |
| Deng, Z | 1 |
| Gu, Y | 1 |
| Jia, G | 1 |
| Di, F | 1 |
| Lei, CC | 1 |
| Lin, KC | 1 |
| Chang, DM | 2 |
| Hsieh, CH | 2 |
| Sun, HL | 1 |
| Lue, KH | 1 |
| Deng, ZY | 1 |
| Li, JW | 1 |
| Weber, MA | 1 |
| Mansfield, TA | 1 |
| Alessi, F | 1 |
| Iqbal, N | 1 |
| Parikh, S | 1 |
| Ptaszynska, A | 1 |
| Gómez-Marcos, MA | 1 |
| Blázquez-Medela, AM | 1 |
| Gamella-Pozuelo, L | 1 |
| Recio-Rodriguez, JI | 1 |
| García-Ortiz, L | 1 |
| Martínez-Salgado, C | 1 |
| Karimi, P | 1 |
| Farhangi, MA | 1 |
| Sarmadi, B | 1 |
| Gargari, BP | 1 |
| Zare Javid, A | 1 |
| Pouraghaei, M | 1 |
| Dehghan, P | 1 |
| Xue, B | 1 |
| Tan, JB | 1 |
| Ning, F | 1 |
| Sun, JP | 1 |
| Zhang, KY | 1 |
| Wang, SJ | 1 |
| Zhang, DF | 1 |
| Qiao, Q | 1 |
| Pang, ZC | 1 |
| Ortega-Cortes, R | 1 |
| Trujillo, X | 1 |
| Hurtado López, EF | 1 |
| López Beltrán, AL | 1 |
| Colunga Rodríguez, C | 1 |
| Barrera-de Leon, JC | 1 |
| Tlacuilo-Parra, A | 1 |
| Marian, AJ | 1 |
| Keenan, T | 1 |
| Rasheed, A | 1 |
| Ho, WK | 1 |
| Malik, R | 1 |
| Felix, JF | 1 |
| Young, R | 1 |
| Shah, N | 1 |
| Samuel, M | 1 |
| Sheikh, N | 1 |
| Mucksavage, ML | 1 |
| Shah, O | 1 |
| Morley, M | 1 |
| Laser, A | 1 |
| Mallick, NH | 1 |
| Zaman, KS | 1 |
| Ishaq, M | 2 |
| Rasheed, SZ | 1 |
| Memon, FU | 1 |
| Ahmed, F | 1 |
| Hanif, B | 1 |
| Lakhani, MS | 1 |
| Fahim, M | 1 |
| Shardha, NK | 1 |
| Ahmed, N | 1 |
| Mahmood, K | 1 |
| Iqbal, W | 1 |
| Akhtar, S | 1 |
| Raheel, R | 1 |
| O'Donnell, CJ | 1 |
| Hengstenberg, C | 1 |
| März, W | 1 |
| Kathiresan, S | 1 |
| Samani, N | 1 |
| Goel, A | 1 |
| Hopewell, JC | 1 |
| Chambers, J | 1 |
| Cheng, YC | 1 |
| Sharma, P | 1 |
| Rosand, J | 1 |
| Boncoraglio, GB | 1 |
| Kazmi, SU | 1 |
| Hakonarson, H | 1 |
| Köttgen, A | 1 |
| Kalogeropoulos, A | 1 |
| Frossard, P | 1 |
| Kamal, A | 1 |
| Dichgans, M | 1 |
| Cappola, T | 1 |
| Reilly, MP | 1 |
| Danesh, J | 1 |
| Rader, DJ | 1 |
| Voight, BF | 1 |
| Saleheen, D | 1 |
| Baturin, AK | 1 |
| Sorokina, EY | 1 |
| Pogozheva, AV | 1 |
| Peskova, EV | 1 |
| Makurina, ON | 1 |
| Tutelyan, VA | 1 |
| Giri, AK | 1 |
| Banerjee, P | 1 |
| Chakraborty, S | 1 |
| Kauser, Y | 1 |
| Undru, A | 1 |
| Roy, S | 1 |
| Parekatt, V | 1 |
| Ghosh, S | 1 |
| Tandon, N | 1 |
| Bharadwaj, D | 1 |
| Hong, T | 2 |
| Molęda, P | 1 |
| Fronczyk, A | 1 |
| Safranow, K | 1 |
| Majkowska, L | 1 |
| Xuan, L | 1 |
| Zheng, F | 1 |
| Zhu, W | 1 |
| Han, JW | 1 |
| Shim, DW | 1 |
| Shin, WY | 1 |
| Kim, MK | 1 |
| Shim, EJ | 1 |
| Koppula, S | 1 |
| Kim, TJ | 1 |
| Kang, TB | 1 |
| Lee, KH | 1 |
| Wei, F | 1 |
| Li, WD | 1 |
| Li, YL | 1 |
| Musha, H | 1 |
| Xing, Y | 1 |
| Mei, CX | 1 |
| Wang, HJ | 1 |
| Wulasihan, M | 1 |
| Gugliucci, A | 2 |
| Fan, N | 1 |
| Xia, Z | 1 |
| Bu, H | 1 |
| Ma, X | 1 |
| Lu, S | 1 |
| Liang, CC | 1 |
| Lin, PC | 1 |
| Lee, MY | 1 |
| Chen, SC | 2 |
| Hsiao, PJ | 1 |
| Hsu, WH | 1 |
| Cicero, AF | 1 |
| Rosticci, M | 1 |
| Bove, M | 1 |
| Fogacci, F | 1 |
| Giovannini, M | 1 |
| Urso, R | 1 |
| D'Addato, S | 1 |
| Iwasa, T | 1 |
| Amiya, E | 1 |
| Ando, J | 1 |
| Watanabe, M | 1 |
| Murasawa, T | 1 |
| Komuro, I | 1 |
| Shi, J | 1 |
| Wang, A | 1 |
| Dalama, B | 1 |
| Mesa, J | 1 |
| Wu, N | 1 |
| Dai, W | 1 |
| Jin, N | 1 |
| Filippatos, TD | 1 |
| Elisaf, MS | 1 |
| Yokoyama, S | 1 |
| Tsuji, H | 1 |
| Hiraoka, S | 1 |
| Nishihara, M | 1 |
| Sipahi, S | 1 |
| Acikgoz, SB | 1 |
| Genc, AB | 1 |
| Yildirim, M | 1 |
| Solak, Y | 1 |
| Tamer, A | 1 |
| Miric, DJ | 1 |
| Kisic, BM | 1 |
| Filipovic-Danic, S | 1 |
| Grbic, R | 1 |
| Dragojevic, I | 1 |
| Miric, MB | 1 |
| Puhalo-Sladoje, D | 1 |
| Fouad, M | 1 |
| Fathy, H | 1 |
| Zidan, A | 1 |
| Maarman, GJ | 1 |
| Andrew, BM | 1 |
| Blackhurst, DM | 1 |
| Ojuka, EO | 1 |
| Sucher, S | 1 |
| Markova, M | 1 |
| Hornemann, S | 1 |
| Pivovarova, O | 1 |
| Rudovich, N | 1 |
| Thomann, R | 1 |
| Schneeweiss, R | 1 |
| Rohn, S | 1 |
| Pfeiffer, AFH | 1 |
| Wu, H | 1 |
| Bian, R | 1 |
| Chang, JB | 1 |
| Hung, YJ | 2 |
| Lee, CH | 1 |
| Wu, CZ | 1 |
| Liang, YJ | 1 |
| Lin, CM | 1 |
| Guo, M | 1 |
| Kanai, A | 1 |
| Kawamura, T | 1 |
| Umemura, T | 1 |
| Nagashima, M | 1 |
| Nakamura, N | 2 |
| Nakayama, M | 1 |
| Sano, T | 1 |
| Nakashima, E | 1 |
| Hamada, Y | 1 |
| Nakamura, J | 1 |
| Hotta, N | 1 |
| Dai, CY | 1 |
| Chuang, WL | 1 |
| Ho, CK | 1 |
| Ou, TT | 1 |
| Huang, JF | 1 |
| Hsieh, MY | 1 |
| Yu, ML | 1 |
| Lippi, G | 1 |
| Montagnana, M | 1 |
| Salvagno, GL | 1 |
| Guidi, GC | 1 |
| Lam, CW | 1 |
| Kong, AP | 1 |
| Tsui, TK | 1 |
| Chan, HM | 1 |
| Tong, SF | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Chan, JC | 1 |
| Sheu, WH | 2 |
| Lee, IT | 2 |
| Chan, YC | 1 |
| Xia, JF | 1 |
| Liang, QL | 1 |
| Hu, P | 1 |
| Wang, YM | 1 |
| Luo, GA | 1 |
| Perez-Pozo, SE | 1 |
| Manitius, J | 1 |
| Feig, DI | 2 |
| Segal, M | 1 |
| Glassock, RJ | 1 |
| Shimada, M | 1 |
| Roncal, C | 2 |
| Miao, Z | 1 |
| Meng, D | 1 |
| Gu, J | 1 |
| Wang, CY | 2 |
| Kramer, CK | 2 |
| von Mühlen, D | 2 |
| Jassal, SK | 2 |
| Barrett-Connor, E | 2 |
| Livesey, G | 1 |
| Heinig, M | 1 |
| Yuzawa, Y | 1 |
| Cambuli, VM | 1 |
| Incani, M | 1 |
| Pilia, S | 1 |
| Congiu, T | 1 |
| Cavallo, MG | 1 |
| Cossu, E | 1 |
| Sentinelli, F | 1 |
| Mariotti, S | 1 |
| Loche, S | 1 |
| Baroni, MG | 1 |
| Negri, C | 2 |
| Stoico, V | 1 |
| Perrone, F | 1 |
| Muggeo, M | 2 |
| Kodama, S | 1 |
| Saito, K | 1 |
| Yachi, Y | 1 |
| Asumi, M | 1 |
| Sugawara, A | 1 |
| Totsuka, K | 1 |
| Saito, A | 1 |
| Sone, H | 1 |
| Rojo-Martínez, G | 1 |
| de la Cruz Almaraz, M | 1 |
| Soriguer, F | 1 |
| García-Fuentes, E | 1 |
| Ljubic, S | 1 |
| Boras, J | 1 |
| Jazbec, A | 1 |
| Lovrencic, MV | 1 |
| Vidjak, V | 1 |
| Erzen, DJ | 1 |
| Mileta, D | 1 |
| Chen, CC | 1 |
| Wu, JY | 1 |
| Chang, CT | 1 |
| Tsai, FJ | 1 |
| Wang, TY | 1 |
| Liu, YM | 1 |
| Tsui, HC | 1 |
| Chen, RH | 1 |
| Chiou, SC | 1 |
| Qiu, Y | 1 |
| Su, M | 1 |
| Gümüş, P | 1 |
| Buduneli, N | 1 |
| Cetinkalp, S | 1 |
| Hawkins, SI | 1 |
| Renaud, D | 1 |
| Kinane, DF | 1 |
| Scott, DA | 1 |
| Oda, E | 1 |
| Kawai, R | 1 |
| Shelmadine, B | 1 |
| Bowden, RG | 1 |
| Wilson, RL | 1 |
| Beavers, D | 1 |
| Hartman, J | 1 |
| Rathmann, W | 3 |
| Strassburger, K | 1 |
| Heier, M | 1 |
| Holle, R | 1 |
| Thorand, B | 1 |
| Giani, G | 1 |
| Meisinger, C | 3 |
| Anan, F | 1 |
| Masaki, T | 1 |
| Ito, Y | 1 |
| Eto, T | 1 |
| Umeno, Y | 1 |
| Eshima, N | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Akin, F | 1 |
| Turgut, S | 1 |
| Bastemir, M | 1 |
| Turgut, G | 1 |
| Kursunluoglu, R | 1 |
| Karasu, U | 1 |
| Guclu, A | 1 |
| Ogbera, A | 1 |
| Fasanmade, O | 1 |
| Kalra, S | 1 |
| Causevic, A | 1 |
| Semiz, S | 1 |
| Macic Dzankovic, A | 1 |
| Cico, B | 1 |
| Dujic, T | 1 |
| Malenica, M | 1 |
| Bego, T | 1 |
| Ong, G | 1 |
| Davis, TM | 2 |
| Hermans, MP | 1 |
| Ahn, SA | 1 |
| Rousseau, MF | 1 |
| Tuomilehto, J | 2 |
| Cameron, MA | 2 |
| Wiik, BP | 1 |
| Larstorp, AC | 1 |
| Høieggen, A | 1 |
| Kjeldsen, SE | 1 |
| Olsen, MH | 1 |
| Ibsen, H | 1 |
| Lindholm, L | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Wachtell, K | 1 |
| Yu, HY | 1 |
| Barskova, VG | 1 |
| Johri, N | 1 |
| Cooper, B | 1 |
| Robertson, W | 1 |
| Choong, S | 1 |
| Rickards, D | 1 |
| Unwin, R | 1 |
| Fu, J | 1 |
| Chien, KL | 2 |
| Lin, HJ | 1 |
| Lee, BC | 1 |
| Hsu, HC | 2 |
| Lee, YT | 2 |
| Chen, MF | 2 |
| Tkacheva, ON | 1 |
| Sharashkina, NV | 1 |
| Novikova, IM | 1 |
| Torshkhoeva, KhM | 1 |
| Bhole, V | 1 |
| Choi, JW | 1 |
| Kim, SW | 1 |
| de Vera, M | 1 |
| Leoncini, G | 1 |
| Vercelli, M | 1 |
| Deferrari, G | 1 |
| Soegondo, S | 1 |
| Oemardi, M | 1 |
| Gumiwang, I | 1 |
| Hami, M | 1 |
| Shakeri, MT | 1 |
| Al-Rawi, NH | 1 |
| Charles, BA | 1 |
| Doumatey, A | 1 |
| Herbert, A | 1 |
| Gerry, NP | 1 |
| Christman, MF | 1 |
| Papanas, N | 3 |
| Papatheodorou, K | 2 |
| Demetriou, M | 2 |
| Papazoglou, D | 2 |
| Gioka, T | 2 |
| Maltezos, E | 3 |
| Yamada, T | 2 |
| Fukatsu, M | 1 |
| Suzuki, S | 1 |
| Wada, T | 1 |
| Joh, T | 1 |
| LI, SH | 1 |
| Elsurer, R | 1 |
| Güner, E | 1 |
| Kirkpantur, A | 1 |
| Hurina, NM | 1 |
| Korpacheva-Zinych, OV | 1 |
| Shuprovych, AA | 1 |
| Magri, CJ | 1 |
| Calleja, N | 1 |
| Buhagiar, G | 1 |
| Fava, S | 1 |
| Vassallo, J | 1 |
| Hari Kumar, KV | 1 |
| Modi, KD | 1 |
| Miao, Y | 1 |
| Ottenbros, SA | 1 |
| Laverman, GD | 1 |
| Brenner, BM | 1 |
| Cooper, ME | 1 |
| Grobbee, DE | 1 |
| Shahinfar, S | 1 |
| Kamatani, N | 4 |
| Naoyuki, K | 1 |
| Fujimori, S | 1 |
| Shin, F | 1 |
| Hada, T | 1 |
| Toshikazu, H | 1 |
| Hosoya, T | 1 |
| Tatsuo, H | 1 |
| Kohri, K | 1 |
| Kenjiro, K | 1 |
| Toshitaka, N | 1 |
| Ueda, T | 1 |
| Takanori, U | 1 |
| Tetsuya, Y | 1 |
| Yamanaka, H | 1 |
| Hisashi, Y | 1 |
| Matsuzawa, Y | 2 |
| Yuji, M | 1 |
| Hurtes, X | 1 |
| Meria, P | 1 |
| Bloomgarden, ZT | 1 |
| Pfister, R | 1 |
| Barnes, D | 1 |
| Luben, R | 1 |
| Bochud, M | 1 |
| Yuan, HJ | 1 |
| Yang, XG | 1 |
| Shi, XY | 1 |
| Zhao, ZG | 1 |
| Ogbera, OA | 1 |
| Okeoghene, OA | 1 |
| Azenabor, A | 1 |
| Lu, B | 1 |
| Wen, J | 1 |
| Tao, X | 1 |
| Bollée, G | 1 |
| Dahan, K | 1 |
| Flamant, M | 1 |
| Morinière, V | 1 |
| Pawtowski, A | 1 |
| Heidet, L | 1 |
| Lacombe, D | 1 |
| Devuyst, O | 1 |
| Pirson, Y | 1 |
| Antignac, C | 1 |
| Knebelmann, B | 1 |
| Kotsiou, S | 1 |
| Nayak, BS | 1 |
| Maharaj, N | 1 |
| Maharaj, SS | 1 |
| Evernden, K | 1 |
| Fane, U | 1 |
| Fatt, LA | 1 |
| Maharaj, D | 1 |
| Maharaj, S | 1 |
| Maharaj, V | 1 |
| Maloney, V | 1 |
| Bell, DS | 1 |
| Perticone, M | 2 |
| Arturi, F | 1 |
| Scarpino, PE | 1 |
| Quero, M | 1 |
| Chonchol, M | 1 |
| Ortalda, V | 1 |
| Abaterusso, C | 1 |
| Resl, M | 1 |
| Clodi, M | 1 |
| Neuhold, S | 1 |
| Kromoser, H | 1 |
| Riedl, M | 1 |
| Vila, G | 1 |
| Prager, R | 2 |
| Pacher, R | 1 |
| Strunk, G | 1 |
| Luger, A | 1 |
| Hülsmann, M | 1 |
| Altemtam, N | 1 |
| Russell, J | 1 |
| El Nahas, M | 1 |
| Dhaun, N | 1 |
| Webb, DJ | 2 |
| Hosokawa, Y | 1 |
| Yamada, Y | 1 |
| Obata, Y | 1 |
| Baden, MY | 1 |
| Saisho, K | 1 |
| Ihara, A | 1 |
| Yamamoto, K | 2 |
| Katsuragi, K | 1 |
| Teixeira de Lemos, E | 1 |
| Pinto, R | 1 |
| Oliveira, J | 1 |
| Garrido, P | 1 |
| Sereno, J | 1 |
| Mascarenhas-Melo, F | 1 |
| Páscoa-Pinheiro, J | 1 |
| Teixeira, F | 1 |
| Reis, F | 1 |
| Håglin, L | 2 |
| Bäckman, L | 1 |
| Törnkvist, B | 1 |
| Abbasi, A | 1 |
| Corpeleijn, E | 1 |
| Peelen, LM | 1 |
| Gansevoort, RT | 1 |
| de Jong, PE | 1 |
| Gans, RO | 2 |
| Kowall, B | 1 |
| Hillege, HL | 1 |
| Stolk, RP | 1 |
| Navis, G | 1 |
| Bakker, SJ | 2 |
| Panero, F | 1 |
| Gruden, G | 1 |
| Perotto, M | 1 |
| Fornengo, P | 1 |
| Barutta, F | 1 |
| Greco, E | 1 |
| Runzo, C | 1 |
| Ghezzo, G | 1 |
| Cavallo-Perin, P | 4 |
| Bruno, G | 2 |
| Maio, R | 1 |
| Tassone, JE | 1 |
| Pascale, A | 1 |
| Hirsch, FF | 1 |
| Pareja, JC | 1 |
| Geloneze, SR | 1 |
| Chaim, E | 1 |
| Cazzo, E | 1 |
| Geloneze, B | 1 |
| Schmid, R | 1 |
| Vollenweider, P | 1 |
| Bastardot, F | 1 |
| Waeber, G | 1 |
| Marques-Vidal, P | 1 |
| Chen, XP | 1 |
| Wan, LY | 1 |
| Cai, XL | 1 |
| Han, XY | 1 |
| Ji, LN | 1 |
| Nezami, N | 1 |
| Safa, J | 1 |
| Salari, B | 1 |
| Ghorashi, S | 1 |
| Khosraviani, K | 1 |
| Davari-Farid, S | 1 |
| Hashemi-Aghdam, Y | 1 |
| Nargabad, ON | 1 |
| Tabrizi, JS | 1 |
| Gu, Q | 1 |
| Hussain, TA | 1 |
| Mathew, TC | 1 |
| Dashti, AA | 1 |
| Asfar, S | 1 |
| Al-Zaid, N | 1 |
| Dashti, HM | 1 |
| Chen, JF | 1 |
| Lee, WJ | 2 |
| Zhu, P | 1 |
| Lin, F | 1 |
| Lin, C | 1 |
| Hong, D | 1 |
| Lin, K | 1 |
| Ndrepepa, G | 1 |
| Braun, S | 1 |
| King, L | 1 |
| Cassese, S | 1 |
| Tada, T | 1 |
| Fusaro, M | 1 |
| Hadamitzky, M | 1 |
| Haase, HU | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| Dixon, JB | 1 |
| Chuang, LM | 1 |
| Lambert, GW | 1 |
| Straznicky, NE | 1 |
| Lambert, EA | 1 |
| Jeemon, P | 1 |
| Prabhakaran, D | 1 |
| Schulze, MB | 1 |
| Takeuchi, F | 1 |
| Isono, M | 1 |
| Katsuya, T | 1 |
| Akiyama, K | 1 |
| Ohnaka, K | 1 |
| Rakugi, H | 1 |
| Yamori, Y | 1 |
| Ogihara, T | 1 |
| Takayanagi, R | 1 |
| Kato, N | 1 |
| Fonseca, VA | 1 |
| Seok, HY | 1 |
| Osgood, K | 1 |
| Krakoff, J | 1 |
| Thearle, M | 1 |
| Saeed, A | 1 |
| Jones, SA | 1 |
| Nuttall, FQ | 3 |
| Gannon, MC | 3 |
| Yokoyama, H | 2 |
| Hirose, H | 1 |
| Moriya, S | 1 |
| Saito, I | 1 |
| Wasada, T | 5 |
| Iwatani, M | 4 |
| Guan, MP | 1 |
| Xue, YM | 1 |
| Liu, SQ | 1 |
| Li, CZ | 1 |
| Niu, T | 1 |
| García Morillo, JS | 1 |
| García-Junco, PS | 1 |
| Miranda Guisado, ML | 1 |
| Vallejo Maroto, I | 1 |
| Pamies Andreu, E | 1 |
| Muñiz Grigalvo, O | 1 |
| Carneado de la Fuente, J | 1 |
| Villar Ortiz, J | 1 |
| Pak, CY | 1 |
| Moe, O | 1 |
| Preminger, GM | 1 |
| Poindexter, JR | 1 |
| Peterson, RD | 1 |
| Pietrow, P | 1 |
| Ekeruo, W | 1 |
| Nakanishi, N | 2 |
| Okamoto, M | 2 |
| Yoshida, H | 2 |
| Matsuo, Y | 2 |
| Suzuki, K | 2 |
| Tatara, K | 2 |
| Kiss, C | 1 |
| Poór, G | 1 |
| Donáth, J | 1 |
| Gergely, P | 1 |
| Paksy, A | 1 |
| Zajkás, G | 1 |
| Antal, M | 1 |
| Tsai, JC | 1 |
| Nishina, K | 1 |
| Filikowski, J | 1 |
| Rzepiak, M | 1 |
| Renke, W | 1 |
| Winnicka, A | 1 |
| Smolińska, D | 1 |
| Kurtul, N | 1 |
| Pence, S | 1 |
| Akarsu, E | 1 |
| Kocoglu, H | 1 |
| Aksoy, Y | 1 |
| Aksoy, H | 2 |
| Tseng, CH | 3 |
| Pasaoglu, H | 1 |
| Sancak, B | 1 |
| Bukan, N | 1 |
| Mitsuhashi, N | 1 |
| Tanaka, Y | 2 |
| Kubo, S | 1 |
| Ogawa, S | 1 |
| Hayashi, C | 1 |
| Uchino, H | 1 |
| Shimizu, T | 1 |
| Watada, H | 1 |
| Kawasumi, M | 1 |
| Onuma, T | 1 |
| Kawamori, R | 1 |
| Charvát, J | 1 |
| Michalová, K | 1 |
| Táborská, K | 1 |
| Chlumský, J | 1 |
| Kvapil, M | 1 |
| Vojácek, J | 1 |
| Mazza, A | 2 |
| Bossone, E | 1 |
| Mazza, F | 1 |
| Distante, A | 1 |
| Lyoussi, B | 1 |
| Ragala, MA | 1 |
| Mguil, M | 1 |
| Chraibi, A | 1 |
| Israili, ZH | 1 |
| Seber, S | 1 |
| Ucak, S | 1 |
| Basat, O | 1 |
| Altuntas, Y | 1 |
| Huang, EJ | 1 |
| Kuo, WW | 1 |
| Chen, TH | 1 |
| Chang, MH | 1 |
| Lu, MC | 1 |
| Tzang, BS | 1 |
| Hsu, HH | 1 |
| Huang, CY | 1 |
| Lee, SD | 1 |
| Niskanen, L | 2 |
| Laaksonen, DE | 1 |
| Lindström, J | 1 |
| Eriksson, JG | 1 |
| Keinänen-Kiukaanniemi, S | 1 |
| Ilanne-Parikka, P | 1 |
| Aunola, S | 1 |
| Hämäläinen, H | 1 |
| Uusitupa, M | 1 |
| Gotoh, M | 1 |
| Yatoh, M | 1 |
| Iguchi, A | 1 |
| Hirooka, Y | 1 |
| Schweim, K | 1 |
| Hoover, H | 1 |
| Daudon, M | 2 |
| Traxer, O | 1 |
| Conort, P | 1 |
| Lacour, B | 1 |
| Jungers, P | 2 |
| Choo, KE | 1 |
| Lau, KB | 1 |
| Chew, PH | 1 |
| Bianchi, C | 1 |
| Malloggi, L | 1 |
| Barontini, R | 1 |
| Corfini, M | 1 |
| Giovannitti, MG | 1 |
| Di Cianni, G | 1 |
| Del Prato, S | 1 |
| Miccoli, R | 1 |
| Zamboni, S | 1 |
| Rizzato, E | 1 |
| Pessina, AC | 2 |
| Tikhonoff, V | 1 |
| Schiavon, L | 1 |
| Casiglia, E | 1 |
| Akande, AA | 1 |
| Jimoh, AK | 1 |
| Akinyinka, OA | 1 |
| Olarinoye, GO | 1 |
| Segal, MS | 1 |
| Sautin, Y | 1 |
| Kang, DH | 1 |
| Gersch, MS | 1 |
| Benner, S | 1 |
| Waring, WS | 1 |
| McKnight, JA | 1 |
| Maxwell, SR | 2 |
| Wakabayashi, I | 1 |
| Masuda, H | 1 |
| Mohora, M | 1 |
| Vîrgolici, B | 1 |
| Coman, A | 1 |
| Muscurel, C | 1 |
| Găman, L | 1 |
| Gruia, V | 1 |
| Greabu, M | 1 |
| Ioachimescu, AG | 1 |
| Brennan, DM | 1 |
| Hoar, BM | 1 |
| Kashyap, SR | 1 |
| Hoogwerf, BJ | 1 |
| van Hoek, M | 1 |
| Sijbrands, EJ | 1 |
| Hofman, A | 1 |
| Witteman, JC | 1 |
| Nath, SD | 1 |
| Voruganti, VS | 1 |
| Arar, NH | 1 |
| Thameem, F | 1 |
| Lopez-Alvarenga, JC | 1 |
| Bauer, R | 1 |
| Blangero, J | 1 |
| MacCluer, JW | 1 |
| Comuzzie, AG | 1 |
| Abboud, HE | 1 |
| Abe, H | 1 |
| Minatoguchi, S | 1 |
| Ohashi, H | 1 |
| Murata, I | 1 |
| Minagawa, T | 1 |
| Okuma, T | 1 |
| Takatsu, H | 1 |
| Takaya, T | 1 |
| Nagano, T | 1 |
| Osumi, Y | 1 |
| Kakami, M | 1 |
| Tsukamoto, T | 1 |
| Hiei, K | 1 |
| Fujiwara, H | 1 |
| Chang, WT | 1 |
| Su, TC | 1 |
| Hu, FB | 1 |
| Koenig, W | 1 |
| Pitocco, D | 1 |
| Zaccardi, F | 1 |
| Di Stasio, E | 1 |
| Romitelli, F | 1 |
| Santini, SA | 1 |
| Ghirlanda, G | 1 |
| Shiraishi, E | 1 |
| Harusato, I | 1 |
| Hosoda, H | 1 |
| Asano, M | 1 |
| Kadono, M | 1 |
| Hasegawa, G | 1 |
| Yoshikawa, T | 1 |
| Brandstätter, A | 1 |
| Kiechl, S | 2 |
| Kollerits, B | 1 |
| Hunt, SC | 1 |
| Heid, IM | 1 |
| Coassin, S | 1 |
| Willeit, J | 2 |
| Adams, TD | 1 |
| Illig, T | 1 |
| Hopkins, PN | 1 |
| Kronenberg, F | 1 |
| Roche, S | 1 |
| Moinade, S | 1 |
| Mohan, V | 1 |
| Snehalatha, C | 1 |
| Jayashree, R | 1 |
| Ramachandran, A | 1 |
| Viswanathan, M | 1 |
| Kameswaran, L | 1 |
| Rocic, B | 2 |
| Breyer, D | 1 |
| Skrabalo, Z | 1 |
| Coniff, RF | 1 |
| Shapiro, JA | 1 |
| Robbins, D | 1 |
| Kleinfield, R | 1 |
| Seaton, TB | 1 |
| Beisswenger, P | 1 |
| McGill, JB | 1 |
| Harper, R | 1 |
| Ennis, CN | 1 |
| Heaney, AP | 1 |
| Sheridan, B | 1 |
| Gormley, M | 1 |
| Atkinson, AB | 1 |
| Johnston, GD | 1 |
| Bell, PM | 1 |
| Yamazaki, K | 1 |
| Griesmacher, A | 1 |
| Kindhauser, M | 1 |
| Andert, SE | 1 |
| Schreiner, W | 1 |
| Knoebl, P | 1 |
| Pietschmann, P | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Rett, K | 1 |
| Wicklmayr, M | 1 |
| Standl, E | 1 |
| Troillet, N | 1 |
| Gerster, JC | 1 |
| Pearl, A | 1 |
| Hale, A | 1 |
| Whitehead, T | 1 |
| Golik, A | 1 |
| Weissgarten, J | 1 |
| Cotariu, D | 1 |
| Cohen, N | 1 |
| Zaidenstein, R | 1 |
| Ramot, Y | 1 |
| Averbukh, Z | 1 |
| Modai, D | 1 |
| Hauner, H | 1 |
| Dannehl, K | 1 |
| Gries, FA | 1 |
| Motala, AA | 1 |
| Omar, MA | 1 |
| Gouws, E | 1 |
| Zazgornik, J | 1 |
| Biesenbach, G | 1 |
| Janko, O | 1 |
| Grafinger, P | 1 |
| Kaiser, W | 1 |
| Stuby, U | 1 |
| Hubmann, R | 1 |
| Georgadze, ZO | 1 |
| Balabolkin, MI | 3 |
| Mamaeva, GG | 1 |
| Liudina, LI | 1 |
| Mishchenko, BP | 1 |
| Arbuzova, MI | 1 |
| Bargero, G | 1 |
| Borra, M | 1 |
| Calvi, V | 1 |
| D'Errico, N | 1 |
| Deambrogio, P | 1 |
| Pagano, G | 3 |
| Jacob, S | 1 |
| Henriksen, EJ | 1 |
| Tritschler, HJ | 1 |
| Augustin, HJ | 1 |
| Dietze, GJ | 1 |
| Ekoé, JM | 1 |
| Thomas, F | 1 |
| Eschwege, E | 2 |
| Delisle, H | 1 |
| Crepaldi, G | 1 |
| Manzato, E | 1 |
| Katsumori, K | 2 |
| Saeki, A | 1 |
| Drabo, PY | 1 |
| Kabore, J | 1 |
| Lengani, A | 1 |
| Ilboudo, PD | 1 |
| Bortolotti, N | 4 |
| Falleti, E | 1 |
| Taboga, C | 4 |
| Tonutti, L | 4 |
| Crescentini, A | 4 |
| Motz, E | 4 |
| Lizzio, S | 3 |
| Russo, A | 4 |
| Bartoli, E | 1 |
| Ragoobirsingh, D | 1 |
| Bennett, F | 1 |
| Morrison, EY | 1 |
| Thomason, H | 1 |
| Sandler, D | 1 |
| Leguen, C | 1 |
| Baxter, MA | 1 |
| Thorpe, GH | 1 |
| Jones, AF | 1 |
| Barnett, AH | 1 |
| Relimpio, F | 1 |
| Losada, F | 1 |
| Pumar, A | 1 |
| García de Pesquera, F | 1 |
| Morales, F | 1 |
| Acosta, D | 1 |
| Astorga, R | 1 |
| Vucić, M | 1 |
| Bozikov, V | 1 |
| Ashcroft, SJ | 1 |
| Madianov, IV | 2 |
| Saperov, VN | 1 |
| Markov, DS | 2 |
| Oreshnikov, EV | 1 |
| Grigor'ev, AA | 1 |
| Markova, TN | 2 |
| Pirisi, M | 1 |
| Giacomello, R | 1 |
| Stel, G | 1 |
| Reaven, GM | 2 |
| Paragh, G | 1 |
| Balogh, Z | 1 |
| Boda, J | 1 |
| Kovács, P | 1 |
| Kárpáti, L | 1 |
| Szabó, J | 1 |
| Leövey, A | 1 |
| Lehto, S | 1 |
| Rönnemaa, T | 1 |
| Laakso, M | 1 |
| Ohashi, K | 1 |
| Yazaki, Y | 1 |
| Yamada, N | 1 |
| Aguirre, F | 1 |
| Martin, I | 1 |
| Grinspon, D | 1 |
| Ruiz, M | 1 |
| Hager, A | 1 |
| De Paoli, T | 1 |
| Ihlo, J | 1 |
| Farach, HA | 1 |
| Poole, CP | 1 |
| Ezsol, Z | 1 |
| Chou, P | 1 |
| Li, CL | 1 |
| Wu, GS | 1 |
| Tsai, ST | 1 |
| Oberhollenzer, F | 1 |
| Egger, G | 1 |
| Alberiche, M | 1 |
| Bonadonna, RC | 1 |
| Turco, S | 1 |
| Torella, R | 1 |
| Leinonen, J | 1 |
| Rantalaiho, V | 1 |
| Lehtimäki, T | 1 |
| Koivula, T | 1 |
| Wirta, O | 1 |
| Pasternack, A | 1 |
| Alho, H | 1 |
| Pogátsa, G | 1 |
| Nanko, H | 1 |
| Iwasaki, N | 1 |
| Iwamoto, Y | 3 |
| Saunders, JP | 1 |
| Donner, TW | 1 |
| Sadler, JH | 1 |
| Levin, GV | 1 |
| Makris, NG | 1 |
| Benzie, IF | 1 |
| Chung, Wy | 1 |
| Tomlinson, B | 1 |
| Fruehwald-Schultes, B | 1 |
| Peters, A | 1 |
| Kern, W | 1 |
| Beyer, J | 1 |
| Pfützner, A | 1 |
| Hammarsten, J | 1 |
| Högstedt, B | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Longo-Mbenza, B | 1 |
| Luila, EL | 1 |
| Mbete, P | 1 |
| Vita, EK | 1 |
| Pitkänen, OM | 1 |
| Vanhanen, H | 1 |
| Pitkänen, E | 1 |
| Wun, YT | 1 |
| Chan, CS | 1 |
| Lui, CS | 1 |
| Omboni, S | 1 |
| Casati, R | 1 |
| Fogari, R | 1 |
| Leonetti, G | 1 |
| Montemurro, G | 1 |
| Nami, R | 1 |
| Pirrelli, A | 1 |
| Zanchetti, A | 1 |
| Wannamethee, SG | 1 |
| Shaper, AG | 1 |
| Alberti, KG | 1 |
| Watanabe-Takahashi, C | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Charles, MA | 2 |
| Courderot-Masuyer, C | 1 |
| Lahet, JJ | 1 |
| Verges, B | 1 |
| Brun, JM | 1 |
| Rochette, L | 1 |
| Nuttall, JA | 1 |
| Damberg, G | 1 |
| Gupta, V | 1 |
| ter Maaten, JC | 1 |
| Teerlink, T | 1 |
| Westerhoff, HV | 1 |
| Heine, RJ | 1 |
| Bo, S | 2 |
| Gentile, L | 2 |
| Repetti, E | 2 |
| Kanda, H | 1 |
| Shoji, T | 1 |
| Kawagishi, T | 1 |
| Tahara, H | 1 |
| Okuno, Y | 1 |
| Nishizawa, Y | 1 |
| Keles, S | 1 |
| Koçer, I | 1 |
| Akçay, F | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Taniguchi, Y | 1 |
| Tsumura, K | 1 |
| Endo, G | 1 |
| Fujii, S | 1 |
| Chen, SY | 1 |
| Chen, CL | 1 |
| Shen, ML | 1 |
| Costa, A | 1 |
| Igualá, I | 1 |
| Bedini, J | 1 |
| Quintó, L | 1 |
| Conget, I | 1 |
| Kanabrocki, EL | 1 |
| Murray, D | 1 |
| Hermida, RC | 1 |
| Scott, GS | 1 |
| Bremner, WF | 1 |
| Ryan, MD | 1 |
| Ayala, DE | 1 |
| Third, JL | 1 |
| Shirazi, P | 1 |
| Nemchausky, BA | 1 |
| Hooper, DC | 1 |
| Seghieri, G | 1 |
| Moruzzo, D | 1 |
| Fascetti, S | 1 |
| Bambini, C | 1 |
| Anichini, R | 1 |
| De Bellis, A | 1 |
| Alviggi, L | 1 |
| Franconi, F | 1 |
| Moriwaki, Y | 1 |
| Suda, M | 1 |
| Agbedana, EO | 1 |
| Higashino, K | 1 |
| Sasaki, N | 1 |
| Yamakawa, M | 1 |
| Kosaka, H | 1 |
| Kotake, H | 1 |
| Mashiba, H | 1 |
| Takeda, A | 1 |
| Olukoga, AO | 1 |
| Erasmus, RT | 1 |
| Akinlade, KS | 1 |
| Okesina, AB | 1 |
| Alanamu, AA | 1 |
| Abu, EA | 1 |
| Mavrikakis, ME | 1 |
| Sfikakis, PP | 1 |
| Kontoyannis, SA | 1 |
| Antoniades, LG | 1 |
| Kontoyannis, DA | 1 |
| Moulopoulou, DS | 1 |
| Sewdarsen, M | 1 |
| Vythilingum, S | 1 |
| Jialal, I | 1 |
| Kamdar, MC | 1 |
| Jitapunkul, S | 1 |
| Chalaprawat, M | 1 |
| Bunnag, S | 1 |
| Bhuvapanich, S | 1 |
| Kangkaya, V | 1 |
| Pasatrat, S | 1 |
| Vajanamarhutue, C | 1 |
| Fontbonne, A | 1 |
| Thibult, N | 1 |
| Warnet, JM | 1 |
| Rosselin, GE | 1 |
| Di Pietro, S | 1 |
| Suraci, C | 1 |
| Tkác, I | 1 |
| Bomba, J | 1 |
| Cvanigová, A | 1 |
| Thalassinos, NC | 1 |
| Shichiri, M | 2 |
| Iwamoto, H | 2 |
| Marumo, F | 1 |
| Taş, S | 1 |
| Zein el Din, RR | 1 |
| Ishihara, M | 1 |
| Shinoda, T | 1 |
| Valesano, G | 1 |
| Magnacca, M | 1 |
| Schmechel, H | 1 |
| Schulze, J | 1 |
| Hanefeld, M | 1 |
| Julius, U | 1 |
| Schwanebeck, U | 1 |
| Lippold, C | 1 |
| Modan, M | 1 |
| Halkin, H | 1 |
| Karasik, A | 1 |
| Lusky, A | 1 |
| Berntorp, K | 1 |
| Lindgärde, F | 1 |
| Mattiasson, I | 1 |
| Shiigai, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovas[NCT01131676] | Phase 3 | 7,064 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Flow Mediated Dilation in Association With Hyperuricemia as Predictors of Cardiovascular Affection in Patients With Systemic Lupus[NCT05342285] | 60 participants (Anticipated) | Observational | 2022-07-30 | Recruiting | |||
| Study of Novel Approaches for Prevention[NCT01183689] | 599 participants (Actual) | Interventional | 2010-08-31 | Completed | |||
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Stu[NCT01986881] | Phase 3 | 8,246 participants (Actual) | Interventional | 2013-11-04 | Completed | ||
| Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial[NCT05042505] | 100 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria[NCT03118739] | Phase 2 | 60 participants (Actual) | Interventional | 2017-05-18 | Completed | ||
| Renal Sensing of the Acidifying Effect of Sulphur-containing Amino Acids: Consequences for the Relation Between Protein Intake and Blood Pressure in Renal Transplant Recipients[NCT02811835] | 1,007 participants (Actual) | Observational [Patient Registry] | 2008-11-30 | Active, not recruiting | |||
| Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders[NCT06092346] | 999 participants (Anticipated) | Observational | 2024-01-03 | Recruiting | |||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| The Bogalusa Heart Study[NCT00005129] | 11,737 participants (Actual) | Observational | 1972-06-30 | Active, not recruiting | |||
| A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia[NCT01984749] | 1,000 participants (Anticipated) | Interventional | 2013-11-30 | Active, not recruiting | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Adverse Metabolic Effects of Dietary Sugar: Ad Libitum vs Energy-balanced Diets[NCT02548767] | 36 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled, 9-month, Parallel Group Study of Allopurinol to Reduce Left Ventricular Mass in Living Kidney Donors (AL-DON)[NCT03353298] | Phase 2 | 71 participants (Actual) | Interventional | 2018-01-17 | Completed | ||
| Genetic-specific Effects of Fructose on Liver Lipogenesis[NCT03783195] | 15 participants (Actual) | Interventional | 2019-01-25 | Completed | |||
| A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study[NCT02958579] | 10,000 participants (Anticipated) | Observational | 2005-01-31 | Recruiting | |||
| The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects[NCT03157960] | 20 participants (Actual) | Interventional | 2012-02-01 | Completed | |||
| Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial[NCT02502071] | Phase 4 | 45 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Neutrophil Gelatinase Associated Lipocalin and Kidney Injury Molecule-1 As Biomarkers of Acute Kidney Injury in Children With Diabetic Ketoacidosis[NCT06032325] | 48 participants (Anticipated) | Observational [Patient Registry] | 2024-01-01 | Not yet recruiting | |||
| A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes[NCT02887677] | Phase 4 | 85 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.) | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309] | 465 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma[NCT05119010] | 60 participants (Anticipated) | Interventional | 2023-03-24 | Recruiting | |||
| Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322] | Phase 4 | 226 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans[NCT01471509] | 300 participants (Anticipated) | Interventional | 1982-08-31 | Suspended (stopped due to Lack of funding) | |||
| The Relationship Between Uric Acid and Inflammatory Markers[NCT01323335] | Phase 1 | 97 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications[NCT00518167] | 522 participants (Actual) | Interventional | 1993-11-30 | Active, not recruiting | |||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Influence of Food Liking of Adding Spices to Replace Dietary Sugar Using Sequential Monadic CLT Methodology[NCT03139552] | 150 participants (Actual) | Interventional | 2016-10-17 | Completed | |||
| Influence on Food Liking of Adding Spices to Replace Dietary Sugar[NCT03134079] | 160 participants (Actual) | Interventional | 2015-09-10 | Completed | |||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Omentectomy for Treatment of Diabetes Mellitus Type 2[NCT00270439] | Phase 1 | 10 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia[NCT01082588] | Phase 4 | 60 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids[NCT00184899] | 20 participants | Interventional | 2005-08-31 | Completed | |||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Heart failure requiring hospitalisation (adjudicated). Percentage of patients with the event are presented. (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 4.1 |
| Empagliflozin 10 mg | 2.6 |
| Empagliflozin 25 mg | 2.8 |
| All Empagliflozin | 2.7 |
"New onset albuminuria defined as urine albumin / creatinine ratio (UACR) ≥30 mg/g.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 51.2 |
| Empagliflozin 10 mg | 51.5 |
| Empagliflozin 25 mg | 51.5 |
| All Empagliflozin | 51.5 |
New onset macroalbuminuria defined as UACR >300 mg/g. Percentage of patients with the event are presented. (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.2 |
| Empagliflozin 10 mg | 10.9 |
| Empagliflozin 25 mg | 11.5 |
| All Empagliflozin | 11.2 |
"Silent MI; defined as presence in the ECG of:~Any Q-wave in leads V2-V3 ≥0.02 seconds or QS complex in leads V2 and V3~Q-wave ≥0.03 seconds and ≥0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two leads of a contiguous lead grouping (I, aVL, V6; V4-V6; II, III, and aVF)~R-wave ≥0.04 seconds in V1-V2 and R/S ≥1 with a concordant positive T-wave in the absence of a conduction defect.~It was also required that there had been no adjudicated and confirmed event of either acute MI, hospitalisation for unstable angina, coronary revascularisation procedures or stent thrombosis following randomisation up to and including the date of the specified ECG measurement.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.2 |
| Empagliflozin 10 mg | 1.6 |
| Empagliflozin 25 mg | 1.6 |
| All Empagliflozin | 1.6 |
"Composite microvascular outcome defined as:~Initiation of retinal photocoagulation~Vitreous haemorrhage~Diabetes-related blindness, or~New or worsening nephropathy defined as:~New onset of macroalbuminuria; or~Doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73m2; or~Initiation of continuous renal replacement therapy, or~Death due to renal disease. Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.5 |
| Empagliflozin 10 mg | 13.9 |
| Empagliflozin 25 mg | 14.1 |
| All Empagliflozin | 14.0 |
"The composite of all events adjudicated (4-point MACE): cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction (excluding silent MI), non-fatal stroke and hospitalization for unstable angina pectoris.This is a key secondary endpoint of the trial.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 14.3 |
| Empagliflozin 10 mg | 12.8 |
| Empagliflozin 25 mg | 12.8 |
| All Empagliflozin | 12.8 |
"Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI (excluding silent MI), and non-fatal stroke.~Percentage of patients with the event are presented." (NCT01131676)
Timeframe: From randomisation to individual end of observation, up to 4.6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 12.1 |
| Empagliflozin 10 mg | 10.4 |
| Empagliflozin 25 mg | 10.5 |
| All Empagliflozin | 10.5 |
Waist circumference will be measured using a Gulik tape measure and following a standardized protocol. Two measures of waist circumference will be taken; if the difference exceeds 1.0 cm, a third measure will be taken. Changes are measured from baseline to year 2. (NCT01183689)
Timeframe: Change from baseline to 2 years
| Intervention | centimeters (Mean) |
|---|---|
| Control Group | 0.21 |
| Small Behavior Changes | -1.06 |
| Large Behavior Changes | -2.21 |
Mean changes in the Center for Epidemiologic Studies Depression (CES-C) Scale. Reference: Turvey, C. L., Wallace, R. B., & Herzog, R. (1999). A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr, 11(2), 139-148. 20 item questionnaire with a possible range of scores is zero to 60, and higher scores indicating the presence of more symptomatology. (NCT01183689)
Timeframe: 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Control Group | 1.68 |
| Small Behavior Changes | 0.60 |
| Large Behavior Changes | 1.73 |
"The Eating Inventory (Stunkard, 1988) is a 51-item self-report instrument, was used to assess the subscale of dietary restraint (e.g., degree of conscious control exerted over eating behaviors; range from 0-21 with higher scores reflecting greater levels of restraint).~Reference: Stunkard, A. J. M., S. (1988). Eating Inventory Manual. New York: Psychological Corporation." (NCT01183689)
Timeframe: 2 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Control Group | 0.39 |
| Small Behavior Changes | 0.59 |
| Large Behavior Changes | 1.27 |
"The Eating Inventory (TFEQ(Stunkard, 1988), a 51-item self-report instrument, was used to assess the subscale of disinhibition (e.g., susceptibility to loss of control over eating; range 0-16, with higher scores reflecting greater levels of disinhibition).~REF: Stunkard, A. J. M., S. (1988). Eating Inventory Manual. New York: Psychological Corporation." (NCT01183689)
Timeframe: Changes at 2 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Control Group | 0.07 |
| Small Behavior Changes | -0.78 |
| Large Behavior Changes | -0.03 |
"Flexible control is characterized by a balanced approach to eating (e.g., taking smaller portions to control weight, engaging in healthy compensation) and is associated with better weight management outcomes (Westenhoefer, Stunkard, & Pudel, 1999). Scores range from 0 to 12 with higher scores reflecting greater levels of flexible control.~REF: Westenhoefer, J., Stunkard, A. J., & Pudel, V. (1999). Validation of the flexible and rigid control dimensions of dietary restraint. Int J Eat Disord, 26(1), 53-64." (NCT01183689)
Timeframe: Changes from baseline to 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Control Group | 0.39 |
| Small Behavior Changes | 0.59 |
| Large Behavior Changes | 1.27 |
"The General Health Index, a one-item question from the CDC's Health-Related Quality of Life measure (Measuring Healthy Days, 2000) required participants to report whether in general their health is excellent (1), very good (2), good (3), fair (4), or poor (5). Lower scores denotes better outcomes.~Ref: Measuring Healthy Days. (2000). Atlanta, Georgia: Centers for Disease Control and Prevention" (NCT01183689)
Timeframe: Changes from baseline to 2 years
| Intervention | 2 year changes in units on a scale (Mean) |
|---|---|
| Control Group | 0.04 |
| Small Behavior Changes | -0.04 |
| Large Behavior Changes | -0.11 |
We calculated homeostatic model assessment insulin resistance (HOMA-IR): fasting glucose in (mg/dl) * fasting insulin in (uU/mL). (NCT01183689)
Timeframe: Change from baseline to 2 years
| Intervention | HOMA-IR (Mean) |
|---|---|
| Control Group | -0.03 |
| Small Behavior Changes | -0.15 |
| Large Behavior Changes | -0.33 |
Mean change in fasting glucose from baseline to 2 years in mg/dl for all participants with year 2 measures (NCT01183689)
Timeframe: 2 years
| Intervention | Mean change from baseline in mg/dl (Mean) |
|---|---|
| Control Group | 1.48 |
| Small Behavior Changes | 0.40 |
| Large Behavior Changes | -0.18 |
Mean change in fasting insulin (uU/ml) from baseline to 2 years (NCT01183689)
Timeframe: 2 years
| Intervention | Mean changes at 2 years in uU/ml (Mean) |
|---|---|
| Control Group | -0.27 |
| Small Behavior Changes | -0.73 |
| Large Behavior Changes | -1.48 |
Change from baseline to 2 years in diastolic blood pressure (NCT01183689)
Timeframe: 2 years
| Intervention | mmHg (Mean) |
|---|---|
| Control Group | -0.41 |
| Small Behavior Changes | -2.14 |
| Large Behavior Changes | -1.33 |
Mean changes from baseline to 2 years in total cholesterol among participants with Year 2 measurements (mg/dl) (NCT01183689)
Timeframe: 2 years
| Intervention | mg/dl (Mean) |
|---|---|
| Control Group | -0.56 |
| Small Behavior Changes | 0.74 |
| Large Behavior Changes | 1.33 |
Mean changes in HDL-C from baseline to year 2 in (mg/dl) for compared among the 3 arms using analysis of variance (NCT01183689)
Timeframe: 2 years
| Intervention | Mean Change from Baseline in mg/dl (Mean) |
|---|---|
| Control Group | -0.09 |
| Small Behavior Changes | 1.43 |
| Large Behavior Changes | 2.12 |
Mean changes between baseline and 2 years in low density lipoprotein cholesterol: LDL-c (mg/dl) (NCT01183689)
Timeframe: 2 years
| Intervention | Mean change in LDL-C in mg/dl (Mean) |
|---|---|
| Control Group | -0.01 |
| Small Behavior Changes | 0.16 |
| Large Behavior Changes | 1.43 |
Compare changes in systolic blood pressure across the three intervention groups (NCT01183689)
Timeframe: Measured at 2 Years
| Intervention | mmHg (Mean) |
|---|---|
| Control Group | 1.73 |
| Small Behavior Changes | -3.72 |
| Large Behavior Changes | -2.66 |
Mean differences in weight changes among intervention groups at 24 months post-randomization (NCT01183689)
Timeframe: 2 years
| Intervention | kilograms (Mean) |
|---|---|
| Control Group | 0.54 |
| Self-regulation With Small Behavior Changes | -0.77 |
| Self-regulation With Large Behavior Changes | -1.50 |
Percentage of those participants whose body mass index at baseline was less than 30 kg/m2 who subsequently transitioned to a body mass index of 30 kg/m2 or more (i.e. met criteria for obesity) sometime during 3 years of follow-up (i.e. at least one visit). Percentages will be compared among the three arms of the trial and summarized with odds ratios Participants were assigned values of 0 or 1 at each exam depending on their obesity level. Inference is based on generalized estimating equations. (NCT01183689)
Timeframe: 3 years
| Intervention | percentage of participants (Mean) |
|---|---|
| Control Group | 16.9 |
| Self-regulation With Small Behavior Changes | 7.9 |
| Self-regulation With Large Behavior Changes | 8.6 |
"Rigid control is characterized by an all-or-nothing inflexibility around dietary rules (e.g., strict calorie counting, with guilt following if calorie-dense foods are consumed) that is associated with poor weight outcomes and more binge eating (Westenhoefer, Stunkard, & Pudel, 1999). Scores range from 0 to 16 with higher scores reflecting greater rigid control.~REF: Stunkard, A. J. M., S. (1988). Eating Inventory Manual. New York: Psychological Corporation." (NCT01183689)
Timeframe: Changes from baseline to 2 years
| Intervention | 2 year changes in units on a scale (Mean) |
|---|---|
| Control Group | 0.35 |
| Small Behavior Changes | 0.22 |
| Large Behavior Changes | 1.75 |
Number of days per week the participant reports weighing themselves. This is divided into two groups: 1) more than once per week and 2) no more than once per week (NCT01183689)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 30 |
| Small Behavior Changes | 44 |
| Large Behavior Changes | 56 |
"Dietary intake was assessed using the 2005 Block Food Frequency Questionnaire (Block FFQ) at baseline and 2 years. This validated, quantitative 110-food item questionnaire is designed to assess relative intake of energy.~REF: Block G, Woods M, Potosky A, Clifford C. Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990; 43:1327-1335." (NCT01183689)
Timeframe: Changes from baseline to 2 years in kilocalories
| Intervention | kilocalories (Mean) |
|---|---|
| Control Group | -134 |
| Small Behavior Changes | -186 |
| Large Behavior Changes | -185 |
Mean weight change from baseline across an average planned follow-up of three years. These mean changes will be compared among the three arms of the trial. (NCT01183689)
Timeframe: 3 years
| Intervention | kilograms (Mean) |
|---|---|
| Control Group | 0.26 |
| Self-regulation With Small Behavior Changes | -0.56 |
| Self-regulation With Large Behavior Changes | -2.37 |
Average over time (average follow-up of 3 years) of the percent of participants within each arm of the trial who gain 1 pound or more at each visit. These percentages will be compared among the three arms generalized estimating equations. Note that weight changes in units of pounds were used to define this outcome so that it may be more clear to participants. Elsewhere in the protocol, weight is reported in kilograms. Percentages at each visit are the percent who gained 1 pound or more from baseline among all who were weighed at that visit. Participants were assigned values of 0 or 1 at each visit depending on their weight gain status. (NCT01183689)
Timeframe: 3 years
| Intervention | percentage gaining 1 pound or more among (Mean) |
|---|---|
| Control Group | 40.8 |
| Self-regulation With Small Behavior Changes | 32.5 |
| Self-regulation With Large Behavior Changes | 23.6 |
All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.92 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.71 |
| Placebo (Overall Cardiovascular Study) | 3.42 |
| All Ertugliflozin (Overall Cardiovascular Study) | 2.82 |
All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 4.35 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 4.91 |
| Placebo (Overall Cardiovascular Study) | 4.59 |
| All Ertugliflozin (Overall Cardiovascular Study) | 4.63 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C. (NCT01986881)
Timeframe: Baseline
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 8.45 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 8.38 |
| Placebo (Ins+/-Met Sub-study) | 8.39 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C. (NCT01986881)
Timeframe: Baseline
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 8.39 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 8.30 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 8.27 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C. (NCT01986881)
Timeframe: Baseline
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | 8.27 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | 8.39 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | 8.21 |
Baseline reflects Week 0 insulin dose. (NCT01986881)
Timeframe: Baseline
| Intervention | Unit/day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 70.76 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 67.29 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 73.20 |
Baseline reflects Week 0 insulin dose. (NCT01986881)
Timeframe: Baseline
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 63.82 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 62.15 |
| Placebo (Overall Cardiovascular Study) | 65.74 |
Baseline reflects Week 0 serum creatinine. (NCT01986881)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.992 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.985 |
| Placebo (Overall Cardiovascular Study) | 0.991 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.998 |
Baseline reflects Week 0 albumin/creatinine ratio. (NCT01986881)
Timeframe: Baseline
| Intervention | mg/g (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 18.00 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 19.00 |
| Placebo (Overall Cardiovascular Study) | 19.00 |
"This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. Including rescue, included data following the initiation of rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Unit/day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.71 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.14 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -0.29 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.48 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.46 |
| Placebo (Overall Cardiovascular Study) | -0.08 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.42 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.38 |
| Placebo (Overall Cardiovascular Study) | -0.04 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.22 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.17 |
| Placebo (Overall Cardiovascular Study) | 0.14 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.25 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.28 |
| Placebo (Overall Cardiovascular Study) | -0.10 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | A1C Percentage (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.35 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.13 |
| Placebo (Overall Cardiovascular Study) | 0.24 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.69 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.67 |
| Placebo (Overall Cardiovascular Study) | -0.19 |
This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.75 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.17 |
| Placebo (Overall Cardiovascular Study) | -0.65 |
This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | Kilograms (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -3.03 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.41 |
| Placebo (Overall Cardiovascular Study) | -0.98 |
This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -3.39 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.83 |
| Placebo (Overall Cardiovascular Study) | -1.29 |
This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | Kilograms (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -3.66 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -4.58 |
| Placebo (Overall Cardiovascular Study) | -1.21 |
This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | Kilograms (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -4.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -7.37 |
| Placebo (Overall Cardiovascular Study) | -0.98 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -1.87 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.13 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -0.25 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -2.04 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -2.41 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.47 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.03 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.32 |
| Placebo (Overall Cardiovascular Study) | -0.40 |
"This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -1.75 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -1.20 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.68 |
This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.46 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.84 |
| Placebo (Overall Cardiovascular Study) | -0.39 |
This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.48 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.35 |
| Placebo (Overall Cardiovascular Study) | -2.60 |
This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.3 |
| Placebo (Overall Cardiovascular Study) | -3.8 |
This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.75 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.93 |
| Placebo (Overall Cardiovascular Study) | -4.41 |
This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.9 |
| Placebo (Overall Cardiovascular Study) | -6.8 |
This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 3.7 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.2 |
| Placebo (Overall Cardiovascular Study) | -1.8 |
This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.22 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.81 |
| Placebo (Overall Cardiovascular Study) | -0.03 |
This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mL/min/1.73 m^2 (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.51 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.18 |
| Placebo (Overall Cardiovascular Study) | -0.30 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -22.09 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -24.31 |
| Placebo (Overall Cardiovascular Study) | -4.39 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -19.39 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -22.59 |
| Placebo (Overall Cardiovascular Study) | -3.63 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -15.28 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -16.16 |
| Placebo (Overall Cardiovascular Study) | 3.59 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -13.87 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -11.15 |
| Placebo (Overall Cardiovascular Study) | -4.69 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.46 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -84.83 |
| Placebo (Overall Cardiovascular Study) | 14.56 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -26.98 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -33.15 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -7.74 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -35.28 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -36.18 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -4.81 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding rescue, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -32.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -34.64 |
| Placebo (Overall Cardiovascular Study) | -17.08 |
"FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -28.28 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -26.97 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -14.76 |
FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -28.63 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -28.97 |
| Placebo (Overall Cardiovascular Study) | -8.76 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.77 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.84 |
| Placebo (Ins+/-Met Sub-study) | -0.19 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.89 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.98 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.23 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.70 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.72 |
| Placebo (Overall Cardiovascular Study) | -0.22 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | A1C Percentage (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | -0.91 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study) | -0.78 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study) | -0.56 |
This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.45 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.58 |
| Placebo (Overall Cardiovascular Study) | 6.16 |
This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.64 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.92 |
| Placebo (Overall Cardiovascular Study) | 7.99 |
This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.96 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.87 |
| Placebo (Overall Cardiovascular Study) | 7.28 |
This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.47 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.77 |
| Placebo (Overall Cardiovascular Study) | 9.42 |
This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.05 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.81 |
| Placebo (Overall Cardiovascular Study) | 3.71 |
This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | Units/Day (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.84 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.69 |
| Placebo (Overall Cardiovascular Study) | 5.57 |
This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.024 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.035 |
| Placebo (Overall Cardiovascular Study) | 0.034 |
This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.037 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.035 |
| Placebo (Overall Cardiovascular Study) | 0.049 |
This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.032 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.036 |
| Placebo (Overall Cardiovascular Study) | 0.059 |
This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.027 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.042 |
| Placebo (Overall Cardiovascular Study) | 0.098 |
This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.034 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.001 |
| Placebo (Overall Cardiovascular Study) | -0.013 |
This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.022 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.032 |
| Placebo (Overall Cardiovascular Study) | -0.002 |
This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mg/dL (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.013 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.023 |
| Placebo (Overall Cardiovascular Study) | 0.004 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.30 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -0.92 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.24 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -1.18 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.93 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -2.91 |
This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.94 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.90 |
| Placebo (Overall Cardiovascular Study) | -0.23 |
This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.27 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.92 |
| Placebo (Overall Cardiovascular Study) | -0.22 |
This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.45 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.42 |
| Placebo (Overall Cardiovascular Study) | -0.64 |
This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.82 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.43 |
| Placebo (Overall Cardiovascular Study) | -1.26 |
This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.86 |
| Placebo (Overall Cardiovascular Study) | 7.29 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.86 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -0.64 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | -0.26 |
"This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding rescue, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.99 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.08 |
| Placebo (Overall Cardiovascular Study) | -0.12 |
This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.97 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -0.95 |
| Placebo (Overall Cardiovascular Study) | -0.15 |
This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.80 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.82 |
| Placebo (Overall Cardiovascular Study) | 0.90 |
This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.55 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.21 |
| Placebo (Overall Cardiovascular Study) | 0.84 |
This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.07 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.26 |
| Placebo (Overall Cardiovascular Study) | 0.53 |
This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.18 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -1.87 |
| Placebo (Overall Cardiovascular Study) | 0.62 |
This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 72
| Intervention | mmHg (Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.28 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -3.46 |
| Placebo (Overall Cardiovascular Study) | 2.72 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.67 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | -2.12 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 0.20 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -2.26 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | -1.54 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | -0.70 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding rescue, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.51 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.75 |
| Placebo (Overall Cardiovascular Study) | 0.03 |
"This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.72 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | -0.80 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | -3.53 |
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -1.84 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -2.41 |
| Placebo (Overall Cardiovascular Study) | 0.75 |
This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 24
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -0.73 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.06 |
| Placebo (Overall Cardiovascular Study) | 17.14 |
This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 36
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 13.33 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 3.33 |
| Placebo (Overall Cardiovascular Study) | 27.03 |
This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 48
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 33.33 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 21.25 |
| Placebo (Overall Cardiovascular Study) | 50.00 |
This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Month 60
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 30.99 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 20.00 |
| Placebo (Overall Cardiovascular Study) | 48.53 |
This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 18
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -13.40 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -14.71 |
| Placebo (Overall Cardiovascular Study) | 0.00 |
This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | -2.53 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | -6.82 |
| Placebo (Overall Cardiovascular Study) | 5.41 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 2.9 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 3.8 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 3.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 0 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 2.7 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 1.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 7.5 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 7.3 |
| Placebo (Overall Cardiovascular Study) | 6.8 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 3.6 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 1.9 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | 2.1 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 59.2 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 62.4 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 61.1 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 48.0 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 54.9 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 47.0 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 85.8 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 84.6 |
| Placebo (Overall Cardiovascular Study) | 85.6 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 47.3 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 25.9 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | 45.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.2 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 8.6 |
| Placebo (Overall Cardiovascular Study) | 5.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 36
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 7.9 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 8.0 |
| Placebo (Overall Cardiovascular Study) | 5.8 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 48
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 8.1 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 9.1 |
| Placebo (Overall Cardiovascular Study) | 7.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 60
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 5.3 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 9.5 |
| Placebo (Overall Cardiovascular Study) | 6.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.0 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 8.8 |
| Placebo (Overall Cardiovascular Study) | 4.7 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 10.9 |
| Placebo (Overall Cardiovascular Study) | 6.1 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 24
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 23.9 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 23.8 |
| Placebo (Overall Cardiovascular Study) | 16.6 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 36
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 23.1 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 22.7 |
| Placebo (Overall Cardiovascular Study) | 16.9 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 48
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 24.9 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 22.7 |
| Placebo (Overall Cardiovascular Study) | 18.2 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Month 60
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 18.6 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 20.0 |
| Placebo (Overall Cardiovascular Study) | 16.5 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study) | 20.7 |
| Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study) | 21.1 |
| Placebo (Insulin +/- Metformin Glycemic Sub-study) | 10.7 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 37.0 |
| Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study) | 32.7 |
| Placebo (Metformin With Sulfonylurea Glycemic Sub-study) | 12.8 |
"A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. Excluding Rescue excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy." (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 32.7 |
| Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study) | 27.8 |
| Placebo (Sulfonylurea Monotherapy Glycemic Sub-study) | 25.0 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 28.4 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 28.2 |
| Placebo (Overall Cardiovascular Study) | 15.5 |
A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. (NCT01986881)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 28.3 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 29.0 |
| Placebo (Overall Cardiovascular Study) | 17.4 |
Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.55 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.00 |
| Placebo (Overall Cardiovascular Study) | 1.70 |
| All Ertugliflozin (Overall Cardiovascular Study) | 1.77 |
Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.92 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.04 |
| Placebo (Overall Cardiovascular Study) | 0.93 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.98 |
Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.75 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.72 |
| Placebo (Overall Cardiovascular Study) | 1.05 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.73 |
Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 3.64 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 4.16 |
| Placebo (Overall Cardiovascular Study) | 4.01 |
| All Ertugliflozin (Overall Cardiovascular Study) | 3.90 |
Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 4.42 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 4.67 |
| Placebo (Overall Cardiovascular Study) | 4.92 |
| All Ertugliflozin (Overall Cardiovascular Study) | 4.54 |
Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 0.87 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 0.98 |
| Placebo (Overall Cardiovascular Study) | 1.15 |
| All Ertugliflozin (Overall Cardiovascular Study) | 0.93 |
Participants who were not on insulin therapy at the start of study medication. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Days (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 602 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 650 |
| Placebo (Overall Cardiovascular Study) | 482 |
Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.36 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.33 |
| Placebo (Overall Cardiovascular Study) | 2.66 |
| All Ertugliflozin (Overall Cardiovascular Study) | 2.34 |
Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive). (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 1.77 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 1.74 |
| Placebo (Overall Cardiovascular Study) | 1.90 |
| All Ertugliflozin (Overall Cardiovascular Study) | 1.76 |
Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date. (NCT01986881)
Timeframe: Up to approximately 6 years
| Intervention | Events per 100 Person-years (Number) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 2.42 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 2.46 |
| Placebo (Overall Cardiovascular Study) | 2.62 |
| All Ertugliflozin (Overall Cardiovascular Study) | 2.44 |
Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. (NCT01986881)
Timeframe: Up to 18 weeks
| Intervention | Days (Median) |
|---|---|
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 59.0 |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 51.0 |
| Placebo (Overall Cardiovascular Study) | 74.0 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 24
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 11.0 | 13.8 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 12.1 | 14.3 |
| Placebo (Overall Cardiovascular Study) | 16.9 | 9.9 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 36
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Participants with albuminuria progression | Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 12.5 | 14.3 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 14.6 | 13.8 |
| Placebo (Overall Cardiovascular Study) | 18.1 | 11.0 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 48
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 14.9 | 12.2 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 19.5 | 11.6 |
| Placebo (Overall Cardiovascular Study) | 21.5 | 9.9 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Month 60
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 14.7 | 14.8 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 18.6 | 11.3 |
| Placebo (Overall Cardiovascular Study) | 22.1 | 10.5 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Week 18
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 7.7 | 14.7 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 7.6 | 14.9 |
| Placebo (Overall Cardiovascular Study) | 10.8 | 10.7 |
Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) <30 (mg/g); Micro-albuminuria: UACR ≥30 and ≤300 (mg/g); Macro-albuminuria: UACR>300 (mg/g). (NCT01986881)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage of Participants with albuminuria progression | Percentage of Participants with albuminuria regression | |
| Ertugliflozin 15 mg (Overall Cardiovascular Study) | 10.2 | 14.8 |
| Ertugliflozin 5 mg (Overall Cardiovascular Study) | 9.5 | 14.6 |
| Placebo (Overall Cardiovascular Study) | 12.9 | 10.2 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL/min/1.73m2 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 59.2 |
| Placebo | 68.1 |
"Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.~This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation." (NCT03118739)
Timeframe: Baseline
| Intervention | Units on a scale (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 60.4 |
| Placebo | 60.6 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (change in percentage in LV dimension) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -14.10 |
| Placebo | -15.37 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.6371 |
| Placebo | 0.7588 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.4833 |
| Placebo | 0.5258 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -2.3143 |
| Placebo | -2.7591 |
(NCT03118739)
Timeframe: Baseline
| Intervention | ms (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 81.13 |
| Placebo | 82.31 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (change in percentage in LV dimension) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -12.07 |
| Placebo | -12.21 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (percentage of LV volume) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 59.77 |
| Placebo | 60.19 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 161.47 |
| Placebo | 161.50 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 66.43 |
| Placebo | 64.63 |
(NCT03118739)
Timeframe: Baseline
| Intervention | g (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 110.27 |
| Placebo | 110.82 |
(NCT03118739)
Timeframe: Baseline
| Intervention | g/mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.696 |
| Placebo | 0.687 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 95.05 |
| Placebo | 96.86 |
(NCT03118739)
Timeframe: Baseline
| Intervention | % (change in percentage in LV dimension) (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 43.47 |
| Placebo | 46.45 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -0.7673 |
| Placebo | -0.7797 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -0.6278 |
| Placebo | -0.6552 |
(NCT03118739)
Timeframe: Baseline
| Intervention | s^-1 (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 2.1059 |
| Placebo | 2.1220 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 1.40 |
| Placebo | 1.19 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 1.579 |
| Placebo | 1.313 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.410 |
| Placebo | 0.358 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 7.51 |
| Placebo | 7.02 |
(NCT03118739)
Timeframe: Baseline
| Intervention | mg/g (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 459.05 |
| Placebo | 411.55 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | ms (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -1.46 |
| Placebo | -1.67 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | g (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 1.80 |
| Placebo | 2.63 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | g/mL (Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | 0.049 |
| Placebo | 0.053 |
LS Mean Percentage Change (95% CI) from Baseline in UACR (NCT03118739)
Timeframe: From Baseline to 12 Weeks of Treatment
| Intervention | Precent change (Least Squares Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -48.65 |
| Placebo | -15.31 |
LS Mean Percentage Change (95% CI) from Baseline in UACR (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | Precent change (Least Squares Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -38.40 |
| Placebo | 21.40 |
LS Mean Percentage Change (90% CI) from Baseline in UACR Compared to Placebo (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | Precent change (Least Squares Mean) |
|---|---|
| Verinurad 9 mg+Febuxostat 80 mg | -49.26 |
| Placebo | NA |
Change from Baseline in Diastolic and Systolic Blood Pressure (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | mm/Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Diastolic BP, mmHg Baseline | Diastolic BP, mmHg 12 weeks (Change from baseline) | Diastolic BP, mmHg 24 weeks (Change from baseline) | Systolic BP, mmHg Baseline | Systolic BP, mmHg 12 weeks (Change from baseline) | Systolic BP, mmHg 24 weeks (Change from baseline) | |
| Placebo | 77.8 | -0.2 | 1.7 | 138.5 | -3.2 | -0.6 |
| Verinurad 9 mg+Febuxostat 80 mg | 74.7 | 1.6 | 2.0 | 136.4 | -0.8 | 0.4 |
Changes in Clinical Chemistry Values (CFB = Change for Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | % hemoglobin bound to glucose (Mean) | ||
|---|---|---|---|
| Baseline Hemoglobin A1C/Hemoglobin, % | Hemoglobin A1C/Hemoglobin, % 12 weeks (CFB) | Hemoglobin A1C/Hemoglobin, % 24 weeks (CFB) | |
| Placebo | 8.28 | 0.13 | 0.22 |
| Verinurad 9 mg+Febuxostat 80 mg | 8.14 | 0.20 | -0.14 |
Changes in Clinical Chemistry Values (CFB = Change for Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | pmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline Aldosterone, pmol/L | Aldosterone, pmol/L 12 weeks (CFB) | Aldosterone, pmol/L 24 weeks (CFB) | Baseline NT-proBNP, pmol/L | NT-proBNP, pmol/L 12 weeks (CFB) | NT-proBNP, pmol/L 24 weeks (CFB) | |
| Placebo | 95.11 | 14.72 | 38.14 | 15.866 | 1.556 | 15.866 |
| Verinurad 9 mg+Febuxostat 80 mg | 134.58 | 1.12 | 9.14 | 23.230 | 4.621 | 6.267 |
LS Mean Percentage Change (95% CI) from Baseline in eGFR (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | -4.40 | 0.55 |
| Verinurad 9 mg+Febuxostat 80 mg | 1.25 | -1.73 |
"LS Mean Change (95% CI) from Baseline in Flow Mediated Dilatation. The flow mediated dilatation metric is obtained using a device from Cordex, and a proprietary algorithm.~This metric represents the volume difference between a baseline arterial compliance curve and hyperemia arterial compliance curve in the positive transmural pressure region. This metric has a direct relationship to a subject's cardiovascular condition. Output range is 0-150. A higher score is indicative of a better flow mediated dilatation." (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Units on a scale (Least Squares Mean) | |
|---|---|---|
| 12 weeks Change from Baseline | 24 weeks Change from Baseline | |
| Placebo | -5.9 | -5.5 |
| Verinurad 9 mg+Febuxostat 80 mg | 0.8 | 0.5 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | s^-1 (Mean) | |||||
|---|---|---|---|---|---|---|
| Diastolic Circumferential Strain Rate (s^-1) (CFB) | Diastolic Longitudinal Strain Rate (s^-1) (CFB) | Diastolic Radial Strain Rate (s^-1) (CFB) | Systolic Circumferential Strain Rate (s^-1) (CFB) | Systolic Longitudinal Strain Rate (s^-1) (CFB) | Systolic Radial Strain Rate (s^-1) (CFB) | |
| Placebo | -0.0384 | -0.0300 | 0.0201 | -0.0743 | -0.0021 | 0.2516 |
| Verinurad 9 mg+Febuxostat 80 mg | -0.0496 | -0.0043 | 0.2348 | 0.0115 | 0.0285 | -0.1917 |
Change from baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | % (change in percentage from baseline) (Mean) | |||
|---|---|---|---|---|
| LV Ejection Fraction (%) (CFB) | Circumferential Strain (%) (CFB) | Longitudinal Strain (%) (CFB) | Radial Strain (%) (CFB) | |
| Placebo | 0.59 | -0.07 | 0.53 | 1.44 |
| Verinurad 9 mg+Febuxostat 80 mg | -2.08 | -0.25 | 0.29 | -2.29 |
Change from Baseline in MRI Variables at Week 24 (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 24 Weeks of Treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| LV End-diastolic Volume (mL) (CFB) | LV End-systolic Volume (mL) (CFB) | LV Stroke Volume (mL) (CFB) | |
| Placebo | -4.93 | -2.48 | -2.44 |
| Verinurad 9 mg+Febuxostat 80 mg | -5.39 | 1.33 | -6.73 |
LS Mean Percentage Change (95% CI) from Baseline in Serum Creatinine (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 3.44 | 0.02 |
| Verinurad 9 mg+Febuxostat 80 mg | -0.60 | 1.93 |
LS Mean Percentage Change (95% CI) from Baseline in Serum Cystatin C (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 0.114 | 3.951 |
| Verinurad 9 mg+Febuxostat 80 mg | 3.252 | 5.412 |
LS Mean Percentage Change (95% CI) from Baseline in Serum High Sensitivity C-reactive Protein (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 11.665 | 9.793 |
| Verinurad 9 mg+Febuxostat 80 mg | 35.863 | -8.002 |
LS Mean Percentage Change (95% CI) from Baseline in sUA (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | Percent change (Least Squares Mean) | |
|---|---|---|
| 12 weeks | 24 weeks | |
| Placebo | 6.86 | 4.73 |
| Verinurad 9 mg+Febuxostat 80 mg | -56.81 | -61.93 |
Changes in Urinalysis (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | mg/dL (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Protein, mg/dL | Protein, mg/dL 12 weeks (CFB) | Protein, mg/dL 24 weeks (CFB) | Baseline Urine Albumin, mg/dL | Urine Albumin, mg/dL 12 weeks (CFB) | Urine Albumin, mg/dL 24 weeks (CFB) | Baseline Urine Creatinine, mg/dL | Urine Creatinine, mg/dL 12 weeks (CFB) | Urine Creatinine, mg/dL 24 weeks (CFB) | Baseline Urine Urate, mg/dL | Urine Urate, mg/dL 12 weeks (CFB) | Urine Urate, mg/dL 24 weeks (CFB) | |
| Placebo | 65.74 | -4.07 | 11.40 | 35.8905 | -0.3019 | 11.6049 | 86.25 | 12.95 | 8.53 | 23.960 | 3.560 | 2.294 |
| Verinurad 9 mg+Febuxostat 80 mg | 72.01 | -11.40 | -16.73 | 38.0907 | -9.4766 | -6.9482 | 96.52 | 5.06 | 7.58 | 28.354 | -13.394 | -10.732 |
Changes in Urinalysis (CFB = Change from Baseline) (NCT03118739)
Timeframe: From Baseline to 12 Weeks and 24 Weeks of Treatment
| Intervention | mg/g (Mean) | ||
|---|---|---|---|
| Baseline Protein/Creatinine, mg/g | Protein/Creatinine, mg/g 12 weeks (CFB) | Protein/Creatinine, mg/g 24 weeks (CFB) | |
| Placebo | 828.52 | -155.44 | 177.11 |
| Verinurad 9 mg+Febuxostat 80 mg | 945.56 | -185.33 | -98.60 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
Urine uric acid crystals were identified by polarized microscopy (Polarized light imaging Zeiss Axiovert 135; 0.3NA objective), and pictures were captured from each urine sample. UA crystals were defined dichotomously as being present or absent. (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | participants (Number) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 14 | 3 |
Urine uric acid were evaluated using a QuantiChrom UA kit assay (DIUA-250) with quantitative colorimetric UA determination at 590 nm (BioAssay System, California, USA). (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | mg/dl (Geometric Mean) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 23.81 | 22.30 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
Overall liking of apple crisp with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: Day of taste testing
| Intervention | score on likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 7.31 |
| Reduced Sugar Recipe | 6.83 |
| Reduced Sugar Plus Spice Recipe | 7.22 |
Overall liking of oatmeal with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.84 |
| Reduced Sugar Recipe | 5.70 |
| Reduced Sugar Plus Spice Recipe | 6.15 |
Overall liking of tea with a 9-point hedonic rating scale instrument (whereby 0 = dislike extremely and 9 = like extremely ) (NCT03139552)
Timeframe: day of taste testing
| Intervention | score on a likert rating scale (Mean) |
|---|---|
| Full Sugar Recipe | 6.00 |
| Reduced Sugar Recipe | 5.62 |
| Reduced Sugar Plus Spice Recipe | 5.85 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 54 |
| Second Place Ranking | 63 |
| Third Place Ranking | 33 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 88 |
| Second Place Ranking | 39 |
| Third Place Ranking | 21 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 66 |
| Second Place Ranking | 41 |
| Third Place Ranking | 42 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 48 |
| Second Place Ranking | 60 |
| Third Place Ranking | 40 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 63 |
| Second Place Ranking | 44 |
| Third Place Ranking | 43 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 49 |
| Second Place Ranking | 50 |
| Third Place Ranking | 50 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 33 |
| Second Place Ranking | 43 |
| Third Place Ranking | 74 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: day of taste testing
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 12 |
| Second Place Ranking | 49 |
| Third Place Ranking | 87 |
Subjects ranked each recipe in order of likability as first, second or third. (NCT03139552)
Timeframe: Day of taste testings
| Intervention | Participants (Count of Participants) |
|---|---|
| First Place Ranking | 34 |
| Second Place Ranking | 58 |
| Third Place Ranking | 57 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/L (Mean) |
|---|---|
| Pravastatin | 0.8063 |
| Placebo | -0.5136 |
(NCT01082588)
Timeframe: Baseline, week 12
| Intervention | mg/dl (Mean) |
|---|---|
| Pravastatin | -25.565 |
| Placebo | -2.913 |
"The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.~The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning." (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | 4.0417 |
| Placebo | 4.125 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -5.625 |
| Placebo | -3.76 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -0.83 |
| Placebo | -0.28 |
This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -2.9583 |
| Placebo | -2.44 |
The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers. (NCT01082588)
Timeframe: Baseline, week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Pravastatin | -9.416 |
| Placebo | -6.48 |
73 reviews available for uric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection.
Topics: Diabetes Mellitus, Type 2; Diuretics; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhi | 2021 |
Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Network Meta-Analysis; Sodium; Uric | 2022 |
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Topics: Animals; Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Gout; Humans; Hypertension; Hyperu | 2021 |
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.
Topics: Adult; Comorbidity; Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric | 2022 |
SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Renal Insuf | 2022 |
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.
Topics: Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Hydrogen Peroxide; Hyperuricemia; Uric Acid | 2022 |
Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Risk Factors; Uric Acid | 2022 |
The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Human | 2022 |
Comment on: Serum uric acid levels and diabetic kidney disease in patients with type 2 diabetes mellitus: A dose-response meta-analysis.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Risk Factors; Uric Acid | 2022 |
Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Topics: Acute Kidney Injury; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Retrospective | 2023 |
Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypertension; Hyperuricemia; Purines; Reactive O | 2022 |
New markers in metabolic syndrome.
Topics: Adipokines; Alkaline Phosphatase; Biomarkers; Diabetes Mellitus, Type 2; Humans; Inflammation; Insul | 2022 |
Type 4 renal tubular acidosis and uric acid nephrolithiasis: two faces of the same coin?
Topics: Acidosis, Renal Tubular; Diabetes Mellitus, Type 2; Humans; Hydrogen-Ion Concentration; Hyperkalemia | 2023 |
Association of hyperuricemia with cardiovascular diseases: current evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hyperuricemia; Mal | 2023 |
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Topics: Diabetes Mellitus, Type 2; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up; Uric Ac | 2023 |
Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: Meta-analysis of correlational evidence.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Diabetes Complications; Diabetes Mellitus, Type 2; Hu | 2019 |
Uric Acid in Metabolic and Cerebrovascular Disorders: A Review.
Topics: Animals; Biomarkers; Blood Glucose; Cardiometabolic Risk Factors; Cerebrovascular Disorders; Diabete | 2020 |
Purine Metabolite Signatures and Type 2 Diabetes: Innocent Bystanders or Actionable Items?
Topics: Diabetes Mellitus, Type 2; Humans; Purines; Uric Acid; Xanthine Dehydrogenase | 2020 |
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
Topics: Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Metabolic Syndrome; Uric Acid | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypo | 2021 |
Uric acid-induced pancreatic β-cell dysfunction.
Topics: Animals; Cell Death; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Secretion; Insulin-Se | 2021 |
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Type 2; Energy Me | 2021 |
Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials.
Topics: Blood Glucose; Blood Pressure; China; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hyperurice | 2021 |
Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hyperuricemia; Hypoglyc | 2017 |
Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.
Topics: Diabetes Mellitus, Type 2; Humans; Hypertension; Hyperuricemia; Risk Factors; Uric Acid | 2017 |
Gout and Metabolic Syndrome: a Tangled Web.
Topics: Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Gout; Humans; Hyperlipide | 2017 |
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; H | 2018 |
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Pha | 2018 |
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.
Topics: Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glucose; Humans; Hypoglycemic Agen | 2018 |
Effect of low-carbohydrate diet on markers of renal function in patients with type 2 diabetes: A meta-analysis.
Topics: Biomarkers; Controlled Clinical Trials as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nep | 2018 |
Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: A cohort study and meta-analysis.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Fo | 2018 |
Effect of Uric Acid on Blood Glucose Levels.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resistance; Nitric Oxide; O | 2018 |
Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Disease | 2019 |
Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Humans; Hypertension; | 2019 |
[The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Sodium-Glucose Trans | 2018 |
Uric acid and the cardio-renal effects of SGLT2 inhibitors.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Heart; Humans; Hypoglycemic Agents; Kidney | 2019 |
High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies.
Topics: Diabetes Mellitus, Type 2; Disease Susceptibility; Humans; Prospective Studies; Publication Bias; Ri | 2013 |
Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Child; Clinical Trials as Topic; Diabetes Mellitus, | 2013 |
Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies.
Topics: Biomarkers; China; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Humans; Incidence; Prediabeti | 2013 |
Undiagnosed diabetes has poorer profiles for cardiovascular and metabolic markers than known diabetes: The Yuport Medical Checkup Center Study.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Pressure; Cardiovascular Diseases; C | 2013 |
Sugar, uric acid, and the etiology of diabetes and obesity.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Sucrose; Disease Models, Animal | 2013 |
Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperuricemia; Male; | 2013 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ne | 2014 |
Epidemiology and clinical pathophysiology of uric acid kidney stones.
Topics: Ammonium Compounds; Animals; Comorbidity; Crystallization; Diabetes Mellitus, Type 2; Humans; Hydrog | 2014 |
Association of serum uric acid and metabolic syndrome in type 2 diabetes.
Topics: Adult; Atherosclerosis; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Cross-Section | 2014 |
Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress.
Topics: Adipocytes; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Differentiation; Cell Movement; | 2014 |
Serum Uric Acid Levels and Diabetic Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysis.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hyperuricemia; Publication Bias; Risk Fact | 2016 |
Fat storage syndrome in Pacific peoples: a combination of environment and genetics?
Topics: Cultural Characteristics; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Dietary Sucrose; E | 2014 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Fructose and uric acid in diabetic nephropathy.
Topics: Adenosine Triphosphate; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2015 |
Genome wide association study of uric acid in Indian population and interaction of identified variants with Type 2 diabetes.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2; Case-Control Studies; Diabetes Melli | 2016 |
[Studies on association between nonalcoholic fatty liver disease and hyperuricemia: current status and future prospects].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Non-alcoholic Fatty | 2016 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Dise | 2016 |
Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Topics: Albuminuria; Animals; Blood Pressure; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Gluc | 2017 |
Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose; Glycat | 2017 |
Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Sucrose; Fructose; Humans; Metabolic Syndrome; Sweetenin | 2009 |
Association between serum uric acid and development of type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Risk Factors; Uric Acid | 2009 |
An update and practical guide to renal stone management.
Topics: Age of Onset; Calcium Oxalate; Calcium Phosphates; Cross-Sectional Studies; Cystine; Diabetes Mellit | 2010 |
[Hyperuricemia and uro-nephrological disorders].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diagnosis, Differential; Humans; Hypertension; H | 2011 |
Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydrogen-Ion Concentration; Insu | 2012 |
The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypertension; Risk | 2011 |
Uric acid and diabetes: Is there a link?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2013 |
[Uric acid metabolism and insulin resistance in type 2 diabetes].
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resista | 2002 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fructose; Genetic Predispo | 2007 |
[Complication of childhood obesity].
Topics: Body Mass Index; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Fatty Liver; Female; Hum | 1995 |
[The metabolic syndrome. Pathophysiologic causes, diagnosis, therapy].
Topics: Arteriosclerosis; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hyperinsulini | 1994 |
[Polymetabolic syndrome].
Topics: Albuminuria; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin; | 1995 |
[Hyperuricemia and insulin resistance].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Humans | 1996 |
The kidney: an unwilling accomplice in syndrome X.
Topics: Diabetes Mellitus, Type 2; Glucose; Homeostasis; Humans; Hyperinsulinism; Hypertension; Insulin; Ins | 1997 |
[From type 2 diabetes to metabolic X syndrome].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hyperinsulinism; Insulin Resistance; Ischemia; Mal | 1999 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; H | 2000 |
Insulin resistance: a chicken that has come to roost.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Fibrinolysis; Genotype; Humans; Hyperinsulinism; Hyperl | 1999 |
[Update on the epidemiology of obesity and type 2 diabetes in France].
Topics: Adolescent; Adult; Body Mass Index; Child; Child, Preschool; Colonic Neoplasms; Coronary Disease; Di | 2000 |
69 trials available for uric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypogl | 2022 |
Uric acid as a predictor of weight gain and cardiometabolic health in the Study of Novel Approaches to Weight Gain Prevention (SNAP) study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Obesity; Risk Factors; Uric Acid; | 2022 |
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Topics: Biomarkers; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Double-Blind Method; | 2022 |
Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Glycolipids; Humans; | 2022 |
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Heart Failure; Humans; | 2022 |
Effects of long-term vitamin D supplementation on metabolic profile in middle-aged and elderly patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blin | 2023 |
The effect of a 6-month walking program on biochemical parameters in sedentary adults with type 2 diabetes mellitus.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; C-Reactive Prot | 2022 |
Risk factors for acute ischemic stroke in patients with type 2 diabetes mellitus.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Di | 2023 |
Plasma uric acid and renal haemodynamics in type 2 diabetes patients.
Topics: Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glome | 2020 |
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Hum | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies | 2020 |
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Heart Disease Risk Factors; | 2020 |
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Topics: 3-Iodobenzylguanidine; Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Death, Sudden, Cardi | 2020 |
Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients.
Topics: Adiposity; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle | 2020 |
Effects of empagliflozin on proinflammatory cytokines and other coronary risk factors in patients with type 2 diabetes mellitus: A single-arm real-world observation.
Topics: Benzhydryl Compounds; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Glucosides; Humans; Risk | 2021 |
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Topics: Aged; Albuminuria; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina | 2021 |
Potential of anthocyanin as an anti-inflammatory agent: a human clinical trial on type 2 diabetic, diabetic at-risk and healthy adults.
Topics: Adult; Aged; Anthocyanins; Anti-Inflammatory Agents; Biomarkers; Blood Glucose; Cholesterol, LDL; Cy | 2021 |
Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Body Mass Index; Diabetes Melli | 2021 |
Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes.
Topics: Aged; Cysts; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperuricemia; Kidne | 2017 |
Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; Joints; Mal | 2018 |
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Gout; Humans; Hypolipidem | 2018 |
Effects of acute fructose loading on levels of serum uric acid-a pilot study.
Topics: Aged; Analysis of Variance; Beverages; Diabetes Mellitus, Type 2; Female; Fructose; Humans; Hyperuri | 2019 |
Higher Serum Uric Acid is a Risk Factor of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes Mellitus.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Lumbar Vertebrae; Middle A | 2020 |
Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Febuxostat; Female; Gou | 2019 |
High-Resistant Starch, Low-Protein Flour Intervention on Patients With Early Type 2 Diabetic Nephropathy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Di | 2019 |
High calcium intake from fat-free milk, body composition and glycaemic control in adults with type 2 diabetes: a randomised crossover clinical trial.
Topics: Adult; Animals; Body Composition; Body Mass Index; Body Weight; Calcium, Dietary; Cross-Over Studies | 2019 |
The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Mass | 2014 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
Topics: Aged; Allopurinol; Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hea | 2013 |
Serum urate levels are unchanged with continuous positive airway pressure therapy for obstructive sleep apnea: a randomized controlled trial.
Topics: Aged; Continuous Positive Airway Pressure; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; M | 2013 |
Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study.
Topics: Adult; Bariatric Surgery; Diabetes Mellitus, Type 2; Female; Gout; Humans; Longitudinal Studies; Mal | 2014 |
The relationship between serum uric acid levels and β-cell functions in nondiabetic subjects.
Topics: Demography; Diabetes Mellitus, Type 2; Female; Humans; Insulin-Secreting Cells; Linear Models; Male; | 2014 |
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Canagliflozin; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2015 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; D | 2015 |
The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study.
Topics: Adult; Aged; Allopurinol; Asian People; Atherosclerosis; Biomarkers; Blood Pressure; C-Reactive Prot | 2015 |
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzhydryl Compounds; Blood | 2016 |
Serum Superoxide Dismutase Is Associated with Vascular Structure and Function in Hypertensive and Diabetic Patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Middle Aged; Oxidative S | 2016 |
The Therapeutic Potential of Resistant Starch in Modulation of Insulin Resistance, Endotoxemia, Oxidative Stress and Antioxidant Biomarkers in Women with Type 2 Diabetes: A Randomized Controlled Clinical Trial.
Topics: Adult; Aged; Antioxidants; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Diabetes Mell | 2016 |
Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2 | 2016 |
Comparison of the effects of diets high in animal or plant protein on metabolic and cardiovascular markers in type 2 diabetes: A randomized clinical trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cohort Studies; Dairy Products; Diabe | 2017 |
Effects of xylooligosaccharides in type 2 diabetes mellitus.
Topics: Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Body Fat Distr | 2008 |
Metabolic basis for low urine pH in type 2 diabetes.
Topics: Adult; Age Factors; Aged; Biomarkers; Body Mass Index; Buffers; Diabetes Mellitus, Type 2; Diabetic | 2010 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2011 |
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Rela | 2011 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Caloric Restriction; Creatinine; Diabetes Mellitus, Type 2; D | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiot | 2012 |
Association of a 27-bp repeat polymorphism in intron 4 of endothelial constitutive nitric oxide synthase gene with serum uric acid levels in Chinese subjects with type 2 diabetes.
Topics: Aged; China; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Introns; Male; Middle Aged; Nitric | 2003 |
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.
Topics: Aged; Arteriosclerosis; Blood Pressure; Carotid Arteries; Cholesterol; Cilostazol; Diabetes Mellitus | 2004 |
The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellit | 2006 |
Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disea | 2006 |
Sex difference in the distribution of atherosclerotic risk factors and their association with peripheral arterial disease in Taiwanese type 2 diabetic patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Body Mass Index; Cohor | 2007 |
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes.
Topics: Acetylcholine; Adult; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2007 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2007 |
Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Topics: Acarbose; Adult; Analysis of Variance; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diet, | 1995 |
A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.
Topics: Adult; Antihypertensive Agents; Bendroflumethiazide; Blood Glucose; Cross-Over Studies; Diabetes Mel | 1995 |
[Forestier disease and metabolism disorders. A prospective controlled study of 25 cases].
Topics: Adult; Aged; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyper | 1993 |
Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans.
Topics: Blood Pressure; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Di | 1999 |
Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies.
Topics: Adult; Aged; Aged, 80 and over; Allantoin; Antioxidants; Biomarkers; Chromatography, High Pressure L | 1999 |
Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans?
Topics: Black People; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Middl | 1999 |
Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 2000 |
Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Topics: Blood Glucose; Chromans; Creatinine; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypogly | 2000 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes.
Topics: Adult; Aged; Animals; Blood Glucose; C-Peptide; Cattle; Circadian Rhythm; Diabetes Mellitus, Type 2; | 2001 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
The relationship between glucose and uric acid metabolism: influence of short term allopurinol on glucose metabolism.
Topics: Adult; Aged; Allopurinol; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Me | 1991 |
505 other studies available for uric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Endogenous fructose is correlated with urinary albumin creatinine ratios and uric acid in type 2 diabetes mellitus.
Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Fructose; Humans; Uric Acid | 2021 |
Changes in serum uric acid levels as a predictor of future decline in renal function in older adults with type 2 diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Gl | 2021 |
Dietary Acid Load Is Positively Associated with the Incidence of Hyperuricemia in Middle-Aged and Older Korean Adults: Findings from the Korean Genome and Epidemiology Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet; Female; Humans; Hyperuricemia; Incidence; Male; Middle | 2021 |
Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Cross-Sectional St | 2021 |
Serum uric acid in early pregnancy and risk of gestational diabetes mellitus: A cohort study of 85,609 pregnant women.
Topics: China; Cohort Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Pregnancy; | 2022 |
The positive association between serum uric acid, impaired fasting glucose, impaired glucose tolerance, and diabetes mellitus in the ELSA-Brasil study.
Topics: Adult; Blood Glucose; Brazil; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; G | 2021 |
Association between uric acid level and incidence of albuminuria in patients with type 2 diabetes mellitus: A 4.5-year cohort study.
Topics: Aged; Albuminuria; Animals; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2021 |
Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fatty Acid | 2022 |
Association of serum fibroblast growth factor 21 with kidney function in a population-based Chinese cohort.
Topics: Biomarkers; China; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth F | 2021 |
Association between hyperuricemia and glycated hemoglobin in type 2 diabetes at the District Hospital of Dschang.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Hospitals, District | 2021 |
Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes.
Topics: Acute Kidney Injury; Aged; Asian People; China; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic | 2022 |
Development of quantitative assay for simultaneous measurement of purine metabolites and creatinine in biobanked urine by liquid chromatography-tandem mass spectrometry.
Topics: Allantoin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Creatinine; Diabetes Mellit | 2022 |
The association between glycaemic level and lipid profile with Albuminuria in Iraqi type 2 diabetes patients - A cross sectional study.
Topics: Adult; Aged; Albuminuria; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2021 |
The relation between serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes in Guilan, north of Iran.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fem | 2022 |
Correlation between serum C-peptide-releasing effects and the risk of elevated uric acid in type 2 diabetes mellitus.
Topics: C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Male; Risk F | 2022 |
Mediating Effect of Body Mass Index and Dyslipidemia on the Relation of Uric Acid and Type 2 Diabetes: Results From China Health and Retirement Longitudinal Study.
Topics: Aged; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Human | 2021 |
Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Huma | 2022 |
ELEVATED LEVEL OF URIC ACID, BUT NOT GLUCOSE, IN AQUEOUS HUMOR AS A RISK FACTOR FOR DIABETIC MACULAR EDEMA IN PATIENTS WITH TYPE 2 DIABETES.
Topics: Aqueous Humor; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glucose; Humans; Macular Edema; Risk | 2022 |
Risk factors and correlation of colorectal polyps with type 2 diabetes mellitus.
Topics: Blood Glucose; Colonic Polyps; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Male; Middle | 2022 |
Snoring and napping independently increased the serum uric acid levels and hyperuricemia risk: The Henan Rural Cohort Study.
Topics: Adult; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Sl | 2022 |
Genetic Risk Score for Plasma Uric Acid Levels Is Associated With Early Rapid Kidney Function Decline in Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Genome-Wide Association Study; Glomerular Filtration | 2022 |
In vitro Interference of Uric Acid on Serum Fructosamine and Blood HbA1c.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fructosamine; Glycated Hemoglobin; Humans; Uric Acid | 2022 |
Association Between Low-Grade Inflammation and Hyperuricemia in Adults With Metabolic Syndrome in Yucatán, México.
Topics: Adult; Biomarkers; C-Reactive Protein; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; H | 2022 |
Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
Topics: Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Sodium; Uric Acid | 2022 |
Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.
Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Endothelial Cells; Glucose; Humans; Hyperglycem | 2022 |
Cardiovascular protection conferred by glucagon-like peptide-1 receptor agonists: A role for serum uric acid reduction?
Topics: Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; | 2022 |
Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypogl | 2022 |
Serum uric acid and diabetic peripheral neuropathy: a double-edged sword.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2023 |
Using Machine Learning Techniques to Develop Risk Prediction Models for the Risk of Incident Diabetic Retinopathy Among Patients With Type 2 Diabetes Mellitus: A Cohort Study.
Topics: Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Machine L | 2022 |
Uric Acid, Genetic Scores and Renal Disease: Merge to Separate?
Topics: Diabetes Mellitus, Type 2; Humans; Kidney; Kidney Diseases; Mendelian Randomization Analysis; Risk F | 2022 |
Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Sodium; Sodium-Glucose Transport | 2022 |
Correlation of dehydroepiandrosterone with diabetic nephropathy and its clinical value in early detection.
Topics: Albumins; Albuminuria; Biomarkers; Cholesterol; Creatinine; Dehydroepiandrosterone; Diabetes Mellitu | 2022 |
Increased Glycemic Variability Evaluated by Continuous Glucose Monitoring is Associated with Osteoporosis in Type 2 Diabetic Patients.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Me | 2022 |
Concurrent presence of high serum uric acid and inflammation is associated with increased incidence of type 2 diabetes mellitus in Korean adult population.
Topics: Adult; Aged; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Middle | 2022 |
Association Between Serum Uric Acid Level and Carotid Atherosclerosis and Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus.
Topics: Carotid Artery Diseases; Carotid Intima-Media Thickness; Cross-Sectional Studies; Diabetes Mellitus, | 2022 |
Genomic DNA Methylation in Diabetic Chronic Complications in Patients With Type 2 Diabetes Mellitus.
Topics: Carotid Intima-Media Thickness; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Ne | 2022 |
Effects of dietary inclusion of Bambara groundnut and sweet orange peels on streptozotocin/HFD type-2 induced diabetes mellitus complications and related biochemical parameters.
Topics: Albumins; Animals; Bilirubin; Citrus sinensis; Creatinine; Diabetes Complications; Diabetes Mellitus | 2022 |
The perirenal fat thickness was independently associated with serum uric acid level in patients with type 2 diabetes mellitus.
Topics: Cholesterol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Kidney; Male; Obesity; Risk | 2022 |
The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study.
Topics: Diabetes Mellitus, Type 2; Genome-Wide Association Study; Gout; Humans; Hypertension; Mendelian Rand | 2022 |
Amino acids, microbiota-related metabolites, and the risk of incident diabetes among normoglycemic Chinese adults: Findings from the 4C study.
Topics: 2-Aminoadipic Acid; Adult; Alanine; Amino Acids; Asparagine; Diabetes Mellitus, Type 2; Glutamic Aci | 2022 |
Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an indepen
Topics: Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Sodium; Stroke Volume; Uric Acid; Ventric | 2022 |
The association between vitamin D levels and heart rate variability in patients with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Heart Rate; Humans; Retrospective Studies; Uric Acid; Vitamin D; Vitamin | 2022 |
Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance.
Topics: Animals; Carboxymethylcellulose Sodium; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; | 2022 |
Assessing the causal associations of obstructive sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian randomization study.
Topics: Diabetes Mellitus, Type 2; Genome-Wide Association Study; Gout; Humans; Mendelian Randomization Anal | 2022 |
Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18 | 2022 |
Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Myocardial Infarction; Natriu | 2022 |
Disordered Glucose Levels Are Associated with Xanthine Oxidase Activity in Overweight Type 2 Diabetic Women.
Topics: Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; M | 2022 |
[Advantages of the use of metformin in patients with impaired uric acid metabolism].
Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Hypoglycemic Agent | 2021 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Diuretics; Electrolytes; Heart Failure; H | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Association between uric acid levels and incidence of type 2 diabetes: Population-based Panasonic cohort study 11.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Risk Factors; Uric Acid | 2023 |
Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: a cross-sectional study.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Prediabetic State; | 2022 |
Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: a cross-sectional study.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Prediabetic State; | 2022 |
Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: a cross-sectional study.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Prediabetic State; | 2022 |
Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: a cross-sectional study.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Prediabetic State; | 2022 |
Association between uric acid level and contrast-induced acute kidney injury in patients with type 2 diabetes mellitus after coronary angiography: a retrospective cohort study.
Topics: Acute Kidney Injury; Coronary Angiography; Diabetes Mellitus, Type 2; Humans; Retrospective Studies; | 2022 |
Association between uric acid level and contrast-induced acute kidney injury in patients with type 2 diabetes mellitus after coronary angiography: a retrospective cohort study.
Topics: Acute Kidney Injury; Coronary Angiography; Diabetes Mellitus, Type 2; Humans; Retrospective Studies; | 2022 |
Association between uric acid level and contrast-induced acute kidney injury in patients with type 2 diabetes mellitus after coronary angiography: a retrospective cohort study.
Topics: Acute Kidney Injury; Coronary Angiography; Diabetes Mellitus, Type 2; Humans; Retrospective Studies; | 2022 |
Association between uric acid level and contrast-induced acute kidney injury in patients with type 2 diabetes mellitus after coronary angiography: a retrospective cohort study.
Topics: Acute Kidney Injury; Coronary Angiography; Diabetes Mellitus, Type 2; Humans; Retrospective Studies; | 2022 |
Elevated serum uric acid is not an independent risk factor for the occurrence of Type 2 diabetic kidney disease in Chinese populations.
Topics: Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; East Asian | 2022 |
Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypertension; Kidney Diseases; Ma | 2023 |
Bidirectional temporal relationships between uric acid and insulin and their joint impact on incident diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Insulin; Middle Aged; Risk Factors; Uric | 2023 |
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Febuxostat; Humans; Hyperurice | 2022 |
Trends in serum uric acid levels among Korean children and adolescents between 2016 and 2020: a nationwide study.
Topics: Adolescent; Body Mass Index; Child; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Huma | 2023 |
Determinants of renal papillary appearance in kidney stone formers: An in-depth examination.
Topics: Diabetes Mellitus, Type 2; Humans; Kidney; Kidney Calculi; Kidney Medulla; Uric Acid | 2023 |
The associations between uric acid with BMDs and risk of the 10-year probability of fractures in Chinese patients with T2DM stratified by age and gender.
Topics: Absorptiometry, Photon; Aged; Bone Density; Cross-Sectional Studies; Diabetes Mellitus, Type 2; East | 2023 |
Non-linear association of fasting C-peptide and uric acid levels with renal dysfunction based on restricted cubic spline in patients with type 2 diabetes: A real-world study.
Topics: C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fasting; Humans; Kidney Diseases; Uri | 2023 |
Association between serum uric acid and phase angle in patients with type 2 diabetes mellitus: A cross-sectional study.
Topics: Body Composition; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Retrospective Studies; | 2023 |
Endocrinology.
Topics: Body Mass Index; C-Peptide; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Typ | 2023 |
Association between brachial-ankle pulse wave velocity and microvascular complications in type 2 diabetes mellitus.
Topics: Ankle; Ankle Brachial Index; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diab | 2023 |
Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury?
Topics: Cholesterol, HDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Ret | 2023 |
Comparative impact of streptozotocin on altering normal glucose homeostasis in diabetic rats compared to normoglycemic rats.
Topics: Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Home | 2023 |
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Hypoglycemic Agents | 2023 |
Serum Uric Acid Levels Are Related to Diabetic Peripheral Neuropathy, Especially for Motor Conduction Velocity of Tibial Nerve in Type 2 Diabetes Mellitus Patients.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Glycated Hemoglobin; Humans; Neural | 2023 |
Extracellular status of thrombospondin-2 in type 2 diabetes mellitus and utility as a biomarker in the determination of early diabetic kidney disease.
Topics: Animals; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Mice; Th | 2023 |
Editorial: from albuminuria to uric acid - emerging risk factors beyond lipids.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Humans; Lipids; Risk Factors; Uric Acid | 2023 |
The correlation between serum uric acid and diabetic kidney disease in adult-onset type 1 diabetes patients in China.
Topics: Adult; China; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerul | 2023 |
Serum Levels of Indoxyl Sulfate and P-cresol in Type II Diabetic Patients With and Without Nephropathy.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Indican; Proteinuria; Uric Ac | 2023 |
Prevalence of Hypouricemia and Hyperuricemia and Looking Beyond Serum Uric Acid in Patients with Newly Onset Type 2 Diabetes Mellitus in Eastern Part of Uttar Pradesh: A Cross-sectional Study.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Prevalence; Risk | 2023 |
The Triglyceride Glucose (TyG) Index as a Sensible Marker for Identifying Insulin Resistance and Predicting Diabetic Kidney Disease.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Insul | 2023 |
Association between the lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes in a healthy population of Northwest China: a retrospective cohort study with a 2-year follow-up period.
Topics: China; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Middle Aged; Non-alcoholi | 2023 |
Serum redox markers in uncomplicated type 2 diabetes mellitus accompanied with abnormal iron levels.
Topics: Advanced Oxidation Protein Products; Antioxidants; Bilirubin; Biomarkers; Diabetes Mellitus, Type 2; | 2023 |
Moderate elevation of serum uric acid levels improves short-term functional outcomes of ischemic stroke in patients with type 2 diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Ischemic Stroke; Male; Prognosis; Risk Factors; Str | 2023 |
Relationship between baseline and changed serum uric acid and the incidence of type 2 diabetes mellitus: a national cohort study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Middle Aged; Risk | 2023 |
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Gout; Hospit | 2023 |
Evaluation of levels of uric acid and lipid profile in hospitalized patients with diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Lipids; Male; Middle Aged; Triglycerides; Ur | 2023 |
Risk factors for diabetic ketoacidosis in acute pancreatitis patients with type 2 diabetes.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Pancreatitis; Prospective S | 2023 |
Uric acid index is a risk for mild cognitive impairment in type 2 diabetes.
Topics: Cognition; Cognitive Dysfunction; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans | 2023 |
High-normal serum uric acid predicts macrovascular events in patients with type 2 diabetes mellitus without hyperuricemia based on a 10-year cohort.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Kidney; Risk Factors; Uric Acid | 2023 |
A study of factors influencing long-term glycemic variability in patients with type 2 diabetes: a structural equation modeling approach.
Topics: Cholesterol; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Latent Class Analysis; Quality | 2023 |
Altered insulin secretion dynamics relate to oxidative stress and inflammasome activation in children with obesity and insulin resistance.
Topics: Case-Control Studies; Child; Diabetes Mellitus, Type 2; Humans; Inflammasomes; Inflammation; Insulin | 2023 |
Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.
Topics: Diabetes Mellitus, Type 2; East Asian People; Glomerular Filtration Rate; Humans; Kidney; Prognosis; | 2023 |
Hip circumference has independent association with the risk of hyperuricemia in middle-aged but not in older male patients with type 2 diabetes mellitus.
Topics: Aged; China; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Male; Middle Aged; Retrospective Stud | 2023 |
Correlation of Serum Uric Acid and Lipid Profile in Patients with Type 2 Diabetes Mellitus.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Lipoproteins, HDL; Nepal; | 2023 |
Clinical characteristics of patients with early-onset diabetes mellitus: a single-center retrospective study.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Ketosis; Male; Re | 2023 |
The role of high fat diet on serum uric acid level among healthy male first degree relatives of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diet, High-Fat; Humans; Insulin; Insulin Resistance; Male; Obesity; Uric | 2023 |
Effects of a two meals-a-day ketogenic diet on newly diagnosed obese patients with type 2 diabetes mellitus: A retrospective observational study.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diet, Ketogenic; Humans; Meals; Obesity; | 2023 |
In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes.
Topics: Diabetes Mellitus, Type 2; Gout; Humans; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2023 |
Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Liver; Liver Cirrhosis; Male; Menopause; Middle Aged; Non | 2023 |
Serum uric acid levels and risk of cardiovascular disease in type 2 diabetes: results from a cross-sectional study and Mendelian randomization analysis.
Topics: Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Genome-Wide Association | 2023 |
Untargeted metabolomics reveals dynamic changes in metabolic profiles of rat supraspinatus tendon at three different time points after diabetes induction.
Topics: Animals; Diabetes Mellitus, Type 2; Metabolome; Rats; Rats, Sprague-Dawley; Rotator Cuff; Uric Acid | 2023 |
Diabetes Impedes the Epigenetic Switch of Macrophages into Repair Mode.
Topics: Diabetes Mellitus, Type 2; Epigenesis, Genetic; Histone Methyltransferases; Humans; Macrophages; Phe | 2019 |
Fructose tolerance test in obese people with and without type 2 diabetes.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fem | 2020 |
Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Topics: Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Correlation of Data; Diabetes Mel | 2020 |
Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function
.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Humans; Insulin-Secreting Cells; Uric Acid | 2019 |
Clinical Features and Microvascular Complications Risk Factors of Early-onset Type 2 Diabetes Mellitus.
Topics: Adult; Age of Onset; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Diabetes Mel | 2019 |
Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus.
Topics: Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Male; Uric | 2020 |
Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2019 |
Association between cumulative serum urate and development of diabetes type II: the Kailuan Study.
Topics: Adult; China; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Male; Middle Aged; Prospective S | 2020 |
Changes Over Time in Uric Acid in Relation to Changes in Insulin Sensitivity, Beta-Cell Function, and Glycemia.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose Tolerance Te | 2020 |
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renin-Angiotensin Syste | 2020 |
Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088-1094.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Risk Factors; | 2019 |
Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. Diabetes Care 2019;42:1088-1094.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Risk Factors; | 2019 |
Refining genome-wide associated loci for serum uric acid in individuals with African ancestry.
Topics: Angiotensin Amide; Black or African American; Diabetes Mellitus, Type 2; Female; Genetic Loci; Genom | 2020 |
Reference intervals for serum 1,5-anhydroglucitol of a population with normal glucose tolerance in Jiangsu Province.
Topics: Adult; Aged; Biomarkers; Blood Glucose; China; Deoxyglucose; Diabetes Mellitus, Type 2; Female; Gluc | 2020 |
Lack of Associations between Elevated Serum Uric Acid and Components of Metabolic Syndrome Such as Hypertension, Dyslipidemia, and T2DM in Overweight and Obese Chinese Adults.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; China; Diabetes | 2019 |
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Topics: Diabetes Mellitus, Type 2; Glycemic Control; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter | 2021 |
A potent risk model for predicting new-onset acute coronary syndrome in patients with type 2 diabetes mellitus in Northwest China.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Pressure; Body Mass Index; China; Cholesterol, LDL; | 2020 |
Mendelian randomization study of serum uric acid levels and diabetes risk: evidence from the Dongfeng-Tongji cohort.
Topics: Aged; Case-Control Studies; China; Diabetes Mellitus, Type 2; Female; Genotype; Humans; Incidence; M | 2020 |
Serum uric acid is independently associated with diabetic nephropathy but not diabetic retinopathy in patients with type 2 diabetes mellitus.
Topics: Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopat | 2020 |
Interactions among endotoxin, uric acid, and lactate in relation to the risk of type 2 diabetes: A population-based study.
Topics: Adult; Aged; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Endotoxins; Female; Humans; | 2020 |
Serum Uric Acid Level as a Harbinger of Type 2 Diabetes: A Prospective Observation in Taiwan.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective | 2020 |
Predictive Factors for Kidney Stone Recurrence in Type 2 Diabetes Mellitus.
Topics: Aged; Asymptomatic Diseases; Body Mass Index; Calcium Oxalate; Causality; Cohort Studies; Comorbidit | 2020 |
Uric acid in diabetic nephropathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; | 2020 |
Sex Differences in the Clinical Profile Among Patients With Gout: Cross-sectional Analyses of an Observational Study.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Gout; Humans; Male; Middle Aged; Sex Cha | 2021 |
Association between Uric Acid and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes Mellitus in China: A Cross-Sectional Inpatient Study.
Topics: Age Factors; Aged; Aged, 80 and over; Body Mass Index; Bone Density; China; Cross-Sectional Studies; | 2020 |
Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Betacoronavirus; Blood Urea Nitrogen; C-Rea | 2020 |
Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Gout Suppressants; Humans; Male; Middle | 2020 |
Sex-Specific Association of Serum Uric Acid Level and Change in Hyperuricemia Status with Risk of Type 2 Diabetes Mellitus: A Large Cohort Study in China.
Topics: Adult; China; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hyperuri | 2020 |
Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, | 2020 |
Assessment of the Role of Serum 25-Hydroxy Vitamin D Level on Coronary Heart Disease Risk With Stratification Among Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol; Cohort Studies; Coronary Disease; Diabetes Mell | 2021 |
Comment on "Is Uric Acid elevation a random finding or a causative agent of diabetic nephropathy?"
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Uric Acid | 2020 |
Allopurinol use and type 2 diabetes incidence among patients with gout: A VA retrospective cohort study.
Topics: Aged; Aged, 80 and over; Allopurinol; Colchicine; Diabetes Mellitus, Type 2; Female; Follow-Up Studi | 2020 |
Exogenous glutamine ameliorates diabetic nephropathy in a rat model of type 2 diabetes mellitus through its antioxidant and anti-inflammatory activities.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2023 |
Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients.
Topics: Adiponectin; Age Factors; Aged; Alanine Transaminase; Biomarkers; Body Mass Index; C-Peptide; Chemok | 2021 |
Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE's obese national population using targeted metabolomics.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Amino Acids, Branched-Chain; Biomarkers; Chromatography, Liqu | 2020 |
Effects of quercetin and metabolites on uric acid biosynthesis and consequences for gene expression in the endothelium.
Topics: Animals; Cattle; Diabetes Mellitus, Type 2; Endothelial Cells; Endothelium; Gene Expression; Humans; | 2021 |
Association between plasma uric acid and insulin resistance in type 2 diabetes: A Mendelian randomization analysis.
Topics: Diabetes Mellitus, Type 2; Female; Genotype; Humans; Insulin Resistance; Male; Mendelian Randomizati | 2021 |
Association of higher arterial ketone body ratio (acetoacetate/β-hydroxybutyrate) with relevant nutritional marker in hemodialysis patients.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; K | 2020 |
Associations of serum uric acid and urinary albumin with the severity of diabetic retinopathy in individuals with type 2 diabetes.
Topics: Albumins; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Retrospective Studies; Uric Acid | 2020 |
Serum uric acid is associated with increased risk of posttransplantation diabetes in kidney transplant recipients: a prospective cohort study.
Topics: Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; | 2021 |
Associations of serum uric acid level with diabetic retinopathy and albuminuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; F | 2020 |
Association between decreased thyroid stimulating hormone and hyperuricemia in type 2 diabetic patients with early-stage diabetic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; China; Diabetes Mellit | 2021 |
Identification of two novel subgroups in patients with diabetes mellitus and their association with clinical outcomes: A two-step cluster analysis.
Topics: Adult; Age of Onset; Aged; Body Mass Index; China; Cluster Analysis; Cohort Studies; Diabetes Compli | 2021 |
The additive effects of kidney dysfunction on left ventricular function and strain in type 2 diabetes mellitus patients verified by cardiac magnetic resonance imaging.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Disease Progression; Femal | 2021 |
Inter-relationship of risk factors and pathways associated with chronic kidney disease in patients with type 2 diabetes mellitus: a structural equation modelling analysis.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Ra | 2021 |
High urinary excretion rate of glucose attenuates serum uric acid level in type 2 diabetes with normal renal function.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycosuria; Humans; Hyperuricemia; Kidne | 2021 |
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Factor VII; Humans; Insulin Resistance; Plasminogen Activator Inhib | 2021 |
Interaction between the rs9356744 polymorphism and metabolic risk factors in relation to type 2 diabetes mellitus: The Cardiometabolic Risk in Chinese (CRC) Study.
Topics: Asian People; Cardiovascular Diseases; China; Diabetes Mellitus, Type 2; Humans; Lipids; Pulse Wave | 2021 |
Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Febuxostat; Humans; Naphthalenes; Propionates; Pyridines; Re | 2021 |
Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population.
Topics: China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Humans; Non-alcoholic Fatty Liver Disease | 2021 |
Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis.
Topics: Aged; Aged, 80 and over; Allopurinol; Diabetes Mellitus, Type 2; Female; Humans; Male; Propensity Sc | 2021 |
The URRAH study.
Topics: Diabetes Mellitus, Type 2; Gout; Heart Failure; Humans; Hypertension; Retrospective Studies; Stroke; | 2021 |
Genetic Predisposition to Type 2 Diabetes and Insulin Levels Is Positively Associated With Serum Urate Levels.
Topics: Adult; Blood Glucose; Causality; Diabetes Mellitus, Type 2; Fasting; Female; Genetic Predisposition | 2021 |
Association between serum uric acid levels and cardiovascular events in hospitalized patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Retrospective Studies; Risk Factors; | 2021 |
Higher Serum Uric Acid Levels Are Associated With an Increased Risk of Vision-Threatening Diabetic Retinopathy in Type 2 Diabetes Patients.
Topics: Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Follow | 2021 |
Association between serum uric acid and bone mineral density in patients with type 2 diabetes: A 6-year longitudinal study in China.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; China; Cross-Sectional Studies; Diab | 2021 |
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway.
Topics: Allopurinol; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Endoplasmic | 2021 |
Relationship of Bone Status with Serum Uric Acid and Bilirubin in Men with Type 2 Diabetes: A Cross-Sectional Study.
Topics: Aged; Bilirubin; Biomarkers; Bone Density; Diabetes Mellitus, Type 2; Humans; Male; Middle Aged; Ret | 2021 |
The Speed of Ingestion of a Sugary Beverage Has an Effect on the Acute Metabolic Response to Fructose.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Eating; Female; Fibroblast Growth Factors; Fructose | 2021 |
Serum uric acid and its change with the risk of type 2 diabetes: A prospective study in China.
Topics: Adult; China; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Male; Prospective Studies; Risk Fact | 2021 |
Metagenomic analysis revealed the potential role of gut microbiome in gout.
Topics: Adolescent; Adult; Aged; Arthritis; Bacteria; Butyrates; Diabetes Mellitus, Type 2; Dysbiosis; Fatty | 2021 |
Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Lipid Metabolism; | 2021 |
Association of serum uric acid with biventricular myocardial dysfunction in patients with type 2 diabetes mellitus.
Topics: Aged; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Echocardiography; Female; Hong | 2021 |
On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Cause of Death; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Forecasting; Human | 2017 |
Effects of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose: A Pilot Study.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Creati | 2017 |
Metabolic syndrome, serum uric acid and renal risk in patients with T2D.
Topics: Acute Kidney Injury; Aged; Albuminuria; Blood Pressure; Body Mass Index; Cholesterol, HDL; Databases | 2017 |
Relationship between serum uric acid and ischemic stroke in a large type 2 diabetes population in China: A cross-sectional study.
Topics: Age Factors; Aged; Biomarkers; Brain Ischemia; China; Cross-Sectional Studies; Diabetes Mellitus, Ty | 2017 |
Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.
Topics: Aged; Blood Glucose Self-Monitoring; Blood Pressure; Blood Pressure Determination; Databases, Factua | 2017 |
Serum uric acid levels are associated with increased risk of newly developed diabetic retinopathy among Japanese male patients with type 2 diabetes: A prospective cohort study (diabetes distress and care registry at Tenri [DDCRT 13]).
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Female; Humans; Japan; M | 2017 |
Serum 25-Hydroxyvitamin D3 Levels Are Associated with Carotid Intima-Media Thickness and Carotid Atherosclerotic Plaque in Type 2 Diabetic Patients.
Topics: Adult; Blood Glucose; Calcifediol; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; | 2017 |
Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes.
Topics: Adult; Age of Onset; Aged; Biomarkers; Blood Glucose; China; Cross-Sectional Studies; Diabetes Melli | 2017 |
Correlation of retinal nerve fibre layer and macular thickness with serum uric acid among type 2 diabetes mellitus.
Topics: Adult; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Follow-Up S | 2017 |
The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Incidence; Male; Middle | 2017 |
Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.
Topics: Aged; Atrial Fibrillation; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyper | 2018 |
Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; | 2017 |
Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients.
Topics: Age Factors; Body Mass Index; Calcium; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Inci | 2017 |
Prevalence and associated factors of diabetic retinopathy in Beijing, China: a cross-sectional study.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Blood Pressure; Body Mass Index; China; Cross-Sectiona | 2017 |
The Association of Uric Acid Calculi with Obesity, Prediabetes, Type 2 Diabetes Mellitus, and Hypertension.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Middle Aged; Obesity; Prediabetic Sta | 2017 |
Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients.
Topics: Adult; Biomarkers; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; Male; Met | 2017 |
Interaction between gender and uric acid on hemoglobin A1c in community-dwelling persons.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glycated Hemoglo | 2018 |
Pancreatic and renal function in streptozotocin-induced type 2 diabetic rats administered combined inositol hexakisphosphate and inositol supplement.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Supplements; Drug Thera | 2017 |
A Point-based Mortality Prediction System for Older Adults with Diabetes.
Topics: Aged; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; | 2017 |
Uric acid and diabetes risk among Chinese women with a history of gestational diabetes mellitus.
Topics: Adult; Asian People; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetes, Gestational; Fema | 2017 |
Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes.
Topics: Aged; Asymptomatic Diseases; Cardiac Conduction System Disease; Confounding Factors, Epidemiologic; | 2017 |
Understanding the Impact of Added Sugar Consumption on Risk for Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Dietary Sucrose; Fructose; Humans; Insulin Resistance; Lipogenesis; Nutri | 2016 |
Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI.
Topics: Aged; Asian People; Biomarkers; Body Mass Index; Bone Density; Bone Diseases, Metabolic; Bone Remode | 2018 |
Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
Topics: Aged; Animals; Biomarkers; Blood Glucose; Chromatography, Liquid; Cross-Sectional Studies; Diabetes | 2017 |
Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle | 2018 |
The relationships among hyperuricemia, body mass index and impaired renal function in type 2 diabetic patients.
Topics: Adult; Aged; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2018 |
Serum 1,5-Anhydroglucitol Concentrations Remain Valid as a Glycemic Control Marker In Diabetes with Earlier Chronic Kidney Disease Stages.
Topics: Adult; Aged; Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabeti | 2019 |
Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study.
Topics: Adult; Age Distribution; Biomarkers; Blood Glucose; Body Mass Index; Case-Control Studies; Diabetes | 2018 |
Correlation between serum uric acid and diabetic peripheral neuropathy in T2DM patients.
Topics: Adult; Aged; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Male; Mi | 2018 |
Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy.
Topics: Adult; Blood Urea Nitrogen; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2018 |
Elevated Serum Xanthine Oxidase Activity Is Associated With the Development of Type 2 Diabetes: A Prospective Cohort Study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus | 2018 |
Serum uric acid to creatinine ratio correlates with β-cell function in type 2 diabetes.
Topics: Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Tolerance Test | 2018 |
Hyperuricaemia and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin; Insulin Resistance; Uric Acid | 2018 |
Longitudinal Associations of Metabolic Syndrome Severity Between Childhood and Young Adulthood: The Bogalusa Heart Study.
Topics: Adolescent; Adult; Aging; Alabama; Black People; Cardiovascular Diseases; Child; Cross-Sectional Stu | 2018 |
Relationship Between Serum Uric Acid and Incident Hypertension in Patients with Type 2 Diabetes.
Topics: Blood Pressure; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Incidence; Ira | 2018 |
Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes.
Topics: Adult; Aged; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2018 |
Analysis on influencing factors of abnormal renal function in elderly patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Typ | 2020 |
Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Hypoglycemic Agent | 2018 |
Single-marker and multi-marker approaches to appraise the relationships between biomarkers and microalbuminuria in Chinese middle-aged and elderly from communities: a cross-sectional analysis.
Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; C-Reactive Protein; China; Cross-Sectional Studies | 2018 |
Glycated hemoglobin targets and glycemic control: Link with lipid, uric acid and kidney profile.
Topics: Adult; Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycated Hem | 2018 |
Temporal relationship between hyperuricemia and obesity, and its association with future risk of type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; China; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Longi | 2018 |
Ethanolic seeds extract of Centratherum anthelminticum reduces oxidative stress in type 2 diabetes.
Topics: Alanine Transaminase; Animals; Antioxidants; Asteraceae; Bilirubin; Creatine Kinase; Diabetes Mellit | 2018 |
[Correlation between fasting C-peptide and serum uric acid in patients with type 2 diabetes mellitus].
Topics: C-Peptide; Diabetes Mellitus, Type 2; Fasting; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
[Serum Uric Acid and Islet β-cell Function in Patients with Pre-diabetes and Type 2 Diabetes Mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin; Insulin R | 2018 |
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Hypoglycemic Agent | 2018 |
Higher serum levels of uric acid are associated with a reduced insulin clearance in non-diabetic individuals.
Topics: Adult; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glomerular Filtration Rate; Gluco | 2018 |
Correlation between serum uric acid and diabetic peripheral neuropathy - association rather than causation.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Uric Acid | 2018 |
Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hyperur | 2019 |
Serum uric acid and metabolic components with special reference to diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2018 |
Untargeted Profiling of Concordant/Discordant Phenotypes of High Insulin Resistance and Obesity To Predict the Risk of Developing Diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diglycerides; Fatty Acids, Unsaturated; Humans; Insulin Resis | 2018 |
[Protective effects of Curcumin analogue L6H4 on kidney from type 2 diabetic rats].
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Curcumin; Diabetes Mellit | 2017 |
Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2018 |
Association of serum uric acid with bone mineral density and clinical fractures in Chinese type 2 diabetes mellitus patients: A cross-sectional study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; China; Cross-Sectional Studies; | 2018 |
Laparoscopic sleeve gastrectomy combined with single-anastomosis duodenal-jejunal bypass in the treatment of type 2 diabetes mellitus of patients with body mass index higher than 27.5 kg/m2 but lower than 32.5 kg/m2.
Topics: Adult; Bariatric Surgery; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; | 2018 |
[Related factors of diabetic nephropathy in patients with type 1 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2018 |
Relationship between inflammatory parameters and cardiovascular and lifestyle factors in the Mugello study oldest old.
Topics: Aged, 80 and over; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cytokin | 2018 |
Interactive effect of serum uric acid and total bilirubin for micro-vascular disease of type 2 diabetes in China.
Topics: Aged; Bilirubin; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2018 |
High serum uric acid is associated with oxidation of nucleosides in patients with type 2 diabetes.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Creatinine; Deoxyguanosine; Diabetes Mellitus, Type 2; Fem | 2018 |
Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2019 |
Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Hum | 2021 |
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Diabe | 2019 |
Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus.
Topics: Biomarkers; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Male; Metabolic Syndrome; Middle | 2019 |
Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study.
Topics: Aged; Blood Pressure; Cholesterol; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glycat | 2019 |
Increased urinary glucose excretion is associated with a reduced risk of hyperuricaemia.
Topics: Adult; Blood Glucose; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose Tol | 2019 |
Association between serum uric acid and large-nerve fiber dysfunction in type 2 diabetes: a cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fema | 2019 |
Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2019 |
U-Shaped Association Between Serum Uric Acid Levels and Cognitive Functions in Patients with Type 2 Diabetes: A Cross-Sectional Study.
Topics: Aged; Cognition; Cognitive Dysfunction; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; | 2019 |
Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Stu
Topics: Adolescent; Blood Pressure; Child; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephro | 2019 |
The association between serum uric acid to creatinine ratio and renal disease progression in type 2 diabetic patients in Chinese communities.
Topics: Adult; Aged; Case-Control Studies; China; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2019 |
Correlations of serum uric acid with glucose and lipid metabolism and renal function of type 2 diabetes mellitus patients.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; H | 2020 |
High Serum Uric Acid Is Associated with Tubular Damage and Kidney Inflammation in Patients with Type 2 Diabetes.
Topics: Aged; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hepatitis A | 2019 |
Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular | 2019 |
Differences in the association between glycemia and uric acid levels in diabetic and non-diabetic populations.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Fem | 2019 |
[The features of pathogenesis of urolithiasis in patients with diabetes mellitus type 2].
Topics: Calcium Oxalate; Diabetes Mellitus, Type 2; Humans; Uric Acid; Urinary Calculi; Urolithiasis | 2019 |
Negative Association of Serum URIC Acid with Peripheral Blood Cellular Aging Markers.
Topics: Aging; Biomarkers; Cellular Senescence; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; | 2019 |
Follow-up of glycemic index before and after Ramadan fasting in type 2 diabetes patients under antidiabetic medications.
Topics: Acidosis, Lactic; Adult; Aged; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Fasting; Female | 2019 |
The Histone Methyltransferase Setdb2 Modulates Macrophage Phenotype and Uric Acid Production in Diabetic Wound Repair.
Topics: Aged; Animals; Carrier Proteins; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; D | 2019 |
The freeze-dried extracts of Rotheca myricoides (Hochst.) Steane & Mabb possess hypoglycemic, hypolipidemic and hypoinsulinemic on type 2 diabetes rat model.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Freeze Drying; H | 2019 |
Fatty acids modulate cytokine and chemokine secretion of stimulated human whole blood cultures in diabetes.
Topics: Adult; alpha-Linolenic Acid; Case-Control Studies; Chemokines; Cytokines; Diabetes Mellitus, Type 1; | 2013 |
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.
Topics: Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Gout; Humans; Hyperuricemia; K | 2013 |
Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus.
Topics: Aged; Atrial Fibrillation; Biomarkers; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type | 2013 |
The prevalence and predictors of androgen deficiency in Taiwanese men with type 2 diabetes.
Topics: Age Factors; Aged; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Sectional Studies; Diabet | 2013 |
Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Female; G | 2013 |
The association between serum uric acid and diabetes mellitus is stronger in women.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Fem | 2013 |
Elevated serum uric acid levels are independent risk factors for diabetic foot ulcer in female Chinese patients with type 2 diabetes.
Topics: Aged; Asian People; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Foot; Female; Follow-Up Studies; | 2014 |
[Analyses on the relative factors regarding diabetic nephropathy].
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Huma | 2013 |
Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes.
Topics: Adult; Aged; Ammonium Chloride; Animals; Biomarkers; Body Mass Index; Case-Control Studies; Diabetes | 2013 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mel | 2013 |
Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients.
Topics: Albuminuria; C-Reactive Protein; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem | 2013 |
Serum total and high-density lipoprotein phospholipids: independent predictive value for cardiometabolic risk.
Topics: Apolipoproteins; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Follo | 2014 |
Postterm births: are prolonged pregnancies too long?
Topics: Body Composition; Body Mass Index; Cerebral Palsy; Child Behavior Disorders; Child, Preschool; Diabe | 2014 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2014 |
[Simultaneous determination of four common nonprotein nitrogen substances in urine by high performance liquid chromatography].
Topics: Chromatography, High Pressure Liquid; Creatine; Creatinine; Diabetes Mellitus, Type 2; Humans; Limit | 2013 |
Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus.
Topics: Adult; Age Factors; Atherosclerosis; C-Reactive Protein; Carotid Arteries; China; Cross-Sectional St | 2014 |
Association of serum uric acid with level of blood pressure in type 2 diabetic patients.
Topics: Aged; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; | 2014 |
Re: Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes.
Topics: Ammonium Chloride; Animals; Diabetes Mellitus, Type 2; Female; Humans; Kidney; Kidney Calculi; Male; | 2014 |
Bariatric surgery as urate-lowering therapy in severe obesity.
Topics: Bariatric Surgery; Diabetes Mellitus, Type 2; Female; Humans; Male; Obesity, Morbid; Uric Acid | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2015 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |
Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; China; Cross-Sectional Studies; Diabetes Mellitus, Typ | 2014 |
The association between serum uric acid and residual β -cell function in type 2 diabetes.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucos | 2014 |
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Respons | 2014 |
Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan--a 3-year prospective study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dise | 2014 |
Serum uric acid and disorders of glucose metabolism: the role of glycosuria.
Topics: Adult; Age Factors; Blood Glucose; Brazil; Community Health Services; Comorbidity; Cross-Sectional S | 2014 |
Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction.
Topics: Adult; Biomarkers; Blood Urea Nitrogen; Case-Control Studies; China; Cholesterol, HDL; Chromatograph | 2014 |
Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes.
Topics: Aged; Asian People; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cross- | 2015 |
Common variants related to serum uric acid concentrations are associated with glucose metabolism and insulin secretion in a Chinese population.
Topics: Adult; Aged; China; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Glucose; G | 2015 |
Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.
Topics: Animals; Carrier Proteins; Cell Line; Chemokine CXCL12; Coculture Techniques; Diabetes Mellitus, Typ | 2015 |
High risk factors of atrial fibrillation in type 2 diabetes: results from the Chinese Kailuan study.
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; China; Diabetes Mellitus, Type 2; Diabetic Angi | 2015 |
Decreased urine uric acid excretion is an independent risk factor for chronic kidney disease but not for carotid atherosclerosis in hospital-based patients with type 2 diabetes: a cross-sectional study.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2 | 2015 |
A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Genetic Loci; Genetic Predisposition to Disease; Humans; M | 2015 |
Plasma metabolomic profiling of patients with diabetes-associated cognitive decline.
Topics: Aged; Area Under Curve; Bile Acids and Salts; Biomarkers; Case-Control Studies; Chromatography, High | 2015 |
[Protective effect of curcumin derivative B06 on kidney of type 2 diabetic rats].
Topics: Animals; Blood Urea Nitrogen; Collagen Type IV; Creatinine; Curcumin; Diabetes Mellitus, Experimenta | 2015 |
Uric Acid is independently associated with diabetic kidney disease: a cross-sectional study in a Chinese population.
Topics: Biomarkers; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2015 |
Uric acid and skin microvascular function: the Maastricht study.
Topics: Adult; Aged; Capillaries; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypere | 2015 |
Does skin microcirculation represent a faithful mirror of uric acid alterations?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Male; Uric Acid; Vascular Stiffn | 2015 |
Association between serum uric acid, aortic, carotid and femoral stiffness among adults aged 40-75 years without and with type 2 diabetes mellitus: The Maastricht Study.
Topics: Adult; Aged; Aorta; Blood Glucose; Cardiovascular Diseases; Carotid Arteries; Compliance; Cross-Sect | 2015 |
Decreased urine uric acid excretion is associated with diabetic retinopathy but not with lower limb atherosclerosis in hospitalized patients with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Biomarkers; China; Comorbidity; Constriction, Pathologic; Cross-Sectional St | 2015 |
Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Atrial Fibrillation; Cross-Sectional Studies; Diabetes Mellitu | 2016 |
Causal or Noncausal Relationship of Uric Acid With Diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Genetic Loci; Genetic Predisposition to Disease; Humans; Male; Ur | 2015 |
Adipose Tissues Characteristics of Normal, Obesity, and Type 2 Diabetes in Uygurs Population.
Topics: Adipose Tissue; Adult; Asian People; Blood Glucose; Blood Pressure; Body Composition; Body Mass Inde | 2015 |
Serum Uric Acid and Risk of CKD in Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Longitudinal Studies; Male; Middle Aged; Renal Insu | 2015 |
Interaction between Marine-Derived n-3 Long Chain Polyunsaturated Fatty Acids and Uric Acid on Glucose Metabolism and Risk of Type 2 Diabetes Mellitus: A Case-Control Study.
Topics: Adult; Aquatic Organisms; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Fatty Acid | 2015 |
Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study.
Topics: Aged; China; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Incidence; Male; Middle Aged; | 2016 |
Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Albuminuria; Comorbidity; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2015 |
Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study.
Topics: Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtr | 2016 |
Uric Acid Levels Can Predict Metabolic Syndrome and Hypertension in Adolescents: A 10-Year Longitudinal Study.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Longitudinal Studies; Ma | 2015 |
[Association of Serum Uric Acid with 2-hour Postload Glucose in Predibetic Patients].
Topics: Blood Glucose; China; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Glucose; Glucose Intoleranc | 2015 |
Association Between Serum Uric Acid and Prevalence of Type 2 Diabetes Diagnosed using HbA1c Criteria Among Chinese Adults in Qingdao, China.
Topics: Adult; Aged; Asian People; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glycat | 2015 |
Models Predictive of Metabolic Syndrome Components in Obese Pediatric Patients.
Topics: Adolescent; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Child; Cross-Sectional Studies; | 2016 |
Genetic Causality in Complex Traits: The Case of Uric Acid.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Humans; Mendelian Randomization Analysis; Polymorphism, | 2016 |
Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Global Health; Humans; Mendelian Randomization Analysis | 2016 |
[The study of the association of polymorphism rs5219 gene KCNJ11 with obesity and the risk of type 2 diabetes among residents of the Moscow Region].
Topics: Body Mass Index; Diabetes Mellitus, Type 2; DNA; Energy Metabolism; Female; Gene Frequency; Genotype | 2015 |
Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)].
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; G | 2016 |
Association between serum uric acid related genetic loci and diabetic kidney disease in the Chinese type 2 diabetes patients.
Topics: Adaptor Proteins, Signal Transducing; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member | 2016 |
A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis.
Topics: Adult; Aged; Asian People; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies | 2016 |
Uric acid, renal function and risk of hypoglycaemia in Chinese type 2 diabetes patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Cross-Sectional Studies; Diabetes Mellitus, Type | 2016 |
Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes.
Topics: Adult; Aged; Asian People; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans | 2016 |
Is Uric Acid a Missing Link between Previous Gestational Diabetes Mellitus and the Development of Type 2 Diabetes at a Later Time of Life?
Topics: Adult; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gluco | 2016 |
[Correlation between serum free fatty acid level and estimated glomerular filtration rate in type 2 diabetic patients].
Topics: Albuminuria; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glomerular Filt | 2016 |
Juniperus rigida Sieb. extract inhibits inflammatory responses via attenuation of TRIF-dependent signaling and inflammasome activation.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Anti-Inflammatory Agents; Apoptosis Regulatory Prote | 2016 |
Serum Uric Acid Levels were Dynamically Coupled with Hemoglobin A1c in the Development of Type 2 Diabetes.
Topics: Adult; Aged; Aged, 80 and over; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; Bl | 2016 |
The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid.
Topics: Adult; Aged; Biomarkers; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Female; H | 2015 |
Fructose surges damage hepatic adenosyl-monophosphate-dependent kinase and lead to increased lipogenesis and hepatic insulin resistance.
Topics: Adenosine Monophosphate; Adenylate Kinase; Allosteric Site; AMP-Activated Protein Kinases; Animals; | 2016 |
Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients.
Topics: Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Liver; Male; Middle | 2016 |
The Relation between Serum Uric Acid and HbA1c Is Dependent upon Hyperinsulinemia in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Creatinine; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Te | 2016 |
Association of Serum Uric Acid Concentration with Diabetic Retinopathy and Albuminuria in Taiwanese Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; Logi | 2016 |
Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Diabetes Mel | 2017 |
Different Contributions of Physical Activity on Arterial Stiffness between Diabetics and Non-Diabetics.
Topics: Age Factors; Aged; Ankle Brachial Index; Blood Pressure; Cholesterol; Diabetes Mellitus, Type 2; Exe | 2016 |
Changes in ideal cardiovascular health status and risk of new-onset type 2 diabetes: The Kailuan prospective study.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; C-Reactive Protein; China; Cholesterol; Diabe | 2016 |
Association of serum calcium and heart failure with preserved ejection fraction in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Blood Glucose; Calcium; China; Cross-Sectiona | 2016 |
Interactive effect of serum uric acid and total bilirubin for cardiovascular disease in Chinese patients with type 2 diabetes.
Topics: Aged; Asian People; Bilirubin; Cardiovascular Diseases; China; Cross-Sectional Studies; Diabetes Mel | 2016 |
Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin.
Topics: Adult; Aged; Asian People; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Female; Glyca | 2016 |
The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitu | 2017 |
Xanthine Oxidase Activity in Type 2 Diabetes Mellitus Patients with and without Diabetic Peripheral Neuropathy.
Topics: Aged; Biomarkers; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Neuropa | 2016 |
Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female | 2016 |
Melatonin protects against uric acid-induced mitochondrial dysfunction, oxidative stress, and triglyceride accumulation in C
Topics: Animals; Antioxidants; Cell Line; Cell Respiration; Diabetes Mellitus, Type 2; Electron Transport; M | 2017 |
Serum uric acid levels are associated with obesity but not cardio-cerebrovascular events in Chinese inpatients with type 2 diabetes.
Topics: Asian People; Cardiovascular Diseases; Cerebrovascular Disorders; China; Cross-Sectional Studies; Di | 2017 |
Serum uric acid to creatinine ratio: A predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Creatinine; Diabetes Mellitus, Type 2; Diabetic Ne | 2017 |
The Role of Uric Acid for Predicting Future Metabolic Syndrome and Type 2 Diabetes in Older People.
Topics: Aged; Aged, 80 and over; Aging; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; | 2017 |
Excretion rates of 1,5-anhydro-D-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; | 2017 |
Association between future events of brain infarction and soluble levels of intercellular adhesion molecule-1 and C-reactive protein in patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Brain Infarction; C-Reactive Protein; Diabet | 2008 |
Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile.
Topics: Adult; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Epidemiologic Meth | 2008 |
High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Reference Values; Reproducibility o | 2008 |
High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Risk Factors; Uric Acid | 2008 |
A novel mutation of SLC22A12 gene causing primary renal hypouricemia in a patient with metabolic syndrome.
Topics: Adult; Aged; Creatinine; Diabetes Mellitus, Type 2; DNA Mutational Analysis; Family; Female; Humans; | 2008 |
Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients.
Topics: Adenosine; Aged; Asian People; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypogl | 2009 |
Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glomerular Filtration R | 2009 |
Fructose ingestion: dose-dependent responses in health research.
Topics: Blood Glucose; Body Weight; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Dose-Response Relatio | 2009 |
Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.
Topics: Albuminuria; Allopurinol; Animals; Blood Pressure; Blood Urea Nitrogen; Cell Line; Diabetes Mellitus | 2009 |
Oral glucose tolerance test in Italian overweight/obese children and adolescents results in a very high prevalence of impaired fasting glycaemia, but not of diabetes.
Topics: Adolescent; Aging; Blood Glucose; Body Mass Index; Child; Cohort Studies; Diabetes Mellitus, Type 1; | 2009 |
Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Kaplan-Meier Estim | 2009 |
[Uric acid predicts type 2 diabetes mellitus in the general population].
Topics: Adolescent; Adult; Aged; Anthropometry; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diseas | 2009 |
Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link.
Topics: Adiponectin; Adult; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2009 |
Levels of retinol-binding protein 4 and uric acid in patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Ty | 2009 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers.
Topics: Carbamates; Diabetes Mellitus, Type 2; Gas Chromatography-Mass Spectrometry; Humans; Hypoglycemic Ag | 2009 |
Salivary antioxidants in patients with type 1 or 2 diabetes and inflammatory periodontal disease: a case-control study.
Topics: Adolescent; Adult; Aged; Antioxidants; Ascorbic Acid; Case-Control Studies; Dental Plaque Index; Dia | 2009 |
Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo study: response to Kramer et al.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Femal | 2009 |
The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.
Topics: Adult; Allopurinol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Gout Supp | 2009 |
Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study.
Topics: Aged; Blood Glucose; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Female; Germany; Glu | 2009 |
Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients.
Topics: Adiposity; Aged; Anthropometry; Blood Glucose; Blood Pressure; Body Composition; Body Mass Index; Di | 2010 |
Angiotensin-converting enzyme gene polymorphism in overweight and obese Turkish patients with insulin resistance.
Topics: Adipose Tissue; Adult; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Fe | 2010 |
Menopausal symptoms and the metabolic syndrome in Nigerian women with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Arthralgia; Body Mass Index; Cholesterol, HDL; Cross-Sectional Studi | 2011 |
Relevance of uric Acid in progression of type 2 diabetes mellitus.
Topics: Age Factors; Aged; Biomarkers; Blood Glucose; Bosnia and Herzegovina; Case-Control Studies; Diabetes | 2010 |
A prospective study of uric acid by glucose tolerance status and survival: the Rancho Bernardo Study.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose | 2010 |
Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Kaplan-Meier Estimate; Mal | 2010 |
Raised natriuretic peptides, big-endothelin-1 and improved beta-cell function in type 2 diabetic males with hyperuricaemia.
Topics: Aged; Atrial Natriuretic Factor; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellit | 2009 |
Serum uric acid, plasma glucose and diabetes.
Topics: Adult; Aged; Asian People; Biomarkers; Blood Glucose; China; Cross-Sectional Studies; Diabetes Melli | 2010 |
[Association between serum uric acid level and peripheral vascular disease of lower extremities in type 2 diabetes mellitus subjects].
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Lower Extremity; Male; Mi | 2010 |
[Carbohydrate metabolic disorders in gout: incidence and clinical features].
Topics: Anthropometry; Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Cholesterol; Diabete | 2010 |
Substance P is associated with the development of obesity, chronic inflammation and type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; C-Reactive Protein; Cholesterol; Diabetes Mellitus, | 2011 |
Ability among adolescents for the metabolic syndrome to predict elevations in factors associated with type 2 diabetes and cardiovascular disease: data from the national health and nutrition examination survey 1999-2006.
Topics: Adolescent; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, | 2010 |
A prediction model for the risk of incident chronic kidney disease.
Topics: Adult; Age Factors; Aged; Asian People; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; | 2010 |
[Lipid lowering, antiinflammatory, and vasoprotective effects of fenofibrate in patients with type 2 diabetes mellitus].
Topics: Adult; Aged; C-Reactive Protein; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Female | 2010 |
Serum uric acid levels and the risk of type 2 diabetes: a prospective study.
Topics: Adult; Age Factors; Alcohol Drinking; Blood Glucose; Body Mass Index; Cholesterol; Creatinine; Diabe | 2010 |
Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studi | 2011 |
Insulin resistance profile among siblings of type 2 diabetes mellitus (preliminary study).
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; | 2010 |
Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus.
Topics: Albuminuria; Blood Glucose; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic | 2011 |
Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics.
Topics: Adult; Antioxidants; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glutathion | 2011 |
A genome-wide association study of serum uric acid in African Americans.
Topics: Black or African American; Black People; Body Mass Index; Diabetes Mellitus, Type 2; Genome-Wide Ass | 2011 |
Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus.
Topics: Adult; Aged; C-Reactive Protein; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Neurop | 2011 |
Elevated serum uric acid predicts impaired fasting glucose and type 2 diabetes only among Japanese women undergoing health checkups.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hyperuricemia; | 2011 |
[Association of elevated uric acid with metabolic disorders and analysis of the risk factors of hyperuricemia in type 2 diabetes mellitus].
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Male; Midd | 2011 |
Serum uric acid associates with the incidence of type 2 diabetes in a prospective cohort of middle-aged and elderly Chinese.
Topics: Aged; Biomarkers; China; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Human | 2011 |
Which anthropometric parameter is best related with urinary albumin excretion and creatinine clearance in type 2 diabetes: body mass index, waist circumference, waist-to-hip ratio, or conicity index?
Topics: Aged; Albumins; Blood Pressure; Body Mass Index; Creatinine; Cross-Sectional Studies; Diabetes Melli | 2011 |
[Interrelations of uric acid metabolism indices with insulin and testosterone levels in men with type 2 diabetes].
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Testosteron | 2010 |
Factors associated with diabetic nephropathy in subjects with proliferative retinopathy.
Topics: Aged; Albuminuria; Blood Pressure; Blood Sedimentation; C-Reactive Protein; Circadian Rhythm; Diabet | 2012 |
Analysis of risk factors for uric acid nephrolithiasis in type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Cross-S | 2011 |
World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, T | 2011 |
No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach.
Topics: Adult; Aged; Alleles; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genome-Wide Associati | 2011 |
Association of serum uric acid with different levels of glucose and related factors.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intoleran | 2011 |
Glycaemic indices and non-traditional biochemical cardiovascular disease markers in a diabetic population in Nigeria.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Chi-Square Distribution; Cro | 2011 |
Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Carotid Steno | 2011 |
Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations.
Topics: Adult; Belgium; Biomarkers; Central Nervous System Diseases; Chi-Square Distribution; Dental Enamel; | 2011 |
Increased serum levels of uric acid are associated with sudomotor dysfunction in subjects with type 2 diabetes mellitus.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Periphera | 2011 |
Relationship of dyslipidemia and uric acid with the risk of myocardial infarction among hypertensive patients in Trinidad.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Fema | 2011 |
Serum uric acid and 1-h postload glucose in essential hypertension.
Topics: Adult; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucos | 2012 |
Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hype | 2012 |
Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus.
Topics: Albuminuria; Atherosclerosis; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 2012 |
A study of the natural history of diabetic kidney disease (DKD).
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Diab | 2012 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2012 |
Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients.
Topics: Adiponectin; Adult; Aged; Blood Pressure; Cholesterol, HDL; Creatinine; Cystatin C; Diabetes Mellitu | 2012 |
Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Exercise; Humans; Inflammation; Lipids; | 2011 |
A structural equation model for assessment of links between changes in serum triglycerides, -urate, and -glucose and changes in serum calcium, -magnesium and -phosphate in type 2 diabetes and non-diabetes metabolism.
Topics: Adult; Biomarkers; Blood Glucose; Calcium; Cardiovascular Diseases; Case-Control Studies; Chi-Square | 2011 |
External validation of the KORA S4/F4 prediction models for the risk of developing type 2 diabetes in older adults: the PREVEND study.
Topics: Adult; Age Factors; Aged; Biomarkers; Blood Glucose; Body Mass Index; Decision Support Techniques; D | 2012 |
Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Chi-Square Distribution; Diabetes Complic | 2012 |
Interaction between uric acid and endothelial dysfunction predicts new onset of diabetes in hypertensive patients.
Topics: Adult; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hyperten | 2013 |
Comparison of metabolic effects of surgical-induced massive weight loss in patients with long-term remission versus non-remission of type 2 diabetes.
Topics: Adiponectin; Adolescent; Adult; Area Under Curve; Blood Glucose; Body Mass Index; Brazil; C-Reactive | 2012 |
Validation of 7 type 2 diabetes mellitus risk scores in a population-based cohort: CoLaus study.
Topics: Age Distribution; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cohort Studies; Diabetes Mellitu | 2012 |
[Predictive value of serum uric acid on type 2 diabetes mellitus].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperuricemia; Male; Middle Aged; Prevalen | 2011 |
High-normal serum uric acid is associated with albuminuria and impaired glomerular filtration rate in Chinese type 2 diabetic patients.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Mal | 2011 |
Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Female; Huma | 2012 |
[Correlation of serum uric acid and islet beta cell functions in female type 2 diabetics].
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin; Insulin-Secreting Cells; Middle Aged; Risk Facto | 2012 |
The presence of overactive bladder wet increased the risk and severity of erectile dysfunction in men with type 2 diabetes.
Topics: Aged; C-Reactive Protein; Cholesterol; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type | 2012 |
Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients.
Topics: Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Chi-Square Distribution; Diabetes Mellitu | 2012 |
Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Hum | 2013 |
Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aspartate Aminotransferases; Blood Glucose; C-Reactive Protein; Cholesterol | 2013 |
Does uric acid qualify as an independent risk factor for cardiovascular mortality?
Topics: Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Risk Factors; | 2013 |
Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors.
Topics: Adiposity; Aged; Body Mass Index; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; D | 2013 |
Genetic impact on uric acid concentration and hyperuricemia in the Japanese population.
Topics: Aged; Asian People; Coronary Disease; Diabetes Mellitus, Type 2; Female; Genetic Loci; Genetic Predi | 2013 |
Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy.
Topics: Animals; Biomarkers; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Mod | 2012 |
Serum uric acid predicts both current and future components of the metabolic syndrome.
Topics: Adolescent; Adult; Black or African American; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fe | 2013 |
A fasting-induced decrease in plasma glucose concentration does not affect the insulin response to ingested protein in people with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Proteins; Fasting; Fatty Acids, N | 2002 |
Significant correlation between insulin resistance and serum gamma-glutamyl transpeptidase (gamma-GTP) activity in non-drinkers.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Body Mass Index; Cholesterol; | 2002 |
[Serum uric acid in type 2 diabetic patients complicated by stroke].
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Ma | 2002 |
Association of GYS1 and beta(3)-AR gene with postprandial hyperglycemia and serum uric acid in type 2 diabetes mellitus.
Topics: Adult; Aged; Alleles; Body Mass Index; Diabetes Mellitus, Type 2; Glycogen Synthase; Humans; Hypergl | 2002 |
[Glucose effectiveness and components of the metabolic syndrome in recently diagnosed hypertensive patients].
Topics: Adult; Aged; Cholesterol, VLDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glucose; | 2002 |
Biochemical profile of stone-forming patients with diabetes mellitus.
Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Calcium Oxalate; Comorbidity; Diabetes Mellitus | 2003 |
Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Humans; Hypertension; Inc | 2003 |
Prevalence of obesity in an elderly Hungarian population.
Topics: Age Distribution; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Case-Control Studies; Com | 2003 |
Clustering of components of the metabolic syndrome and risk for development of type 2 diabetes in Japanese male office workers.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Cholesterol, LDL; Cluster Analysis; Dia | 2004 |
Selected risk factors of ischemic heart disease in Polish seafarers. Preliminary report.
Topics: Adult; Age Distribution; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Me | 2003 |
Adenosine deaminase activity in the serum of type 2 diabetic patients.
Topics: Adenosine Deaminase; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; In | 2004 |
Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes.
Topics: Aged; Arterial Occlusive Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2004 |
Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus.
Topics: Adult; Antioxidants; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Erythrocytes; Female; Fr | 2004 |
[Relation between diabetes compensation, albuminuria and biochemical parameters and the results of stress myocardial SPECT in asymptomatic type 2 diabetics].
Topics: Albuminuria; C-Reactive Protein; Coronary Circulation; Coronary Disease; Diabetes Mellitus, Type 2; | 2004 |
Reduced serum homocysteine levels in type 2 diabetes.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet; Female; G | 2005 |
Gender-specific leptinemia and its relationship with some components of the metabolic syndrome in Moroccans.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Female; | 2005 |
Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan.
Topics: Aged; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Lo | 2005 |
Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy.
Topics: Aged; Albuminuria; Bilirubin; Biomarkers; Blood Glucose; C-Reactive Protein; Chromatography, High Pr | 2006 |
Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Finland; Glucose Tolerance Test; Humans; Male; Middle Aged | 2006 |
Serum uric acid concentrations in type 2 diabetes: its significant relationship to serum 1,5-anhydroglucitol concentrations.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol; Creatinine; Deoxyglucose; Diabetes Mellitu | 2005 |
Metabolic effect of a LoBAG30 diet in men with type 2 diabetes.
Topics: Blood Chemical Analysis; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carb | 2006 |
Type 2 diabetes increases the risk for uric acid stones.
Topics: Age Factors; Aged; Body Mass Index; Calcium; Diabetes Mellitus, Type 2; Female; Humans; Hydrogen-Ion | 2006 |
Cardiovascular risk factors in pre-pubertal Malays: effects of diabetic parentage.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Case-Control Studies | 2007 |
Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome.
Topics: Aged; Atherosclerosis; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease | 2008 |
Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL).
Topics: Aged; Biomarkers; Blood Glucose; Cholesterol; Coronary Disease; Creatinine; Diabetes Mellitus, Type | 2007 |
Serum uric acid level as an independent component of the metabolic syndrome in type 2 diabetic blacks.
Topics: Adult; Aged; Black People; Diabetes Mellitus, Type 2; Epidemiologic Studies; Female; Humans; Hypertr | 2007 |
Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Atherosclerosis; Biomarkers; Body Mass Index; Carotid A | 2009 |
Diabetic foot patients with and without retinopathy and plasma oxidative stress.
Topics: Acute-Phase Proteins; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Foot; Di | 2007 |
Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study.
Topics: Aged; Biomarkers; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Mi | 2007 |
High serum uric acid as a novel risk factor for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hyperuricemia; Incidence; Male; Nether | 2008 |
Genome scan for determinants of serum uric acid variability.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Chromosome Mapping; Diabetes Mellitus, Type 2; Femal | 2007 |
Plasma uric acid and the risk of type 2 diabetes in a Chinese community.
Topics: Adult; Aged; Asian People; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; | 2008 |
Uric acid, type 2 diabetes, and cardiovascular diseases: fueling the common soil hypothesis?
Topics: Asian People; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Multivariate A | 2008 |
Diabetes and nephrolithiasis.
Topics: Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Nephrolithiasis; Prevalence; Uric Acid | 2007 |
Serum uric acid, mortality and glucose control in patients with Type 2 diabetes mellitus: a PreCIS database study.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Uric Acid | 2008 |
Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemo | 2008 |
Sex-specific association of the putative fructose transporter SLC2A9 variants with uric acid levels is modified by BMI.
Topics: Adult; Aged; Austria; Body Mass Index; Diabetes Mellitus, Type 2; Female; Genetic Variation; Genotyp | 2008 |
[Study of the course of development in 84 non-insulin-dependent diabetics over a 5-to-10-year period. Their therapeutic outcome].
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1983 |
Serum uric acid concentrations in offspring of conjugal diabetic parents.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Obesity; Uric Acid | 1984 |
Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus | 1995 |
Serum urate as a free radical scavenger in diabetics.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Free Radical Scavengers; Humans; Luminescent M | 1993 |
Renal uric acid handling in non-insulin-dependent diabetic patients with elevated glomerular filtration rates.
Topics: Creatinine; Diabetes Mellitus, Type 2; Female; Fructosamine; Glomerular Filtration Rate; Hexosamines | 1993 |
Association of elevated serum uric acid with coronary heart disease in diabetes mellitus.
Topics: Adolescent; Adult; Aged; Biomarkers; Body Weight; Coronary Disease; Cross-Sectional Studies; Diabete | 1993 |
High risk of progression to NIDDM in South-African Indians with impaired glucose tolerance.
Topics: Analysis of Variance; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Ethnicity; Fasting; Fem | 1993 |
[Serum uric acid level in type 1 and type 2 diabetic patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus | 1996 |
[Kidney lesions in non-insulin dependent diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; G | 1995 |
Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type 2; Diabeti | 1996 |
Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid.
Topics: Aged; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasti | 1996 |
Effect of maternal diabetes on the pattern of selected insulin resistance syndrome parameters in normal glucose tolerant subjects of two Algonquin Indian communities in Quebec.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, | 1996 |
[Diabetes mellitus at the National Hospital Center of Ouagadougou (Burkina Faso)].
Topics: Adult; Burkina Faso; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Me | 1996 |
Total radical-trapping antioxidant parameter in NIDDM patients.
Topics: Antioxidants; Ascorbic Acid; Diabetes Mellitus, Type 2; Female; Free Radicals; Humans; Male; Malondi | 1997 |
Kidney function in phasic insulin dependent diabetes mellitus in Jamaica.
Topics: Albuminuria; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1997 |
Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus.
Topics: Adult; Antioxidants; Ascorbic Acid; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellit | 1997 |
Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients.
Topics: Administration, Oral; Aged; Apolipoproteins; Biguanides; Blood Glucose; Blood Pressure; Body Constit | 1997 |
Plasma uric acid and total antioxidant status in patients with diabetes mellitus.
Topics: Adult; Antioxidants; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Human | 1997 |
[Hyperuricemia as a risk factor for noninfectious diseases in the inhabitants of Chuvashia].
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; M | 1997 |
Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients.
Topics: Antioxidants; Ascorbic Acid; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 1997 |
Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
Topics: Apolipoprotein A-I; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; | 1997 |
Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus.
Topics: Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Proportiona | 1998 |
Improved glycemic control in a diabetic patient after discontinuation of allopurinol administration.
Topics: Allopurinol; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Glycosuria; Gout Suppres | 1998 |
Oxidative damage, plasma antioxidant capacity, and glucemic control in elderly NIDDM patients.
Topics: Adult; Aged; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Erythrocytes; Fasting; Fructosa | 1998 |
Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects.
Topics: Antioxidants; Ascorbic Acid; Blood Glucose; Blood Proteins; Diabetes Mellitus, Type 2; Female; Gluco | 1998 |
Progression to type 2 diabetes among high-risk groups in Kin-Chen, Kinmen. Exploring the natural history of type 2 diabetes.
Topics: Adult; Age Factors; Blood Glucose; Body Constitution; Body Mass Index; Cholesterol, HDL; Diabetes Me | 1998 |
Meal-generated oxidative stress in type 2 diabetic patients.
Topics: Analysis of Variance; Antioxidants; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Type 2; Fatty A | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Intolerance; Homeos | 1998 |
Diabetes mellitus after liver transplantation: a possible relation with the nutritional status.
Topics: Albuminuria; Bilirubin; Blood Glucose; Blood Proteins; C-Peptide; Cyclosporine; Diabetes Mellitus, T | 1998 |
The association between the total antioxidant potential of plasma and the presence of coronary heart disease and renal dysfunction in patients with NIDDM.
Topics: Aged; Antioxidants; Ascorbic Acid; Biomarkers; Chromatography, High Pressure Liquid; Coronary Diseas | 1998 |
Severe protracted lichenoid eruption and hyperuricemia following administration of alacepril.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diabetes Mellitus, Type 2; Female; Follow | 1999 |
Serum leptin is associated with serum uric acid concentrations in humans.
Topics: Adipose Tissue; Analysis of Variance; Body Constitution; Body Mass Index; Case-Control Studies; Cros | 1999 |
Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Arteriosclerosis; Blood Pressure; Body Height; Body M | 1999 |
Maternal effect of Type 2 diabetes mellitus on insulin sensitivity and metabolic profile in healthy young Mexicans.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinin | 1999 |
Metabolic syndrome is associated with changes in D-mannose metabolism.
Topics: Aged; Blood Glucose; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Female; Glucose Intole | 1999 |
[Main causes of hyperuricemia in diabetes mellitus].
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycosuria; | 2000 |
Hyperuricaemia in Type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Body Mass Index; Coronary Disease; Creatinine; Cross-Sectional Studies; Diabete | 1999 |
Physical activity, metabolic factors, and the incidence of coronary heart disease and type 2 diabetes.
Topics: Adult; Biomarkers; Body Mass Index; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; E | 2000 |
Ascorbyl free radical release in diabetic patients.
Topics: Antioxidants; Ascorbic Acid; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Typ | 2000 |
The potential role of adenosine in the pathophysiology of the insulin resistance syndrome.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Adipose Tissue; Animals; Coronary Disease; | 2001 |
Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cohort Studies; Diabetes M | 2000 |
Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female | 2001 |
Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes.
Topics: Aged; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; Logistic Models; Male; Middle Aged; Phe | 2001 |
Diabetic cataract and the total antioxidant status in aqueous humor.
Topics: Aged; Antioxidants; Aqueous Humor; Case-Control Studies; Cataract; Diabetes Mellitus, Type 2; Humans | 2001 |
Hypophosphataemia: cause of the disturbed metabolism in the metabolic syndrome.
Topics: Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, | 2001 |
Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey.
Topics: Adult; Alcohol Drinking; Asian People; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; H | 2001 |
Clinical features of familial gout and effects of probable genetic association between gout and its related disorders.
Topics: Age of Onset; Alcohol Drinking; Body Mass Index; Comorbidity; Creatinine; Cross-Sectional Studies; D | 2001 |
Uric acid concentration in subjects at risk of type 2 diabetes mellitus: relationship to components of the metabolic syndrome.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Chemistry; Colorimetry; Diabetes Mellitus, Ty | 2002 |
Circadian variation in oxidative stress markers in healthy and type II diabetic men.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Biomarkers; Case-Control Studies; Circadian Rhythm; Deoxyg | 2002 |
Increase in serum uric acid is selectively associated with stroke in type 2 diabetes.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Stroke; Uric Acid | 2002 |
Two cases in whom pyrazinamide does not inhibit the uricosuric action of benzbromarone.
Topics: Adult; Benzbromarone; Diabetes Mellitus, Type 2; Drug Interactions; Female; Humans; Kidney; Kidney D | 1992 |
Two cases of persistent hypouricemia associated with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Kidney Tubules; Male; Probenecid | 1992 |
Plasma urate in diabetes: relationship to glycaemia, glucose disposal, microvascular complications and the variations following oral glucose.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1991 |
Clinical and laboratory parameters in adult diabetics with and without calcific shoulder periarthritis.
Topics: Adult; Aged; Aged, 80 and over; Calcinosis; Calcium; Cholesterol; Diabetes Mellitus, Type 2; Female; | 1991 |
Coronary risk factors in newly diagnosed and previously diagnosed type 2 diabetic men with myocardial infarction.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Di | 1991 |
Risk factors for NIDDM in white population. Paris prospective study.
Topics: Aged; Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type | 1991 |
Metabolic abnormalities in first-degree relatives of type 2 diabetics.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance | 1990 |
[Uric acid--a risk factor or atherosclerosis marker in type 2 diabetes?].
Topics: Aged; Arteriosclerosis; Biomarkers; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 1990 |
Renal handling of uric acid.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycosuria; Humans; Kidney Tubules; Reference Values; | 1990 |
Diabetic hypouricemia as an indicator of clinical nephropathy.
Topics: beta 2-Microglobulin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dietary Prot | 1990 |
Automated fructosamine assay with improved accuracy used to quantify nonenzymatic glycation of serum proteins in diabetes mellitus and chronic renal failure.
Topics: Adult; Autoanalysis; Azo Compounds; Blood Glucose; Blood Proteins; Child; Detergents; Diabetes Melli | 1990 |
Co-occurrence of hypercalciuria and hypouricaemia in type 2 diabetic patients.
Topics: Blood Pressure; Calcium; Creatinine; Diabetes Mellitus, Type 2; Humans; Middle Aged; Phosphates; Ref | 1989 |
[HDL cholesterol in diabetes mellitus type II].
Topics: Aged; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; T | 1989 |
[The value of hypertension and metabolic factors on the development of coronary heart disease in type II diabetic patients].
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Electrocardiography; Humans | 1988 |
Elevated serum uric acid--a facet of hyperinsulinaemia.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hu | 1987 |
Platelet sodium kinetics, blood pressure and serum urate: aberrations in non-obese men at risk for type 2 diabetes mellitus.
Topics: Binding Sites; Blood Platelets; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Kinetics; Male; M | 1987 |
Diabetic renal hypouricemia.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Tubules; Male; Midd | 1987 |